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1. INTRODUCTION TO THE SCIENTIFIC WORK 
 
Cognitive deficits and impairments of higher brain functions are the most burdening 
features in various neuropsychiatric disorders (e.g. Elvevag and Goldberg, 2000). Up 
to now, there are no satisfying proven treatments targeting the main cognitive 
domains affected in neuropsychiatric diseases (e.g. Stroup et al., 2006). In light of an 
increasingly aging society in industrialized countries and the herewith associated 
cognitive decline, novel neuroprotective / neuroregenerative approaches are 
desperately needed. The present cumulative thesis was conducted in the framework 
of the Göttingen Research Association for Schizophrenia (GRAS) and addresses two 
related topics: first, a novel experimental approach in mice combining genetic and 
environmental factors for modelling cognitive deficits relevant to schizophrenia, and 
second, the effect of erythropoietin (EPO) on improving higher cognitive functions 
(i.e. learning and memory, attention, executive functions) in mice. The thesis includes 
one book chapter and three original first-author publications. The chapter (El-Kordi, 
Radyushkin, Adamcio et al., 2009) gives a state-of-the-art overview of previous, 
present and future rodent models of schizophrenia. It highlights the urging need for 
valid and reliable animal models of this burdening disease. Moreover, it defines for 
the first time “DSM criteria for rodent schizophrenia”. On these grounds, the first 
paper evolves (Radyushkin, El-Kordi et al., 2010) which combines a complexin2 null 
mutation in mice as a genetic factor and a mild parietal neurotrauma applied during 
puberty, as an environmental factor. This genetic-environmental model yielded 
several phenotypes relevant to schizophrenia. The second publication (El-Kordi, 
Radyushkin and Ehrenreich, 2009) demonstrates the effect of EPO treatment on 
several types of learning, attention and executive control in mice. It sheds light on 
methodological approaches to study these functions in rodents and uncovers the role 
of EPO in improving these domains in healthy mice. From there, I wanted to obtain 
more mechanistic insight into EPO mediated cognitive improvement. For that 
purpose, I characterized the cognitive performance of constitutively active EPOR 
overexpressing mice (cEPOR under the α-calcium/calmodulin-dependent protein 
kinase II (α-CaMKII) promoter). This third paper shows the effects of EPOR on 
cognition when overexpressed in selected hippocampal and cortical neurons, which 
are highly relevant to higher brain functions (Sargin, El-Kordi et al., 2010, submitted). 
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Impairments of higher brain functions are believed to be the core of various 
neuropsychiatric diseases, in particular schizophrenia (Elvevag and Goldberg, 2000). 
Schizophrenia is a debilitating disorder that affects approximately 1% of the 
population across cultures. It comprises positive symptoms (delusions, 
hallucinations), negative symptoms (social withdrawal, alogia, affective flattening) 
and cognitive symptoms (deficits in working memory, sustained attention and 
executive functions) (Wong and Van Tol, 2003). Knowledge about its neurobiological 
causes is still nascent. Accordingly, animal models of schizophrenia often lack 
construct validity. The observation that concordance rate in monozygotic twins 
amounts to only 50% made clear that environmental risk factors (e.g. neurotrauma, 
drug abuse, obstetric complications, etc.) likely act as necessary 'second hit' to 
trigger the disease process in a genetically predisposed individual.  Previously, 
animal models with high face validity addressed only one factor, e.g. alterations in 
neurotransmitter systems, neonatal brain lesions, etc. (for review, see Lipska, 2004), 
and thus lack construct validity. Based on this ‘second hit hypothesis’ (e.g. Bayer et 
al., 1999; Maynard et al., 2001), recent animal models emerged unifying genetic and 
environmental factors (for review, see Ayhan et al., 2009).  
 
Despite moderate success in mimicking schizophrenia in rodents, and recent 
pharmacological innovations in treatment, improving cognitive deficits remains a 
challenging task.  Up to now, treatment of schizophrenia mainly addresses positive 
symptoms and is still based on antagonising the dopaminergic system, specifically 
blockade of D2 receptor (Miyamoto et al., 2005). New antipsychotic medications, so 
called atypical antipsychotics, act on partial blockade of several members of the 
serotonin receptor family (e.g. 5-HT1A, 5-HT2A, 5-HT2C) besides their affinity to D2 
and other receptors (Mortimer, 2004). This new generation of antipsychotics have 
fewer undesirable side effects, in contrast to the old generation. However, they often 
lead to weight gain, sedation and metabolic alterations (for review, see Simon et al., 
2009). Most importantly, in spite of attenuating positive symptoms and alleviating 
mood and motivation, they still have limited effects on improving cognition (for review, 
see Galletly et al., 2000). Nevertheless, in recent years, several reports appeared 
targeting neural systems implicated in the cognitive deficits observed in 
schizophrenia. Specifically α7-nicotinic agents proved to be potential promising 
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candidates for ameliorating cognitive impairment (for review, see Buchanan et al., 
2007; Radek et al., 2010).  
 
Although often debated (Rund, 2009), limited neurodegenerative processes are 
almost always evident in the schizophrenic brain (Lieberman, 1999). Treating 
cognitive impairments in schizophrenia is so tedious due to the structural 
abnormalities, which seem to be pharmacologically non-modifiable (Harvey, 2009). 
The ongoing neurodegeneration in schizophrenics renders neuroregenerative / 
neuroprotective agents potentially attractive candidates for treating cognitive deficits 
in this disease. Neuroprotective compounds give a long-lasting improvement of 
symptoms and aim at slowing a continuous disease process (Sargin, Friedrichs et al., 
2010, in press). Interestingly, a recent study of our group demonstrated the effect of 
EPO on delaying gray matter loss in association with cognitive improvement in 
chronic schizophrenia (Wüstenberg et al., 2010). 
 
Justifiably, in the last decade, EPO has in an unprecedented manner attracted 
attention as a candidate for neuroprotection / neuroregeneration (Sargin, Friedrichs 
et al., 2010, in press). Since its introduction to the clinic to treat chronic renal failure, 
several reports have been accumulating highlighting the effect of EPO on improving 
cognitive functions (Ehrenreich et al., 2008; Jelkmann, 1992). For a long time, the 
effect of EPO on cognition was attributed to its direct action on the hematopoietic 
system and to enhanced tissue oxygenation. However, several lines of evidence 
convincingly prove that EPO-mediated cognitive improvement is independent of its 
hematopoietic properties and represents a direct action in the brain (Ehrenreich et al., 
2008; Sakanaka et al., 1998; Sirén et al., 2009; Zhang et al., 2009).  
 
EPO is a 165 amino acid glycoprotein with a molecular mass of approximately 30.4 
kDa. It acts via binding to its specific transmembrane receptor, (EPOR), belonging to 
the cytokine type 1 receptor subfamily. Homodimerization of 2 transmembrane EPOR 
molecules leads to binding of a single EPO molecule and induces a conformational 
change which initiates EPOR-associated JAK2 transphosphorylation. Downstream 
signaling molecules are subsequently activated including signal transducers and 
activators of transcription (STATs), phosphatidylinositol-3 kinase (PI3K)/AKT, 
RAS/extracellular signal-regulated kinase (ERK1/2), nuclear factor kappa B (NF-
 8
kappa B) and calcium (Brines and Cerami, 2005; Sirén et al., 2001). Activation of 
these signaling cascades leads to further activation of anti-apoptotic factors, 
stimulation of cell differentiation, including induction of cellular shape-change and 
growth, or modulation of plasticity (Sargin, Friedrichs et al., 2010, in press).  
 
The discovery of EPO/EPOR system in the brain (Masuda et al., 1993) made it a very 
promising candidate for treating brain disorders. In recent years, it has been shown 
that EPO is a potent agent for treating cognitive dysfunctions in several 
neuropsychiatric and neurological diseases (Ehrenreich, Fischer et al., 2007; 
Ehrenreich, Hinze-Selch et al., 2007). However, the mechanisms of its action on 
improving higher cognitive functions (e.g. attention and behavioral control) have not 
been studied so far.  
 
2. FOCUS OF MY PHD THESIS 
 
The present thesis addresses (1) a novel experimental approach in mice combining 
genetic and environmental factors for modelling cognitive deficits relevant to 
schizophrenia. (2) The effect of EPO on improving higher cognitive functions (i.e. 
learning and memory, attention, executive functions) in mice and the underlying 
physiological mechanisms. It includes 4 publications (one first-author book chapter, 
two first-author published papers and one first-author submitted paper).  
 
2.1. AIMS OF PROJECT I 
 
The first project addressed a novel experimental approach in mice, based on the 
‘second hit hypothesis’ of schizophrenia. In this framework, a book chapter giving a 
state-of-the-art of past, present and future rodent models of schizophrenia has been 
published. The original study has been designed to investigate the effect of 
combining a complexin2 null mutation in mice (genetic predisposition) with a juvenile 
parietal neurotrauma as a second hit (environmental trigger). We hypothesized that 
only mutant lesioned mice will exhibit schizophrenia relevant behavioral, cognitive 
and MRI alterations. 
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2.2. AIMS OF PROJECT II 
 
The second project aimed at studying the effect of EPO on higher brain functions in 
mice. For that purpose we investigated under healthy conditions in absence of 
intervening disease variables the effect of chronic EPO administration on different 
types of learning and memory, attention and executive functions in 28-days old male 
C57Bl/6 mice. In this study, we made use of a sequential operant paradigm, the five 
choice serial reaction time task (5CSRTT).  
 
2.3. AIMS OF PROJECT III 
 
To obtain a mechanistic insight in EPO-mediated cognitive improvement, we have 
designed the third study, investigating the effect of over-expression of EPOR in 
selected cell populations. For this purpose, we studied the cognitive performance of 
constitutively active EPOR overexpressing mice (cEPOR under the α-
calcium/calmodulin-dependent protein kinase II (α-CaMKII) promoter). These mice 
over-express the EPO receptor only in the pyramidal neurons of cortex and 
hippocampus. Their behavior was extensively analyzed using a wide behavioral test 
battery.  
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3. AN EXPERIMENTAL APPROACH COMBINING GENETIC AND 
ENVIRONMENTAL FACTORS FOR INDUCING A SCHIZOPHRENIA-
LIKE PHENOTYPE IN MICE 
 
 
3.1. OVERVIEW OF PROJECT I 
Schizophrenia is a frequent and devastating disease characterized by positive, 
negative, and cognitive symptoms (American-Psychiatric-Association, 2000; van Os 
and Kapur, 2009; Wong and Van Tol, 2003). Its underlying etiology is still poorly 
understood (Sawa and Snyder, 2002). Consequently, animal models addressing 
central constructs of the disorder are widely lacking. In contrast, models with face 
validity, where juvenile rodents are exposed to lesions or pharmacological 
interventions, have been used for many years (for review, see Lipska, 2004). 
The genetic basis of this disorder is indisputable. However, the concordance rate in 
monozygotic twins is only 50% (Gottesman and Shields, 1976), pointing to additional, 
environmental risk factors (Bayer et al., 1999). Animal models reliably representing 
the disease phenotype should account for the interaction between genetic and 
environmental triggering factors. Based on the 'second hit hypothesis', we designed 
an experimental approach for modeling schizophrenia which combines a genetic 
(complexin2 (Cplx2) null mutation) and an environmental factor (mild parietal cortical 
lesion during puberty) to induce schizophrenia-like phenotype in mice. 
Since schizophrenia is seen as a "disease of the synapse" (Harrison and 
Weinberger, 2005) synaptic molecules moved into research focus. Among others, 
complexins (CPLX), which are presynaptic proteins that modulate neuronal 
exocytosis (for review, see Brose, 2008), have been associated with schizophrenia 
(Harrison and Eastwood, 1998; Lee et al., 2005; Sawada et al., 2002). Previous 
studies characterizing Cplx2-/- mice reported a mild behavioral phenotype consisting 
of slight motor deficit and impaired learning in Morris water maze (Glynn et al., 2003; 
Glynn et al., 2007; Yamauchi et al., 2005). Regarding environmental factors, 
neurotrauma (Malaspina et al., 2001; McAllister, 1998), and particularly lesions 
affecting the right parietal lobe have been linked with schizophrenia-like psychosis 
(Sachdev et al., 2001; Zhang and Sachdev, 2003).  Several years ago, we have 
developed a mouse model, based on findings of a longitudinal study on patients with 
childhood onset schizophrenia (Thompson et al., 2001). In our mouse model (Sirén et 
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al., 2006) a small standardized lesion is set during puberty onto the right parietal 
cortex which initiates a bilateral neurodegenerative process very similar to that 
occurring endogenously in schizophrenia for – up to now – unknown reasons (Sargin 
et al., 2009).  
By combining Cplx2 null mutation with neurotrauma, we provide further experimental 
evidence that a genetic predisposition (affecting neurodevelopment) in addition to an 
environmental risk factor (triggering neurodegeneration) can give rise to alterations 
relevant to schizophrenia in mouse behavior and brain morphology. 
Several months after lesion we found, that only Cplx2 null mutants showed reduced 
pre-pulse inhibition, deficit of spatial learning, and loss of inhibition after MK-801 
treatment. Forced alternation in T-maze, object recognition, social interaction and 
elevated plus maze tests were unaltered in all groups. The previously reported mild 
motor phenotype of Cplx2 null mutants was accentuated upon lesion. MRI 
volumetrical analysis revealed a decrease of hippocampal volume exclusively in 
lesioned Cplx2 null mutants. 
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3.2. ORIGINAL BOOK CHAPTER 
 
 
El-Kordi A, Radyushkin K, Adamcio B and Ehrenreich H (2009). Rodent models of 
schizophrenia: Past, present and future. In: Endophenotypes of Psychiatric and 
Neurodegenerative Disorders in Rodent Models. Ed. Granon S. Signpost. 
 
Personal contribution 
I was responsible for literature search and writing the chapter.  
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Abstract 
      Schizophrenia is a devastating disease that 
affects approximately 1% of the population all over 
the world and across cultures. Up to now, neither 
satisfying treatment nor fundamental understanding 
of etiology and pathogenesis of this heterogeneous 
group of diseases are available. In contrast to many 
other brain diseases, schizophrenia has long been 
seen as a mysterious, non-organic and stigmatising 
condition.  Even  nowadays,  the point of  view        exists
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that schizophrenia cannot affect species other than humans and requires 
developed language to manifest itself. The first animal models of 
schizophrenia-associated symptoms evolved when antipsychotic drugs had to 
be tested for efficacy in preclinical studies. These first models were crude, 
aimed at creating a phenotype that could be influenced by antipsychotics but 
did not model any real features of schizophrenia. In this regard, major 
advance in the field came within the last years. Animal models have been 
developed that try to cover various aspects of schizophrenia, i.e. positive 
symptoms (particularly hyperactivity), negative symptoms (social behavior 
and withdrawal) and cognitive dysfunction (working memory, attention). 
There is not only improvement in defining suitable animal models, but also in 
the validity of behavioral paradigms used for classifying schizophrenia-like 
phenotypes in rodents. This chapter will summarize “DSM criteria for rodent 
schizophrenia”, describe (1) models that have been used in the past, (2) 
models that have been introduced recently and (3) models that are being 
developed, combining genetic and environmental factors, in order to more 
adequately represent the disease phenotype. To conclude, an animal model of 
schizophrenia is desperately needed not only to improve prevention and 
treatment options for schizophrenic patients, but also to gain insight into 
relevant pathophysiological processes leading to the disease. 
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Introduction 
 Schizophrenia is a devastating brain disorder characterized by positive 
symptoms (e.g. delusions, hallucinations and formal thought disturbances), 
negative symptoms (e.g. social withdrawal, affective flattening and alogia) and 
cognitive deficits (e.g. attention, executive functions and working memory) [1]. 
The latter are getting more and more in the focus of research and are thought to 
be central to the social and behavioral disability of schizophrenic patients [2, 3]. 
According to the Diagnostic and Statistical Manual of Mental Disorders (4th 
edition; DSM-IV) of the American Psychiatric Association [4], the estimated 
lifetime prevalence of schizophrenia is between 0.5% and 1%. This estimation 
is found across all cultures worldwide and has remained unchanged since 1900 
[5]. The heterogeneity of symptoms of schizophrenia as well as the lack of 
clearly measurable disease specific pathology [6], together with the fact that 
manifestation of this complex disorder in humans is most reliably diagnosed 
through language make developing rodent model of schizophrenia a difficult 
and challenging undertaking.  
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 This chapter takes the reader to a time travel through the history of 
rodent models of schizophrenia, without intending to review all possible 
animal models of schizophrenia and their theoretical underpinnings. It is the 
attempt to illustrate the different stages and conceptual frameworks of the 
development of valid and reliable rodent models of schizophrenia. For 
primate models, the interested reader is referred to the review of Ellenbroek 
and Cools [7]. The difficulty of reliably modeling mental disorders, believed 
to be quite uniquely “human”, in simpler model systems such as mice, makes 
the formulation and fulfilling of validity criteria an imperative condition. The 
next section discusses criteria which have to be met in an animal model of 
mental disorders in general and of schizophrenia in particular. An overview is 
provided about schizophrenia symptoms which have a clear homology in 
rodents and thus are translatable to a simpler organism. 
 
1. Validity issues in animal models of psychiatric 
disorders 
 Animal models for psychiatric disorders are becoming an indispensable 
tool in investigating the mechanisms that underlie a human disease. 
Moreover, they are of great importance for the development of new treatment 
strategies. This is not only the case for animal models for physical disorders, 
such as diabetes mellitus and hypertension, it also holds true for mental 
disorders like depression and schizophrenia. But modeling mental disorders 
in rodents is more complex and challenging compared to modeling a physical 
condition with clear-cut pathophysiological mechanisms and well-defined 
diagnostic criteria. As Kornetsky and Markowitz [8] reported, animal models 
of physical disorders have the attribute of close similarity between the 
physiologic condition in animals and humans. But even in these areas, similar 
behaviors in various species may exist for different reasons, and therefore, 
have different meanings [9]. Nevertheless, modeling a highly cognitive 
condition in a cognitively lower organism has to be regarded as an 
experimental compromise. As McKinney and Moran [9] pointed out, an 
animal model can never be exactly the same as the condition being modeled. 
Accordingly, prevailing animal models do not attempt to represent a 
complete animal equivalent of the human condition. This is obvious when 
modeling such heterogeneous brain disorder as schizophrenia. Rather, animal 
models are developed to study specific causative or mechanistic aspects of 
the corresponding disease [10].  
 There are different levels on which an animal model may represent a disease: 
1. It may reproduce inducing factor(s); 2. It may mimic phenomenology and 3. It 
may show responsiveness to already existing treatments [11]. Thus, the degree 
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to which an animal model accurately mimics the real human condition varies 
according to the aspects that it intends to represent [11]. In this context, the 
concept of validity is of great importance. Initially, McKinney and Bunney [12] 
proposed minimal requirements an animal model has to meet: 1. similarity of 
inducing conditions; 2. similarity of behavioral states produced; 3. common 
underlying biological mechanisms; and 4. reversal by clinically effective 
treatment techniques [adapted from ref. 9, see also ref. 12]. Later, Willner [13] 
pointed out, that animal models should possess predictive, face and construct 
validity. Although this was originally stated in the framework of animal 
models for depression, it also holds true for other animal models of psychiatric 
disorders, including schizophrenia.  
 Predictive validity, in its broadest sense, concerns the ability of a model 
to make successful predictions or to forecast, for example, the behavior of the 
animal in a specific experimental situation. A model with high predictive 
validity allows to draw extrapolation of the effect of a given experimental 
manipulation from one species (e.g. rodents) to other species (e.g. humans), 
and from one setting (e.g. laboratory) to another one (e.g. “real life”) [14]. In 
a more narrow sense, predictive validity implies that treatments proven to be 
effective in humans have also to be effective in the animal model. This notion 
is quite similar to the concept of pharmacological isomorphism proposed by 
Matthysse [15]. For the purpose of this chapter, we use the term predictive 
validity in its narrow sense.  
 The second validity issue is that of face validity. Face validity implies, in 
its simplest definition, the similarity of symptomatology. This concept is 
similar to the criterion of behavioral isomorphism by Kornetsky and 
Markowitz [16] and the concept of symptom similarity by Matthysse [15]. 
Symptoms elicited in animal models with high face validity resemble those 
seen in humans.  
 The third aspect of validity which animal models have to fulfill is the 
concept of construct validity. It is believed to be the most important aspect 
in validating animal models of complex disorders such as schizophrenia [14]. 
This concept refers to the theoretical background or constructs underlying  
the disease process. Animal models with construct validity have a sound 
theoretical rationale. Thus they go in accordance with constructs 
characterizing schizophrenia patients. For example, animal models are based 
on the construct that schizophrenics have a deficient information processing.  
 According to Ellenbroek and Cools [7], predictive validity has the 
lowest, while construct validity has the highest hierarchy of validity issues. 
Concerning animal models of schizophrenia in particular, various researchers 
proposed specific and theoretically sound criteria, which have to be met       
in an animal model trying to mimic the disease’s pathophysiology, 
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symptomatology, etiology, and to pave the way for developing new treatment 
strategies. For example, Matthysse and Haber [17] defined standards which a 
model of schizophrenia has to satisfy. Although most of these standards were 
drug related, and thus fit perfectly well to a pharmacological animal model of 
schizophrenia, these criteria may be incorporated with other complementing 
standards addressing other issues, such as etiology and cognitive 
symptomatology. For instance, Ellenbroek and Cools [7], proposed criteria 
adapted from Willner [18] addressing aspects of predictive, face and 
construct validity. Reviewing these standards with their corresponding 
empirical background is beyond the scope of this chapter. The interested 
reader is referred to [7, 18].  
 After discussing standards guiding the development and assessment of 
animal models for psychiatric disorders, with a main focus on schizophrenia, 
how should a rodent model mimicking the schizophrenia symptomatology and 
possessing predictive, face and construct validity look like? Which symptoms 
do rodents show that may be translatable to disturbances seen in humans with 
schizophrenia? And how can these symptoms and behavioral traits be reliably 
measured? As mentioned earlier in this chapter, modeling schizophrenia is a 
great challenge for behavioral neuroscientists, not only due to the heterogeneity 
of symptoms, but also due to the simple fact, that rodents do not possess a 
crucial tool, which has a diagnostically indispensable value, that is verbal 
communication. As McKinney and Moran [9] stated, no animal analogies exist 
for the characteristics of auditory hallucinations, flatness of affect, thought 
alienation, thoughts spoken aloud, delusions of control, voices speaking to the 
patient to just name a few [see also ref. 9]. However, rodents have a wide 
behavioral repertoire, and their lack of human-like verbal communication 
should not discourage researchers from trying to model these symptoms.  
 The next section will focus on behavioral domains an animal model of 
schizophrenia has to show to be regarded as valid. We will illustrate the 
symptoms in schizophrenia patients with their corresponding behavioral traits 
in rodents and behavioral paradigms used to assess these traits.  
 
2. Behavioral domains affected in schizophrenia 
 In the context of modeling brain disorders in rodents, many people wonder: 
“How does a schizophrenic mouse look like?” In our opinion, and based on 
human phenomenological data, a rodent model for schizophrenia should not 
show complete cognitive disability. Despite the fact that schizophrenia is a 
burdening and devastating brain disorder, which compromises normal social 
interaction, patients do not have a general intellectual disability comparable to 
that seen in patients suffering from mental retardation. Thus, what has to be 
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modeled is not debility or apparently eccentric and bizarre behavior in each and 
every respect. Rather, subtle deficits in particular cognitive domains, ideally 
under specific conditions and experimental manipulations, should be present in 
a valid model of schizophrenia. In the last years, many researchers made very 
accurate attempts to relate rodent behaviors of potential relevance to clinical 
phenomena in schizophrenia [11, 19]. Table 1 summarizes the main domains or 
symptom clusters found in schizophrenia with their corresponding findings in 
humans and the behavioral aspects, which have to be proven in a rodent model 
of schizophrenia. Figure 1 illustrates some of the behavioral set-ups for testing 
and assessing positive (A) and negative symptoms (B) as well as cognitive 
functions (C, D) mentioned in Table 1. The following section will illustrate 
behavioral and cognitive domains implicated in schizophrenia, amenable to 
modeling in rodents.  
 
Table 1. Schizophrenia symptoms which might be mimicked in a rodent model. 
 
Domain Schizophrenia in humans Rodent phenotype 
 
Positive 
symptoms 
 
Hallucinations, delusions, thought 
disorders 
 
Lack of reliable readouts in rodents 
  Psychomotor agitation 
 
 
 
 
 
 
 
Stereotypy 
 
Spontaneous hyperlocomotion 
Increase in PCP- or MK-801-induced 
hyperlocomotion 
Increase in amphetamine-induced 
hyperlocomotion 
Increase in stress-induced hyperlocomotion 
Reduced haloperidol-induced catalepsy 
 
Circling movements, repetitive behaviors 
 
Negative 
symptoms 
 
Social withdrawal 
 
Decreased preference to social novelty  
Decreased social interaction 
Decreased nesting in the home cage 
Decreased huddling in the home cage 
  Affect flattening 
 
Anhedonia 
 
Lack of reliable readouts in rodents 
 
Decrease in sucrose preference 
 
Cognitive 
symptoms 
 
Working memory deficits 
 
Impaired performance in T-maze 
Impaired performance in 8-arm maze 
  Deficit of attention 
 
Impaired latent inhibition 
Decreased sustained attention in 5CSRTT 
Increased distractibility in 5CSRTT 
  Executive function deficits 
 
Increased reaction time in 5CSRTT 
Increased premature responses in 5CSRTT 
Decreased set-shifting ability 
  Disturbance of sensorimotor gating 
 
Diminished PPI, retarded startle habituation 
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Figure 1. Experimental paradigms to address schizophrenia-like behavioral traits in 
mice. A. Hyperactivity in open field as evidence for psychomotor agitation. The 
behavior of a mouse, placed in a big circular or rectangle arena, is recorded by a 
computer, equipped with a video-tracking system. Total distance traveled and pike 
velocity serve as readouts of motor hyperactivity, which in turn are seen as indirect 
evidence for positive symptoms of schizophrenia. B. Tri-partite test for sociability and 
social memory in mice. In an experimental chamber with 3 compartments, the mouse 
has the option to stay (1) in close proximity with an unfamiliar mouse, kept in a small 
wire cage, (2) in the compartment with an empty cage or (3) in the central compartment. 
The proportion of time spent in interaction with the unfamiliar mouse is used as a 
readout for sociability. In order to evaluate social memory, the test mouse, right after 
sociability testing, is offered the choice between two mice – one that is familiar and one 
that is new. The proportion of time spent in interaction with the new mouse (normally 
higher as compared to the familiar mouse) is the readout for social memory. C. Prepulse 
inhibition of the startle response. Like many species, including Homo Sapiens, mice 
show a startle response to a sudden acoustic stimulus. To measure the amplitude of such 
a response, the mouse is placed in a small restriction cage on a platform, attached to a 
vibration sensor. The amplitude of oscillations, evoked by body muscle contractions, 
triggered by a 120dB white noise pulse, is recorded by a computer. The mouse responses 
are measured in two types of trials – with and without a weak stimulus (prepulse), 
applied 50-500msec before the pulse. The degree of response reduction in “prepulse 
trials” in comparison to “pulse only trials” is calculated. D. Five choice serial reaction 
time task as a test of attention. In order to get a reward, the mouse has to make a nose-
poke response into one of 5 holes where a light signal is randomly presented for a short 
period of time (0.8sec). The number of omitted signal presentations serves as a main 
readout for attention. In order to further characterize the attention of the mouse, 
additional trials with application of distracting stimuli are used. 
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2.1. Positive symptoms 
 As mentioned earlier in this chapter, there is no assessable rodent behavior 
equivalent to hallucinations and disorganized thoughts [9]. Thus, investigators 
have to rely on other overt behavioral traits indicative of positive symptoms. 
Interestingly, modeling positive symptoms in rodents, initially in rats, has a 
long tradition in the context of studying the effect of antipsychotic drugs. 
Hyperlocomotion is seen as a valid indicator for positive symptoms in rodents. 
Thus, several studies have used spontaneous hyperlocomotion and increased 
vertical (i.e. rearing) and horizontal motor activity in the open field as a 
measure for positive symptoms in rodents [20-24].  
 
2.2. Stereotypy 
 Stereotypy is a repetitive, unvarying and seemingly functionless behavior 
found in various psychiatric disorders. Repetitions can be manifest at different 
functional levels. For example, in the motor domain (tics and tremor), 
executive motor functions (rituals), cognitive domain in form of preoccupation 
with specific thoughts (rumination) and in planning and strategic domain, 
resulting in cognitive inflexibility [25]. Stereotypy has often been regarded as a 
hampering symptom of schizophrenia. It comprises different behavioral 
features, e. g. brief motor tics, mannerisms and complex ritualistic behavior 
[25]. These disturbances seem to be due to excess of subcortical dopaminergic 
activity [26]. Another phenomenologically similar symptom, i.e. 
perseverations, has been also implicated in schizophrenia. Perseverations are 
also repetitive hampering behaviors. However, they are often described in the 
context of mental states. Ridley [25] defines stereotypy as the excessive 
production of one type of motor act or mental state, whereas perseveration 
refers to a restriction of choices of action while the repetitive behavior is not 
excessive. We will not discuss modeling perseverations in rodents, as there are 
barley any data pointing to this feature. Stereotypy has been documented in 
various species, especially in captive animals [e.g. ref. 27]. This phenomenon is 
widely spread among laboratory animals [for review, see ref. 28]. In rats, 
administration of dopamine agonists (e.g. apomorphine) has been reported to 
induce stereotyped locomotion, sniffing, licking and gnawing [29]. Thus, 
rodents bear the ability of showing stereotyped behavior, moreover, this also 
depends on genetic and environmental factors [29].  
 
2.3. Negative symptoms: Social behavior 
 Social deficits are believed to be a hallmark of schizophrenia and belong to 
negative symptoms of the disease. Social functions including interacting and 
communicating with others, maintaining employment and having a functional 
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role in community are affected in various psychiatric disorders, however, they 
are characteristic for schizophrenia [30]. Social deficits are even apparent long 
before the disease onset. Moreover, it is widely recognized that social and 
cognitive functions are interrelated [for review, see ref. 31]. Even though 
rodents manifest a limited spectrum of social behaviors, they enable measuring 
functions like social interest, interaction and social preference. Furthermore, 
rodents emit ultrasonic vocalizations in various contexts [32], another trait of 
social behavior and communication, recently exploited for the demonstration of 
autistic symptoms in a mouse model of monogenic heritable autism [33]. Social 
traits have been often assessed in rodent models of schizophrenia. Another 
feature of negative symptoms is flattened affect and anhedonia. Whereas 
flattened affect is virtually not assessable in rodents, measuring anhedonia and 
reward sensitivity has a long tradition. A classic method of assessing anhedonia 
in rodents is sucrose preference [for review, see ref. 34]. 
 
2.4. Cognitive functions: Prepulse inhibition and latent 
inhibition 
 Prepulse inhibition (PPI) of the acoustic startle response is a valuable and 
traditional measurement widely used in schizophrenia research. It has been 
repeatedly reported that schizophrenia patients manifest deficits in PPI [for 
review, see ref. 35]. PPI is a measure for sensorimotor gating and pre-
attentive information processing [36]. Detailed description of this procedure 
as well as parametric issues have been reviewed elsewhere [37]. A wealth of 
studies have reported the effect of dopamimetics, NMDA antagonists and 
antipsychotics on PPI performance of rodents [38].  
 Another paradigm with great experimental tradition is latent inhibition 
(LI). Latent inhibition is defined as the poor evidence for learning a stimulus 
that previously was presented without any consequence, as compared to a 
novel or previously attended stimulus [39]. LI is believed to be a measure for 
attentional processes, which are severely disrupted in schizophrenia patients, 
although data of LI in some schizophrenia patients delivered also conflicting 
results [40]. Several dopaminergic agonists as well as glutamatergic 
compounds disrupt LI [41, 42]. It has also been demonstrated, that clozapine 
reverses the amphetamine-induced LI deficits in rats [43]. Various studies 
have used LI in the framework of establishing animal models of 
schizophrenia. Some of these will be discussed later in this chapter.  
 
2.5. Memory 
 Perhaps one of the most intensively studied affected cognitive domains in 
schizophrenia is memory. In particular, working memory has gained a 
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considerable amount of scientific attention. Deficits in memory processes 
have been consistently reported in individuals with schizophrenia [for review, 
see ref. 44]. Several studies have demonstrated altered activation of prefrontal 
cortical brain regions, substantially involved in executive functions and 
working memory [e.g. refs. 45, 46]. Notably, deficits in working memory are 
believed to be a behavioral and cognitive marker for schizophrenia, as some 
studies have demonstrated that working memory deficits are specific to 
schizophrenia, not to other mental disorders [47]. Working memory is, 
simply speaking, the ability to hold information in temporary storage to 
successfully complete the running task [48]. Again, rodents have a wide 
repertoire of behavioral traits, thus allowing assessment of memory functions. 
Due to space limitations, we will not review tasks used to assess memory in 
rodents. Several papers give an extensive and adequate overview of memory 
tasks, predominantly working memory, of rodents [49, 50].  
 Taken together, rodents possess various behavioral traits which are 
analogous to clinical domains implicated in schizophrenia. This provides the 
ground for developing rodent models of the disease. In the following 
sections, existing rodent models will be discussed and evaluated on the basis 
of their validity issues.  
 
3. “Past” 
  In this part we will discuss animal models which have been used in the 
past. The time categorization “past, present and future” should not be 
understood as a judgment of the scientific impact of these models. Rather, we 
are using this classification to illustrate the scientific trend and to describe the 
progress, based on clinical and basic research, made in the context of 
modeling schizophrenia in animals. For the purpose of this chapter, we adapt 
the definition of animal models made by Marcotte and colleagues [10]. Thus, 
an animal model is “an experimental manipulation that elicits behavioral and 
neurochemical changes that can be related to schizophrenia using the criteria 
for predictive, construct and face validity” [10]. Reliable and well 
characterized indicators of schizophrenia in humans such as deficient 
information processing and pre-attentive functions as measured by prepulse 
inhibition [51] and latent inhibition should not be considered animal models 
for schizophrenia in their own right. These are valid behavioral paradigms 
widely used in schizophrenia research and are therefore important single 
tools within a battery characterizing the behavioral phenotype of a potential 
animal model.  
 For simplicity, “past” animal models are here subdivided into two big 
groups: 1. Pharmacological models and 2. Neurodevelopmental models.  
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3.1. Pharmacological animal models 
 Perhaps the most famous hypothesis on the pathophysiology of 
schizophrenia is the dopamine hypothesis of schizophrenia [52, 53]. In brief, 
the hypothesis states, that there is an excess of dopamine in the brains of 
schizophrenia patients [53]. This hypothesis was expanded and revised in the 
last years, also to account for negative and cognitive symptoms of 
schizophrenia [for review, see refs. 54, 55]. Nowadays, it is widely believed, 
that some deficits seen in schizophrenia are due to two dopamine related 
processes: Hyperactive dopamine system in mesocortical brain regions, 
accounting for positive symptoms, and hypoactive prefrontal dopamine 
system resulting in negative symptoms and cognitive deficits [55, 56].  
 Effects of amphetamine administration on non-schizophrenics [57] as 
well as reports describing schizophrenia-like symptoms elicited by 
amphetamine (so called “amphetamine psychosis”, [58]) were some hints 
directing to the formulation of the dopamine hypothesis of schizophrenia. It 
is thus not surprising that the first rodent models of schizophrenia were 
those using dopamimetics to elicit schizophrenia-like symptoms. 
Administration of amphetamine and related psychotomimetics in rodents 
reliably elicits hyperlocomotion and stereotypy [23], behavioral alterations 
that are widely believed to be schizophrenia relevant traits analogous to 
positive symptoms in humans [19]. As mentioned earlier in this chapter, the 
correspondence between rodent “positive symptoms” and positive symptoms 
in schizophrenia patients might be debatable. However, the reliable 
replications of this finding in rodents, as well as the involvement of the 
relevant neurotransmitter systems make this feature of dopamimetics 
administration very useful for comparison among species and different 
models [10].   
 Animal models using psychotomimetics have also another important 
feature: Dopamine agonists disrupt PPI. This is the case for humans [59] as 
well as for rodents [60]. Based on the finding, that schizophrenia patients 
have disrupted PPI [61, 62] and that disruptions in sensorimotor gating and 
information processing are believed to be some of the characteristics of the 
disorder, pharmacological rodent models of schizophrenia, at least those 
using dopamimetics, seem to have at least some construct validity. 
Interestingly, antipsychotic medication, such as clozapine, reverses PPI 
deficits in some schizophrenia patients [63] and in apomorphine-treated 
rodents [64]. To sum up, previous rodent models using psychotomimetics or 
dopamine agonists succeeded in eliciting some core features of schizophrenia 
in rodents. Despite fairly good predictive and face validity, the construct 
validity is still limited [10], due to ignoring the genetic basis of the disease 
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[e.g. ref. 65]. On the other hand, it is not surprising, that pharmacological 
models have good predictive validity as they elicit psychosis in healthy 
humans [57] and deteriorate symptoms in schizophrenia patients [66]. 
Nevertheless, the involvement of dopamine and its interactions with other 
neurotransmitter systems in the pathophysiology of schizophrenia is not yet 
resolved. Moreover, there are some treatment-resistant schizophrenia 
patients, who do not benefit from dopamine antagonists [67, 68]. Also the 
lack of responding of negative symptoms upon classic antipsychotic 
medication reduces the construct validity of dopamine models.  
 Not only dopamimetics attracted attention regarding their potential 
involvement in the pathophysiology of schizophrenia. The administration of 
the dissociative anesthetic phencyclidine (PCP) – and its analogue ketamine – 
in healthy subjects was reported to produce a syndrome closely resembling 
schizophrenia with positive symptoms (paranoia, hyperlocomotion and 
auditory hallucinations), negative symptoms (social withdrawal, affective 
flattening and anhedonia) and cognitive symptoms (e.g. impaired working 
memory) [69]. PCP and ketamine are noncompetitive NMDA glutamate 
receptor antagonists. Their schizophrenia resembling effect was first 
discovered during their initial use as anesthetics [70]. Clinical data showed 
decreased glutamate levels in the cerebrospinal fluid of schizophrenic 
patients [71]. Moreover deficits in PPI due to administration of NMDA 
antagonists are reversed by clozapine, an atypical antipsychotic [72, 73]. 
Based on the effect of PCP in healthy volunteers, it was proposed that 
schizophrenia may involve reduced NMDA receptor function [74, 75]. In 
rodents, PCP and related substances such as MK-801 produce a picture 
similar to that in humans. Intrastriatal injections of a selective NMDA 
receptor antagonist, AP5, in rats led to a selective impairment in working 
memory (T-maze) performance, while spatial memory (radial arm maze) was 
intact [76].  Also in the rat, administration of MK-801 and PCP significantly 
disrupted PPI [77]. Moreover, rats treated with PCP had deficits in social 
behavior, while the typical antipsychotic haloperidol reversed some of these 
deficits [78]. For a review on rodent glutamate models of schizophrenia, the 
reader is referred to [74].  
 Although the glutamate hypothesis of schizophrenia may bear many 
similarities with the clinical manifestation of schizophrenia [for a discussion 
see ref. 74] and possesses good predictive and face validities, again, as the 
case with the dopamine hypothesis, the construct validity is limited [10]. For 
example, some findings in PPI are highly dose dependant. In some cases, 
sub-anesthetic PCP and ketamine administration did not have any effect on 
PPI. In other cases, it even elicited an enhanced inhibition [79]. Indeed, there 
are various interactions between the glutamatergic and dopaminergic systems 
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[80] and both seem to be involved in the neurobiology of schizophrenia. But 
the way how one neurotransmitter system or another elicits/affects the wide 
spectrum of symptoms over the course of the disease remains unclear.  
 To conclude, pharmacological animal models addressing different 
neurotransmitter systems, involved in the pathophysiology of 
schizophrenia, are undoubtedly of great value for unraveling of disease and 
treatment mechanisms. Nevertheless, pharmacological models, directly 
manipulating specific neurotransmitter systems, could not account for some 
other features of schizophrenia, for example neuroanatomical abnormalities 
in patients [81] and relatives [82], or cognitive deficits in first-degree 
relatives [83, 84]. These and other features are out of the scope of direct 
pharmacological induction. Other models were developed to address aspects 
of disease dynamics and course. These models will be discussed in the next 
section. 
 
3.2. Neurodevelopmental models 
3.2.1. Clinical evidence and theoretical basis 
 As was shown in the section before, most conventional animal models 
have studied effects of direct manipulations of specific neurotransmitter 
systems, especially dopamine. This is due to the strong implications of 
dopamine in the disorder. However, it has become clear that models based on 
direct manipulations of the dopaminergic system have a limited heuristic 
(“serving to discover”) value [11]. Moreover, they do not address 
mechanisms involved in either cortical deficits [85] or the postpubertal onset, 
that also characterizes schizophrenia. Structural abnormalities in the brains of 
schizophrenia patients have been excessively documented and led to the 
assumption, that degenerative and/or neurodevelopmental processes are 
involved in the etiology of the disorder. For example, enlargement of the 
lateral and third ventricles [86], reduced volume of cortical grey matter [87] 
and smaller anterior hippocampi [86] were some widely reported findings. 
The reductions of grey matter do not seem to be a general deficit; rather it 
appears that they affect association cortices such as those located in the 
superior temporal gyrus, in the dorsal prefrontal cortex and in limbic regions 
including hippocampus and anterior cingulate [81, 88]. Importantly, many of 
these abnormalities were found in first-episode [89], never medicated 
subjects. Thus, the structural pathology seems to reflect a primary disease 
process [3]. 
 The hippocampus and the prefrontal cortex (PFC) proved to be 
imperative for the pathology of the disease, both due to structural 
abnormalities [81, 88, 90, 91] and partially corresponding cognitive defects 
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[92, 93], a core feature of the disease. For instance, reduced regional cerebral 
blood flow in the dorsolateral PFC (DLPFC) in chronic schizophrenia during 
performance of an established executive task, the WCST [85, 93] was 
reported. The discovery that the prefrontal cortex could regulate subcortical 
dopamine [94] offered a promising link between the suggested subcortical 
dopamine dysregulation and data assuming the involvement of the PFC in 
schizophrenia [93]. Other data also consistently reported cell loss in the 
hippocampus [95], while initial reports of hippocampal neuron misplacement 
in the superficial layers of the adjacent entorhinal cortex have not been 
replicated in various following studies [96]. However, PFC structural 
abnormalities were less consistently replicated, while hippocampal pathology 
was most reliably observed [for review, see ref. 81]. 
 There has been a considerable debate, whether the observed structural 
abnormalities and clinical manifestations are due to neurodegenerative 
processes or whether they are a result of neurodevelopmental deficit [97, 98]. 
The clinical deterioration [99] as well as the progressive cortical grey matter 
loss [100] may reflect the involvement of degenerative processes. On the 
other hand, ventricular enlargement and size do not seem to correlate with the 
duration of untreated illness [101]. Whereas gliosis in postmortem studies 
[102], evidence for most degenerative processes [103], is lacking, recent 
evidence suggests a role of apoptotic mechanisms in the disease process [104, 
105]. Interestingly, schizophrenia patients do not seem to carry an increased 
risk of Alzheimer disease [106]. It has also been reported, that intellectual 
and cognitive functions do not much further decline with age in 
schizophrenia [107]. Taking all these points into account, schizophrenia is a 
primarily neurodevelopmental disorder, with neurodegenerative processes 
contributing to pathophysiology and disease progression. 
 Neurodevelopmental models of schizophrenia test the hypothesis that 
schizophrenia is caused by a defect in brain development [108]. Some models 
attempt testing etiological theories, studying the role of maternal malnutrition 
[109, 110], viral infections during pregnancy [111] and obstetric 
complications [112]. Others address the impact of disrupted neuronal 
maturation and synaptogenesis [113] and the relevance of early stressful 
events [114]. Discussing all these models in detail is out of the scope of this 
chapter. Readers are referred to Lipska and Weinberger [11], for review.  
 In this chapter we will focus on another group of neurodevelopmental 
models with quite promising implications for schizophrenia: Lesion models. 
First, we will report on existing lesion models targeting different brain areas 
with implication in schizophrenia. Then, we will focus on the neonatal 
hippocampal lesion model, which possesses significant validity concerning 
modeling disease emergence, course, and core symptoms of schizophrenia.  
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3.2.2. Lesion models  
 Based on the pathology observed in specific brain regions in 
schizophrenic patients, it became obvious to investigate whether disrupting 
these neuronal and functional circuitries would mimic clinical manifestations 
seen in schizophrenia. This idea was operationalized by damaging 
corresponding brain regions in adult rodents, and studying the direct effect on 
behavior and cognition of this disruption. There is a great deal of research 
done in the adult (i.e. at postnatal day 42) rodent brain. While first attempts in 
inducing a lesion were crude and relatively tissue unspecific (e.g. aspiration 
lesions), newer approaches became more precise with less damage to 
adjacent tissue. For instance, a widely used method to disrupt specific brain 
sites is the stimulation of excitatory glutamate release or the administration of 
direct glutamate receptor agonists (e.g. kainic acid), and thus producing 
relatively selective lesions, damaging predominantly pericaryal sites [115]. 
Electrolytic lesion techniques, on the other hand, destroy neuronal cell bodies 
as well as axons. 
 In the 70ties, scientists developed methods for selectively lesioning 
central norepinephrine and dopamine containing neurons in the neonatal rat 
brain. This was done by using 6-hydroxydopamine, an approach, originally 
applied in animal models of Parkinson’s disease as well as in mimicking self-
injurious behavior in the context of the Lesh-Nyhan syndrome [116, 117].  
 Another approach addressed the transient, not permanent, inactivation of 
specific brain regions during a critical time window of brain development. 
Lipska and colleagues [118], used tetrodotoxin (TTX), a potent and specific 
blocker of the voltage-gated Na+-channels to inactivate the ventral 
hippocampus in neonatal rats. As its effect is completely reversible, this 
method does not result in permanent, vast damage of the brain.  
 
The prefrontal cortex (PFC) 
 It is not surprising, that a region like the PFC with its subdivisions is one 
of the most intensively studied brain sites in schizophrenia [44, 85, 93, 119]. 
As mentioned earlier, abnormalities in structure as well as metabolism were 
consistently reported in human studies. Also cognitive functions, which arise 
from this brain area (e.g. organization of behavior, behavior monitoring, 
executive attention, inhibition and facilitation) are often reported to be 
compromised in schizophrenia patients [44, 89]. In the rat, medial and lateral 
PFC are considered as homologues of the primate dorsal PFC and orbital 
PFC, respectively. The medial PFC (MPFC) is implicated in working 
memory tasks. It has been hypothesized that the MPFC is primarily engaged 
in the temporary storage and processing of information lasting from 
milliseconds to several seconds [120]. Lesions of the rat adult MPFC result in 
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various behavioral and neurochemical deficits also seen in schizophrenia, for 
example, increased responsiveness to dopamine agonists [121], decrease in 
haloperidol-induced catalepsy and initiation of stereotypic behavior [122], 
apomorphine-induced PPI deficits [123] as well as hypersensitivity to stress 
[124]. Fourteen days – but not 28 days – postoperatively, bilaterally ibotenic 
acid MPFC lesioned rats showed increased spontaneous locomotion as well 
as apomorphine-induced hyperactivity. Levels of noradrenalin in the 
cingulate cortex were reduced, while dopamine, DOPAC as well as 
homovanillic acid in the medial striatum were increased [124]. Also deficits 
in higher brain functions were apparent in MPFC lesioned animals. Ibotenic 
acid lesioned rats manifested symptoms resembling those of dysexecutive 
syndrome in humans. MPFC lesions resulted in disruption of decisional 
processes, as the performance of the lesioned rats was on a random level in a 
task addressing decision making [125]. In an analogue of the WCST, which 
is usually applied to assess executive functions in humans and widely used in 
schizophrenia research, the performance of electrolytically MPFC lesioned 
adult rats was impaired, while the LI effect was intact [126]. In a recent study 
comparing lateral and medial prefrontal cortical lesions in rats, lateral 
prefrontal lesions did not affect the behavior of the experimental group in any 
of the paradigms used in this study. On the other hand, an increase in PPI was 
reported in rats with medial prefrontal cortex lesions, while LI was not 
affected [127].  
 Lesions affecting the PFC with its subdivisions resemble somewhat the 
cognitive symptoms of schizophrenia. It was mentioned earlier, that the 
dopamine innervation in the MPFC is implicated in the regulatory inhibition 
of several dopamine terminal fields. Several lines of evidence propose that 
specifically the MPFC can influence subcortical dopamine [128-131].  
 The behavioral alterations seen in the studies discussed above go in 
concert with augmented mesolimbic and nigrostriatal dopamine activity [132-
135]. Treatments counteracting these effects (e.g. neuroleptics) reverse 
behavioral symptoms [132, 133]. Thus, lesions in the PFC have good 
predictive and face validity. However, the lack of evidence for a “lesion” 
underlying the behavioral and cognitive disturbances seen in schizophrenia 
presents a great obstacle for the construct validity. This is of course an aspect 
which also holds true for the following lesion models, addressing different 
brain regions.  
 
Thalamus 
 The thalamus is a composite of multiple nuclei that relay and filter 
sensory inputs, a function which involves multiple corticostriatothalamic 
loops modulated by the cerebral cortex [for review, see ref. 136]. Based on 
 Ahmed El-Kordi et al. 226
human data, the thalamus and its nuclei moved into the scope of interest in 
schizophrenia research. Thalamic nuclei are involved in the regulation of PPI 
and sensorimotor gating [137], both are features affected in schizophrenia 
patients [35]. Furthermore, using magnetic resonance imaging, it was shown 
that lower relative glucose metabolism in the pulvinar was associated with 
more hallucinations and more positive symptoms, while lower relative 
glucose metabolism in the mediodorsal thalamic nucleus was associated with 
more negative symptoms in non-medicated patients [138]. Also other studies 
could replicate similar findings of reduced thalamic activity [139], pointing to 
deficits in filtering and information processing seen in schizophrenia patients 
[62]. Decreased activation within the whole thalamus, anterior nuclei and the 
medial dorsal nucleus were found using fMRI during performance of 
memory tasks in patients [140]. While functional findings seem to be 
consistent, structural findings are to a certain degree heterogeneous. Some 
post-mortem studies proved abnormalities in thalamic volumes in 
schizophrenia [141], while others failed to replicate this finding [142]. 
 Among other thalamolimbic sites, the habenular complex is believed to 
be a key component in various physiological functions. It builds the dorsal 
diencephalic conduction system with both the stria medullaris and fasciculus 
retroflexus [143, 144] and serves as a link between the limbic forebrain and 
the midbrain-extrapyramidal motor system. The habenula was reported to be 
involved in some psychiatric disorders [144] including schizophrenia [145, 
146]. Lesions of the habenula lead to a variety of behavioral alterations. 
Specifically, habenula-lesioned rats tested in a task measuring attention (Five 
choice serial reaction time task, 5CSRTT) demonstrated a time-dependant 
behavioral pattern. After the lesion, rats had an increase in premature, 
impulsive responding, which improved with time. Selective attention did not 
show deficits at the beginning, but deteriorated afterwards. Administration of 
amphetamine increased, while haloperidol decreased premature responding 
[147]. These findings serve as a link between attentional deficits in 
schizophrenia, limbic dopaminergic hyperactivity and potential structural 
abnormalities in the habenular complex. Additionally to thalamic structural 
abnormalities seen in schizophrenic patients [148], this finding is in some 
agreement with the deficit in attentional performance of affected individuals 
[149]. However, thalamus lesions often produce a syndrome of central pain 
and ataxia [for review, see ref. 150], symptoms not observed in 
schizophrenia. As with other lesion models, the construct validity is very 
limited.  
 In the context of subcortical lesion models, there are various studies 
looking at the effect of intracerebroventricular lesion using kainic acid [e.g. 
refs. 151, 152, 153]. Administration of kainic acid in the rat brain leads to an 
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immediate as well as delayed neuronal cell death in the hippocampus and 
other regions of the medial temporal lobe. It was originally used as an animal 
model of neurodegeneration, implying potential relevance of these 
mechanisms for the pathophysiology of schizophrenia, too [153]. 
Intracerebroventricularly administered kainic acid produces an increase in 
locomotor activity in a novel environment. More grooming was also reported 
at the beginning of testing in lesioned rats [152]. Additionally, increased 
dopamine receptor binding in the nucleus accumbens has been reported 
[151], a finding, which was also observed in adult lesions of the 
hippocampus, that will be discussed below.  
 The apparent destruction and artificiality of this lesion type hamper 
drawing a link to schizophrenia, despite the resemblance of some symptoms. 
Nevertheless, this model results quite often in seizures [e.g. ref. 151] and 
unnecessary suffering of the animals, and should be regarded with caution.  
 
Hippocampus 
 As mentioned earlier, the hippocampal formation gained a significant 
amount of experimental attention due to consistent findings in schizophrenia 
patients [86, 154] and because this brain site projects to the prefrontal cortex 
[155, 156] and participates in the regulation of the mesolimbic dopamine 
system [157]. In this section we will consider hippocampal lesions, again in 
the adult rat. Research has been focused predominantly on two parts of the 
hippocampal formation: Dorsal and ventral hippocampus (DH and VH, 
respectively) with both leading to different phenotypes. Ventral hippocampal 
lesions have been reported to result in differential neurochemical pattern in 
cortical and subcortical areas, resembling core symptoms of schizophrenia. 
This site has been chosen as lesion target because it directly projects to the 
prefrontal cortex [158] and corresponds to the anterior hippocampus in 
humans, the region which shows structural abnormalities in schizophrenic 
patients [86]. Both lesions of the DH and the VH enhance various dopamine-
mediated behaviors, e.g. spontaneous locomotion, amphetamine-induced 
hyperactivity and stereotypy [122, 159, 160], while the behavioral effects 
observed were site specific. For instance, ibotenic acid lesions of the DH 
induced a transient increase in spontaneous locomotion, but not in 
amphetamine-induced hyperactivity [159]. On the other hand, VH lesion 
permanently affects both exploratory activity and amphetamine-induced 
hyperactivity [160]. Indeed, spontaneous activity following hippocampal 
lesion has been reported to be site specific [161] with permanent increase 
after ventral or combined dorsal-ventral lesions, but only transient increase 
after dorsal lesions. One reason for this finding might be that major 
hippocampal striatal projections arise in the ventral hippocampus and 
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innervate ventral parts of the striatum [162]. Moreover, it has been proposed, 
that the dorsal hippocampus might affect striatal functions indirectly through 
its connections with the ventral part [163]. In a study comparing prefrontal 
cortical and both hippocampal (VH and DH) lesions, rats with either MPFC 
or VH lesions showed reduced haloperidol-induced catalepsy, while DH 
lesions did have no significant effect. Also in the same study, DH as well as 
VH ibotenic acid lesions demonstrated less frequent oral stereotypies than 
control animals [122]. Both dopamine antagonist-induced catalepsy and 
dopamine agonist-induced stereotypies are believed to be largely dependent 
on postsynaptic dopamine-mediated mechanisms in the striatum [122].  
 The results shown in studies using adult hippocampal lesions, especially 
ventral lesions, have great resemblance with schizophrenia symptoms, 
predominantly addressing positive symptoms and dopamine-mediated 
deficits. Thus, adult hippocampal lesion models have both face and predictive 
validity.   
 The most limiting shortcoming of all lesion studies in general is the lack 
of observed lesions in schizophrenia. In particular, brain injuries in the adult 
do not lead to schizophrenia. However, they may give rise to various 
dopamine-mediated symptoms, which are observed in schizophrenia and can 
be reversed by neuroleptics. Structural abnormalities as well as neurologic 
soft signs in schizophrenia patients led to the idea, that there is an early 
developmental injury that remains relatively silent until adulthood [85, 164]. 
In this context, schizophrenia represents a unique case, as it was shown, that 
the degree of functional compensation increases with the postinjury interval 
(also called “Kennard principle” [165]). Schizophrenia represents the 
opposite process with successful functional sparing during short postinjury 
intervals (i.e. before adulthood) and deficient sparing during long postinjury 
periods (i.e. after puberty, adulthood) resulting in the emergence of the 
already described schizophrenia symptoms. Following this rationale, Lipska 
and co-workers – among others – suggested, that the effects of early (i.e. 
neonatal) hippocampal damage in limbic dopamine systems would not be 
attenuated by maturation, instead, it would emerge with maturation (the so 
called “schizophrenia principle” instead of “Kennard principle”) [166]. The 
following section will therefore focus on a very influential animal model of 
schizophrenia: The neonatal ventral hippocampal lesion model.  
 
The neonatal hippocampal lesion  
 As described above, adult lesions enhanced our understanding 
concerning mesolimbic and corticostriatal dopaminergic pathways. However, 
their heuristic value in modeling a broad spectrum of schizophrenia 
symptoms as well as disease emergence and progression is somehow limited. 
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Following the procedure used in adult lesions, excitotoxic agents (e.g. 
ibotenic acid) were also applied in the neonatal lesion model. The main 
difference is the lesion time point. In this model, bilateral lesions to the 
ventral hippocampus were made on postnatal day 7 (PD 7), thus inducing an 
insult of the hippocampus, which disrupts the development of relevant 
cortical and subcortical circuitry in which the hippocampus participates. 
Again, the lesion targeted the ventral hippocampus, because it directly 
projects to the prefrontal cortex [158] and corresponds to the anterior 
hippocampus in humans, a region, whose relevance for schizophrenia was 
demonstrated [86].   
 The most intriguing aspect of this animal model is the postpubertal 
emergence of symptoms. Tested at PD 35, lesioned rats do not show 
significant behavioral aberrations. However, testing them at PD 56 (i.e. early 
adulthood), rats with VH lesion demonstrate symptoms similar to 
psychotomimetic models discussed earlier as well as to schizophrenia [166]. 
Providing that results of this model have been reviewed repeatedly and 
intensively elsewhere [10, 11, 108], we will focus on some predominantly 
behavioral features of this model with high face validity.  
 Similar to sensitization to psychostimulants, neonatally lesioned rats 
show at PD 56, but not at PD 35, increased activity as response to novelty as 
well as after amphetamine administration. These symptoms were reversed by 
haloperidol. At PD 70, neonatally lesioned rats display markedly increased 
activity after stress [166]. The changes in the reported behaviors are believed 
to be primarily related to increased mesolimbic and nigrostriatal dopamine. It 
has also been reported, that lesioned rats showed no differences in 
haloperidol-induced catalepsy when tested on PD 35, while apomorphine 
administration increased locomotor activity at this time point. Contrary to 
that, as young adults (PD 56), lesioned rats showed reduced catalepsy 
following haloperidol, while the apomorphine-induced hyperactivity was still 
apparent [167]. Interestingly, clozapine (as an atypical antipsychotic) as well 
as haloperidol (typical antipsychotic) could suppress hyperlocomotion [168], 
but clozapine was not effective for reversing social deficits [169].  
 Other studies demonstrated that neonatally ventral hippocampal lesioned 
rats have altered dopamine release in the striatum, nucleus accumbens and in 
the frontal cortex in response to mild repeated stress as well as after chronic 
haloperidol administration. This manifested itself in a modest reduction in 
baseline striatal dopamine release, which became more pronounced after 
chronic stress [170]. Contrary, chronic haloperidol treatment resulted in 
increased dopamine release in the same regions.  
 Concerning motivational and reward related behaviors, which are 
involved in the negative symptoms in schizophrenia, some studies reported 
 Ahmed El-Kordi et al. 230
deficits in reward mechanisms [171], reduction in saccharine preference as 
well as deficit in amphetamine-induced conditioned place preference only in 
neonatal VH lesion, not in adult lesion [172]. Also there are various findings 
supporting the face validity of this model, as they show social deficits 
resembling those seen in schizophrenia.  
 The observed decrease in social interaction time [173] was increased by 
clozapine in some studies [174], but not in others [169]. It has also been 
shown, that social memory is impaired and that haloperidol was partially 
effective in attenuating this symptom [175]. It is intriguing, however, that 
social deficits were observed at both PD 35 and PD 65, although 
hyperactivity was only present after puberty [169]. Interestingly, deficits in 
spatial memory were also observed with no time delay. They were present at 
PD 25, 40 and 80 [176]. These findings resemble the clinical picture seen in 
schizophrenia, with negative symptoms, e.g. social withdrawal, and some 
cognitive deficits existing already long before the onset of positive 
symptoms.  
 Also, deficits in working memory and functions which require the 
functional integrity of the PFC have been demonstrated in this model. For 
example, in a study using T-maze, two related working memory tasks were 
applied: 1. The continuous delayed alternation and 2. The discrete paired-trial 
delayed alternation task [177]. Lesioned rats required longer time to learn the 
former, while working memory was shown to be compromised in the latter. 
Furthermore, deficits in sensorimotor gating and attentional processes have 
also been reported in neonatal VH lesioned rats [178, 179]. Consistent with 
other studies [180], there was no difference in startle response, but there were 
deficits in PPI which were reversed by atypical, but not typical, 
antipsychotics [179]. The reported behavioral phenotype seems to be 
mediated by genetic influence, which might attenuate or enhance the 
susceptibility to the VH lesion effects [181].  
 Interestingly, these symptoms could not be explained by the boost of 
gonadal hormones in puberty, as the absence of these by means of castration 
did not prevent the emergence of behavioral disturbances in adulthood. On 
the contrary, it enhanced those linked primarily to the mesolimbic dopamine 
system [182]. Furthermore, it has been shown that removal of PFC neurons in 
adult animals with neonatal lesions can restore some of the behavioral 
alterations [183]. This suggests that this behavioral phenotype is due to 
abnormal or dysregulated PFC activation resulting in increased subcortical 
firing upon dopaminergic subcortical stimulation.  
 Concerning molecular and electrophysiologic aspects, a considerable 
amount of research suggests that abnormal cortical interaction between the 
neurotransmitter systems dopamine, glutamate and GABA may give rise to 
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cortical dysfunction in the neonatally VH lesioned rats. Many of these 
findings have been observed in schizophrenic patients, e.g. reduced glutamate 
decarboxylase-67 (GAD-67) expression, reduced BDNF expression and 
changes in neuronal morphology  [for overview, see refs. 108, 184, 185].  
 Interestingly, it has been shown that neonatal VH lesions lead to 
prominent and widespread cell death even in brain areas distant from the 
lesion site, while cell death is restricted to the lesion area in the analogous 
adult model [186]. 
 Unlike pharmacological models, the neonatal VH lesion model affects 
other neuroanatomic and functional systems outside the hippocampus and 
elicits a unique time-dependent behavioral and physiological phenotype 
reminiscent of schizophrenia. As was mentioned before, this model possesses 
good predictive as well as face validity. Many symptoms are reversed by 
atypical antipsychotics resembling treatment effects observed in clinical 
populations. As was discussed earlier in this chapter, newer studies based on 
this model also apply transient, not permanent, “lesions”. Using tetrodotoxin 
makes the transient inactivation of the VH during a critical period of 
neurodevelopment possible [187]. The behavioral phenotype induced by this 
model is similar to that of the permanent lesion, however, the magnitude is 
smaller compared with those observed after the excitotoxic lesion. Moreover, 
the reversible hippocampal disconnection does not lead to significant social 
deficits as seen in the permanent model [118].  
 To sum up, adult and neonatal lesions discussed in this section produce 
symptoms relevant for schizophrenia, while the neonatal lesion model has 
more heuristic value and resembles the clinical course and temporal pattern 
as well as the symptoms of the disease. Table 2 illustrates the phenotype of 
both adult and neonatal lesion models and compares their main 
corresponding findings.  
 As it was portrayed in this section, lesion models, whether in adult animals 
or in the neonate, enhanced our understanding concerning putative temporal as 
well as physiologic mechanisms of relevant features of schizophrenia. They 
filled the gap, which was present in pharmacological models and illustrated a 
potential mechanism underlying the delayed emergence of psychotic 
symptoms. Compared to direct pharmacological manipulation models, lesion 
models accounted for many schizophrenia relevant symptoms. However, the 
most prominent shortcoming in these models is their artificial character in 
inducing a “lesion”. Recent developments are still based on the idea of early 
brain injuries, which might be induced by different toxins or other hazardous 
agents. These might act directly on the brain (neurotrauma, brain contusion, 
viral infections, malnutrition, etc.) or indirectly via psychological mechanisms 
(e.g. psychosocial stressors and psychotrauma). But this is not the only possibility 
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Table 2. Comparison between the phenotype of adult versus neonatal bilateral ventral 
hippocampal lesion in the rat. 
 
Domain Adult lesion 
(at postnatal day 42+) 
Neonatal lesion 
(at postnatal day 7) 
Hypersensitivity  
to stress 
Adult lesion does not lead to 
hypersensitivity to stress  
(i.e. no increased activity  
after saline injection or after  
swim stress) [160] 
 
Neonatal lesion leads to 
hypersensitivity to stress and 
resembles in this respect the adult 
lesion of the medial prefrontal 
cortex [124] 
 
Haloperidol-induced 
catalepsy 41% decrease of catalepsy 51% decrease of catalepsy [167] 
Apomorphine-induced 
hyperactivity Both lesions lead to apomorphine-induced hyperactivity [167, 172] 
Apomorphine-induced 
stereotypy Reduced stereotypic responses
Potentiation of stereotypic responses 
[167] 
Memory No memory impairment Memory impairment [177] 
Reward sensitivity No deficit Deficit in reward sensitivity [172] 
Cellular and neuronal 
pattern of lesion 
Cell death is restricted to the 
ventral hippocampal area 
Widespread and prominent cell 
death, even in sites distant from  
the lesion area (striatum, 
nucl.accumbens, cortical areas 
surrounding the VH) [186] 
 
for inducing a lesion. Indeed, recent models are guided by the notion of 
“genetic lesion”. In other words, the observed phenotype in conventional adult 
and neonatal lesion models might be produced not by means of mechanical 
induction, but, due to dysfunctions in neuronal maturation, migration and/or 
differentiation. Providing that schizophrenia has a strong genetic background 
and due to the recent vast development and advance in genetic engineering and 
technology, present models focus on the effects of some candidate genes, 
which have been shown to be involved in the pathophysiology of schizophrenia 
in population studies. These models are the topic of the next section.  
 
4. “Present” 
4.1. Genetic models 
 Schizophrenia is a highly heritable disease. The population incidence is 
0.17-0.57 per 1000, and the point prevalence is 2.4-6.7 per 1000 reflecting 
the typical disabling chronic clinical course of the disease [188]. Using 
family, twin and adoption studies, it has been demonstrated, that the morbid 
risk of schizophrenia in relatives correlates with the degree of genes shared 
[189]. In contrast to lifetime morbid risk in general population of 1% [190], 
the incidence of schizophrenia is 6%-17% in first degree relatives             
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(e.g. parents, siblings) of an individual with schizophrenia. In monozygotic 
twins, who have 100% of their genes in common, the morbid risk increases to 
approx. 50%. Notably, even in this case, where the genetic background is 
identical, the risk to be affected is – fortunately – not fully determined. This 
fact gives credence to the role of non-genetic factors, e.g. environmental and 
social influences. Interestingly, the risk estimations as well as the emergence 
of schizophrenia seem to be universal [191] and fairly consistent across 
different racial groups [192].  
 The main focus of present schizophrenia research is set on the 
elucidation and determination of genetic factors increasing susceptibility to 
the disease. Studies in the last two decades have demonstrated that 
schizophrenia is not a monogenic, unifactorial disease. There is almost 
uniform agreement on the involvement of non-Mendelian mode of 
inheritance. The prevailing notion implies polygenic transmission with 
interacting environmental factors [189]. New research approaches aim at 
identifying genetic markers, which significantly co-exist with the disease in a 
relatively diagnosis-specific manner within affected families (i.e. genetic 
linkage studies) or within populations (i.e. genetic association studies) [193].  
 A great body of clinical and basic research evidence shed light on the 
putative role of some susceptibility genes for schizophrenia. Indeed, it has 
been an enormous amount of genetic linkage and whole genome scan studies 
accumulating for the last twenty years. Some of which has been evaluated in 
large meta-analysis studies [194, 195].  
 The vastly increasing advances in genomics and gene technologies 
facilitated the investigation of the genetic underpinnings of complex 
behavior. In contrast to the leading part of the rat in the past, the laboratory 
mouse settled into the center of scientific attention as being the most 
important model organism in the study of psychiatric genetics. This is not 
only due to the biological and physiological homology in wide parts of brain 
organization as well as the numerous features of behavioral repertoires mice 
and humans share, but also to practical issues (e.g. efficiency in breeding, 
economical maintenance, space saving due to small body size, etc.) that have 
contributed to the wide popularity of the laboratory mouse as a main 
modeling organism for molecular psychiatric research [196]. Besides, mouse 
and human genomes have been reported to share many similarities [197].  
 Improved and precise methods in gene targeting, conditional knock-out 
and transgenic technologies [198] as well as targeted mutations paved the 
way for studying and modeling complex issues like depression, circadian 
rhythm, narcolepsy, aggression, social interaction and stress-related 
behaviors [199, 200] in the mouse. Indeed, current methods open the 
opportunity for generating mutant mice carrying virtually any given gene of 
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interest [196]. This development was also supported by the increasing 
understanding of molecular and cellular mechanisms in concert with genetic 
influences in modulating sophisticated functions, e.g. cognition.  
 The availability of the Mouse Genome Database, which unites genomic 
and phenotypic information about the laboratory mouse and contains (up to 
September 2007) approximately 29.000 sequenced genes [201] and the vast 
sequencing of the mouse genome [202] accelerated the generation of diverse 
mouse models of psychiatric disorders, including schizophrenia, all over the 
world. However, despite the optimistic perspective evolved from current 
technical advances and the fast increasing efforts to complete the mosaic of 
the genetics of schizophrenia and mental disorders, developments in this field 
have soon posed various further problems. These could be divided in two 
groups: First, methodological considerations inherent in genetic modeling of 
mental disorders and addressing cognitive functions in mice and, second, the 
nature of clinical diagnosis of schizophrenia including the lack of objective 
and clear-cut markers of the disease. 
 In addition to disease heterogeneity and the lack of objective state-
independent markers, the plurivalent outcomes of genetic modifications as 
well as the imperfect relation between genes and behaviors underline the 
necessity of quantifiable, detectable and reliable disease markers. In this 
context, studies of biological markers of psychiatric disorders have yielded an 
overwhelming amount of ambiguous biological and physiological indicators, 
many of which are not disease-specific and tend to confound with other 
physiological parameters. Moreover, these often single findings have limited 
reproducibility both among and within patients [203]. Taking this into 
consideration, the definition of “endophenotypes” (i.e. intermediate 
phenotypes) presents a useful tool for diagnosing and studying the genetic 
mechanisms in mental disorders [204]. According to Gottesman and Gould 
[205], endophenotypes have to fulfill the following criteria to be called such: 
(1) The endophenotype is associated with illness in the population. (2) It is 
heritable. (3) It is state-independent (i.e. it is detectable in the affected 
individual whether or not the illness is active). (4) Endophenotype and illness 
co-segregate within families. (5) It is found in affected as well as in 
unaffected family members to a higher rate than in the general population. 
 In the previous sections some putative endophenotypes have been 
discussed. For example, sensorimotor gating (usually measured by means of 
prepulse inhibition) and working memory tasks are believed to be 
endophenotypic behavioral and cognitive domains, respectively. Additionally, 
hippocampal size and morphology as well as frontal lobe volume and activity 
have consistently been implicated in schizophrenia and fulfill the above 
mentioned criteria for endophenotypes [for review, see refs. 205, 206].  
Rodent models of schizophrenia 235 
 Giving the fact, that genes affect cognitive functions and behavioral 
features [for example frontal functions, ref. 207], it is not surprising that 
various such genes have been discovered and found to be altered in 
schizophrenia patients [e. g. ref. 208]. As noted previously, such candidate 
genes have been successfully linked to the disease, even though they are not 
necessarily disease-specific. Their physiological roles and functions are 
pleiotropic, e.g. affecting different neuronal circuitry and interacting with 
various neurotransmitter systems.  
 The first genetic mouse models of schizophrenia were based on 
disrupting dopaminergic and glutamatergic neurotransmitter systems, 
continuing the study of dopamine and glutamate hypothesis of schizophrenia. 
Thus, these models were again set on the assumption that the schizophrenic 
phenotype arises from a disturbed neurotransmitter function. Since 
schizophrenia is not the result of disruption of a single neurotransmitter 
system, these models had essentially the same limitations as pharmacological 
models, even though many of them reliably mimic schizophrenia symptoms 
[6, 209, 210].  
 For the sake of brevity, we will not discuss all genes that have been 
implicated in schizophrenia. Instead, we will focus on six candidate genes           
(i. e. genes that have a neurobiologic role in signal transduction, neuronal 
maturation, neurite outgrowth and/or neurotransmission and are localized 
within putative disease-linked regions): Neuregulin1 (NRG1), Complexin 2 
(CPLX2), Disrupted-in-schizophrenia 1 (DISC1), Catechol-O-methyl transferase 
(COMT), Regulator of G-protein signaling 4 (RGS4) and Dystrobrevin-
binding protein 1 (DTNBP1). As noted previously, the list of candidate genes 
of schizophrenia is growing daily. However, associating a gene with the 
disease in a small number of studies does not automatically qualify it for 
being called “candidate gene”. In addition, not all genes linked with the 
disease seem to be biologically plausible, as they have no overt role in the 
pathophysiology.  
 Thus, the genes selected in this chapter unify some aspects: (1) They have 
been repeatedly and consistently reported to be involved in the disease. (2) 
They seem to have a biologically plausible overt role. Consequently, modeling 
them in mice might provide good construct validity. (3) Some of them have 
been implicated in cognition. (4) Studies in which they are disrupted delivered 
promising potential in terms of face and predictive validity.  
 In one case, complexin 2, evidence of being a schizophrenia candidate 
gene in humans or mouse models is somehow sparse. It may ultimately turn 
out to be a non disease-specific risk gene modulating the disease phenotype 
[211]. In this context, a great part of work in our lab is currently focusing    
on it.      As we do not attempt to give an overview of  the enormous and steadily 
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growing amount of literature on genetic mouse models of schizophrenia, we 
recommend to the reader recent reviews providing an overview of other 
promising genes [212-214]. 
 In the following section, the above mentioned genes will be discussed. 
First, their relevance for schizophrenia as well as their main physiological 
features and roles will be addressed. Then, evidence concerning their 
endophenotypes will be presented, where applicable. Finally, data are given 
on respective mouse models regarding the domains locomotor activity, 
stereotypy, social behavior, sensorimotor gating, latent inhibition, memory 
and effect of antipsychotic administration. Table 3 provides an overview of 
the behavioral phenotype of mice, mutant for the here presented candidate 
genes of schizophrenia.  
 
4.1.1. Neuregulin 1 (NRG1) 
 NRG1 was identified as being a susceptibility gene for schizophrenia in a 
genome-wide linkage scan study of 33 Icelandic families with schizophrenia 
[22]. The systematic study of the locus 8p21-22 revealed association between 
the disease and a multi-marker haplotype at the 5’ end of NRG1 gene [22]. 
This has been confirmed in other samples [215, 216], although allelic 
heterogeneity was present in many cases [217-219]. Several meta-analyses 
have supported the association between NRG1 and schizophrenia [220-222] 
and diverse studies have been recently reviewed elsewhere [223]. However, 
as often observed in genetic studies of mental illness, negative results 
claiming non-association have also been found [224-226]. Notably, it has 
recently been reported that NRG1 shows extreme population differences in 
allele and haplotype frequencies [227]. Taking this into account, conflicting 
results from different populations should not be surprising.  
 Neuregulin 1 belongs to the family of growth and differentiation factors. 
Through its interaction with the ErbB tyrosine kinase transmembrane 
receptors it induces differentiation and growth of neuronal, glial and other 
cell types. NRG1 gene is a huge, complex gene that spans more than 1.1 
megabase and produces diverse isoforms through alternative splicing. For an 
extensive discussion on the NRG1-ErbB signaling mechanisms, the reader is 
referred to [228, 229], for diverse physiological roles of NRG1 to [230, 231].  
 Further evidence points to NRG1 signaling involvement in PFC 
physiology and neurotransmission [232]. For instance, ErbB4, a crucial 
NRG1 receptor, is localized at GABAergic terminals of the PFC [233] which 
is, as we noted previously, one of the most studied brain sites involved in 
schizophrenia. Furthermore, a recent study has demonstrated, that altered 
NRG1/ErbB4 signaling results in NMDA receptor hypofunction in 
schizophrenia [234]. Additionally, ErbB4 is implicated in activity-dependent 
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maturation and plasticity of synaptic structure. Thus, genetic defects in 
NRG1/ErbB4 signaling might lead to glutamatergic hypofunction [235], 
another line of evidence strengthening a role for NRG1 as a susceptibility 
gene for schizophrenia.  
 Even though the NRG1 gene is one of the most promising candidate 
genes studied for schizophrenia, its cognitive and clinical correlates have 
received relatively little attention. A number of studies elucidate its putative 
involvement in cognitive dysfunction in schizophrenia. The study by Hall and 
colleagues [236] showed an association between a risk-allele within the 
NRG1 gene (SNP8NRG243177), which is part of the risk-associated 
haplotype “deCODE” [22, 237], and decreased activation in frontal and 
temporal brain regions, increased development of psychotic symptoms and 
lower premorbid IQ.  
 A recent MRI study proved the association between the Icelandic at-risk 
haplotype (HAPICE) with lower hippocampal volumes in schizophrenia 
patients and their non-affected relatives [216]. Hippocampal volume 
reductions have been widely replicated in schizophrenia patients and their 
unaffected family members, for example in twin studies [238, 239]. As 
mentioned previously, hippocampal volume and size are believed to be 
consistent endophenotypic markers for schizophrenia and other mental 
disorders. Interestingly, children who carry the at-risk variant of the NRG1 
gene have significantly larger grey and white matter volumes, independently 
of whether they were affected by childhood-onset-schizophrenia (COS) or 
not. However, COS risk allele carriers demonstrate a steeper rate of 
subsequent brain matter volume decline into adolescence [240]. These 
findings support a role for the NRG1 gene in defects of neurodevelopment in 
schizophrenia.  
 Considering mouse data, genetic inactivation of the NRG1 gene in mice 
is associated with abnormalities in several types of schizophrenia-relevant 
behavior. Thus, spontaneous locomotor activity in the open field is increased 
in NRG1 mutants [22, 241]. Moreover, the atypical antipsychotic clozapine 
reduces this hyperactivity [22]. NRG1 mutants also show a selective 
impairment in response to social novelty [242], which is similar to social 
deficit observed in schizophrenia patients. Some behavioral tests related to 
cognitive deficits in schizophrenia were altered in NRG1 mutant mice. 
Prepulse inhibition, which is believed to be a test for sensorimotor gating 
[37], is impaired in NRG1 mutant mice [22]. Latent inhibition, which – with 
certain limitations – might reflect selective attention [39], is also disrupted in 
NRG1 mutant mice [243]. Contrary, other cognitive processes such as spatial 
learning and working memory appear to be intact in NRG1 knock-out (KO) 
mice [242].  
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 Taken together, clinical evidence as well as data from mouse models on 
NRG1 support its candidacy as a susceptibility gene for schizophrenia. NRG1 
knockout mouse models deliver fairly good construct and face validity. 
Pharmacological interventions using antipsychotics have also proved to 
reverse the schizophrenia-like symptoms in this knockout mouse model and 
thus, predictive validity of this line of research is quite satisfying. However, 
the pleiotropic role of the NRG1 gene in neurodevelopment and neural 
plasticity complicate the understanding of its role in cognition and 
schizophrenia.  
 
4.1.2. Complexin 2 (CPLX2) 
 In contrast to the other candidate genes presented here, which have been 
repeatedly and intensively studied, complexins are just starting to move in the 
focus of scientific attention regarding schizophrenia. Complexins are 
presynaptic proteins, which play a key role in the modulation of neuronal 
exocytosis. They form a family of four small (134-160 residues) charged 
proteins, which are subdivided into two subfamilies: CPLX1/2 and CPLX3/4 
[244]. CPLX1 is specifically expressed in the central nervous system. 
CPLX2, on the other hand, was detected in other, non-neuronal tissue [245]. 
CPLX3/4 are predominantly expressed in the ribbon synapses of the retina 
[244].  
 Various studies reported decreased CPLX2 mRNA and protein levels in 
postmortem hippocampal tissue of schizophrenia patients [246, 247]. As 
discussed previously, there is no doubt about the central role of the 
hippocampal formation in schizophrenia. Cause and significance of these 
findings regarding CPLX2 is still unclear. CPLX2 may not play the role of a 
typical candidate gene for schizophrenia but rather be a contributor/modifier 
of disease progression/severity. As such, it obviously also plays a part in 
diseases as different as Alzheimer disease, alcoholism or Huntington’s 
Disease [211].  
 Few behavioral data exist on mice carrying a targeted deletion of the 
complexin 2 gene. For example, spatial learning and memory are not affected 
in CPLX2 mutant mice [248]. However, CPLX2 KO mice are more 
vulnerable to maternal deprivation stress in comparison to wild type control 
animals [248]. Two other studies have demonstrated electrophysiological 
alterations, which are not directly related to a schizophrenia phenotype. 
However, it has been shown that LTP in CA1 and CA3 in the hippocampus is 
reduced in CPLX2 KO [249]. Further characterization of schizophrenia 
related behavior of CPLX2 mutant mice is required. To conclude, complexin 
2 appears to be an interesting gene in the context of schizophrenia, albeit 
more in the sense of a non-specific disease modifier. 
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4.1.3. Disrupted-in-schizophrenia 1 (DISC1) 
 DISC1 gene is one of the most intensively studied candidate genes for 
schizophrenia. There is a great body of evidence pointing to its association 
with major psychiatric disorders [250], e.g. bipolar disorder, schizophrenia 
[251] and the autism spectrum [252]. DISC1 was first identified and located 
at the breakpoint of a balanced chromosomal translocation t(1;11)(q42.1; 
q14.3) in a large Scottish family which displayed a variety of psychiatric 
disorders [253]. The breakpoint at 1q was cloned and it was shown that it 
includes two genes, called DISC1 and DISC2 [254].  
 Several association and linkage studies in different populations [see also 
ref. 250 for review] supported its candidacy for the involvement in 
psychiatric disorders. Many studies have shown associations between allelic 
variations in DISC1 and risk to develop schizophrenia. For example, it has 
been reported that a single three-locus haplotype within the DISC1 gene was 
over-transmitted to individuals affected with schizophrenia in a family-based 
association study in a Finnish population [255]. In addition, over-
representation of five SNPs in the gene in schizophrenia patients has also 
been reported [256].  
 DISC1 is a complex gene, whose involvement in and implications for 
development and neuroplasticity are still poorly understood. It has 13 exons 
spanning over 200kb. The protein it encodes (consisting of 854 amino acids) 
is associated with various cytoskeletal proteins involved in centrosomal and 
microtubule function, cell migration, neurite outgrowth, membrane 
trafficking of receptors and possibly mitochondrial functioning [212, 257]. 
Additionally, a role in regulating adult neurogenesis has recently been 
reported [258]. In the human brain, DISC1 is expressed in cerebral cortex and 
hippocampus [259], both regions implicated in schizophrenia.  
 In the mouse brain, DISC1 is expressed from embryonic day 10 on to 
adult age, pointing to its role in neurodevelopment [260]. DISC1 interacts 
with many other proteins, including the nuclear distribution element-like 1 
(NDEL1) protein, the nuclear protein lissencephaly 1 (LIS1), the 
fasciculation and elongation protein zeta-1 (FEZ1) and phosphodiesterase 
4B (PDEB4). Interestingly, significantly reduced expression of  NDEL1, 
FEZ1 and LIS1 in the hippocampus and DLPFC of brains from 
schizophrenia patients has been reported, while DISC1 expression remained 
unaltered [261].  
 There is a strong body of clinical [262] as well as molecular evidence 
linking DISC1 with different cognitive and behavioral phenotypes relevant to 
schizophrenia [250 for review]. The molecular link emerged from the 
interaction of DISC1 with PDEB4 [263]. PDEB4 belongs to the family of 
phosphodiesterases which are orthologous to the Drosophila learning and 
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memory gene dunce [264]. Notably, phosphodiesterases play an imperative 
role in inactivating cAMP, which is a key signaling molecule implicated in 
learning and memory [for review, see refs. 265, 266].  
 Thus, alterations in this gene, as was shown from human studies, have 
deleterious effects on learning and memory. Mice carrying a point mutation 
leading to conversion from leucine to proline at residue 100 (L100P) of final 
DISC1 protein were shown to be abnormal in many types of schizophrenia 
related behavior tests [21]. Thus, DISC1 mutants show increase in locomotor 
activity in open field, deficit in prepulse inhibition and latent inhibition. 
Interestingly, all these alterations were sensitive to clozapine treatment [21]. 
DISC1 mutants also show deficit in working memory. However, social 
behavior of these mice was unimpaired [21].   
 Taken together, the DISC1 gene has proven to be a candidate gene for 
schizophrenia. DISC1 mutant mouse models demonstrate good predictive and 
partially also face validity. The construct validity is again a difficult issue, 
because schizophrenia is not a monogenic disorder. However, the 
involvement of DISC1 in the disease seems to be quite unequivocally 
accepted, although it is still unclear how alterations in the DISC1 gene can 
contribute to the emergence of the disorder.  
 
4.1.4. Catechol-O-methyl transferase (COMT) 
 The gene encoding the enzyme catechol-o-methyl transferase (COMT), 
located at the chromosomal region 22q11, has been implicated in 
schizophrenia, bipolar disorder, anorexia nervosa, anxiety and other mental 
disorders [267, 268]. Its putative involvement in schizophrenia is quite 
apparent, due to its key role in dopamine catabolism. COMT has also been 
intensively studied in the context of the microdeletion syndrome involving its 
chromosomal locus (velo-cardio-facial syndrome), in which a high 
prevalence of psychotic and affective symptoms has been reported [269]. 
Many studies have been conducted focusing on a functional polymorphism 
that substitutes a valine to methionine at codon 158. This constellation 
influences enzymatic activity and consequent dopamine metabolism. 
Homozygous carriers for the Met allele have the lowest activity, resulting in 
reduced dopamine degradation. This allele has been shown to be associated 
with PFC activation [270] and improved performance in frontal cortical tasks 
[271]. Conversely, the Val allele confers higher activity and has been 
relatively consistently linked to reduced performance in PFC-related tasks 
[271, 272].  
 As with the other previously mentioned genes, COMT studies have 
delivered mixed results. While some studies have supported the association 
between Val/Met polymorphism and schizophrenia [273, 274], other 
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studies found no association [275, 276]. Conflicting results emerged also 
from meta-analyses [277, 278] pointing to only a small effect of the COMT 
allelic variation on schizophrenia risk. Concerning the neurocognitive 
phenotype of the Val/Met polymorphism, there is a growing number of 
studies showing COMT involvement in PFC related functions [for review, 
see refs. 271, 279-282].  
 According to Craddock and colleagues [283], it cannot be ruled out, that 
a variation elsewhere in the COMT or neighbouring genes, such as ARVCF, 
is basis of the susceptibility to schizophrenia. Neither the mechanisms of how 
COMT regulates cognition nor its candidacy as a vulnerability gene have yet 
been clarified. The same conflicting pattern of evidence is found in mouse 
models of this gene. Mice lacking COMT did not show a prominent 
behavioral phenotype.  
 Thus, except for an increase in aggression, these mice show no changes 
in schizophrenia related types of behavior. The PPI and locomotor activity in 
open field are not affected in COMT mutants [20]. In conclusion, despite its 
apparent role in the physiology of the dopaminergic system and its potential 
implication in dopamine-mediated cognitive functions, the role of COMT in 
the pathophysiology of schizophrenia is still obscure. 
 
4.1.5. Dystrobrevin-binding protein 1 (DTNBP1) 
 A considerable body of evidence supports the involvement of the gene 
encoding dystrobrevin-binding protein 1 (DTNBP1) – synonym: Dysbindin1 – 
in the etiology of schizophrenia [284-286]. Nevertheless, some studies in 
diverse populations failed to find associations between schizophrenia and 
certain haplotypes of SNPs in the DTNBP1 gene [287-289]. DTNBP1 gene is 
located on chromosome 6p22.3 and encodes a 40-50 kDa protein that binds 
both α- and β-dystrobrevin. Both are members of the dystrophin glycoprotein 
complex [290], which is concentrated at postsynaptic densities in different 
brain areas.  
 DTNBP1 mRNA has been found to be expressed in diverse brain sites, 
including frontal and temporal cortices, nucleus accumbens, thalamus, 
amygdala and hippocampus. The reduction of DTNBP1 mRNA in multiple 
layers of the DLPFC in schizophrenia patients [291] as well as a selective 
decline in DTNBP1 expression presynaptically in the hippocampus support 
DTNBP1 as a candidate gene for schizophrenia [292]. Additionally, Talbot 
and colleagues  [292] have reported an inverse correlation of DTNBP1 
levels with the vesicular glutamate transporter 1 (VGluT-1) in the 
hippocampus of schizophrenia patients. This finding may support the 
involvement of this gene in schizophrenia. As noted earlier in this chapter, 
one of the original hypotheses on schizophrenia pathophysiology is the 
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glutamatergic hypothesis, pointing to a glutamatergic hypofunction as basis 
of clinical features [293].  
 Neuropsychological data underline the putative function of DTNBP1 in 
cognitive deficits reported in this disease. Several studies succeeded in 
identifying high-risk haplotypes in the DTNBP1 gene [e. g. 294, 295] as well 
as in linking these with specific clinical features of the disease. For example, 
carriers of a high-risk haplotype were more likely to manifest high levels of 
negative symptoms in an Irish study of high-density schizophrenia families 
[296]. Another study reported that a variation in DTNBP1 is associated with 
negative symptoms [297]. These findings are of great interest in light of 
previously discussed effects of glutamatergic antagonists on inducing 
negative symptoms in healthy individuals [69]. Taken together, these data 
suggest DTNBP1 to be involved in mechanisms related to affect and mood 
domains of schizophrenia.  
 Different studies have reported relations between variants in DTNBP1, 
poor premorbid functioning and childhood-onset-schizophrenia (COS) [298], 
higher cognitive decline [299] as well as deficits in early visual processing 
[300]. Moreover, DTNBP1 variants have been reported to be involved in 
frontal brain functions in healthy subjects [301].  
 Despite promising evidence from clinical and basic research, DTNBP1 
does not seem to be the ideal “schizophrenia candidate” gene. Disruptions in 
the dystrophin-associated protein complex result in Duchenne muscular 
dystrophy [302]. A murine spontaneous mutation in the DTNBP1 gene leads 
to Hermansky-Pudlak syndrome type 7 (HPS7), which is characterized by 
oculocutaneous albinism, prolonged bleeding and pulmonary fibrosis [303]. 
The sandy mouse (sdy) is a rodent model of HPS7. In this context, no 
schizophrenia-related behavioral features have been reported. This might be 
seen as a drawback for the candidacy of DTNBP1; however, considering 
conflicting human data as well as the complexity of schizophrenia 
pathophysiology and clinical manifestation, it should not be too surprising 
that alteration in this gene in a model organism like mice does not lead to an 
apparent phenotype, which satisfies validity criteria.  
 
4.1.6. Regulator of G-protein signaling 4 (RGS4) 
 RGS4, which is localized at the chromosomal locus 1q23, is a 
particularly interesting candidate gene for schizophrenia, as clinical and basic 
research data show its biological implication in the disease. Also, this gene 
appears to be a target of the physiological response to environmental stimuli 
(e.g. stress). Stress in turn is regarded as one crucial factor for the emergence 
of psychiatric disorders.  
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 According to Levitt and colleagues [304], there are principally three lines 
of evidence supporting the candidacy of RGS4: First, genetic studies showing 
the association between schizophrenia and non-functional polymorphisms in 
the RGS4 gene [305-307]; second, decreased RGS4 expression in cortical 
regions in schizophrenia patients in a disease-specific pattern [308] and third, 
the differential regulation of RGS4 in the brain and its responsiveness to 
chronic stress [304, 309].  
 Although many studies have succeeded in associating RGS4 with 
schizophrenia [306] other studies conducted in different populations could 
not fully support this association [310-312]. Possible reasons for these 
conflicting results might be diagnostic differences between samples, 
heterogeneous and small sample sizes and/or locus heterogeneity. However, 
the biological and cellular role and function of RGS4 gene make it a very 
attractive and promising candidate. RGS4 was one of the earliest studied 
members of the RGS (regulators of G-protein signaling) family, which has 
been shown to be a highly diverse protein family. Regulator of G-protein 
signaling control the duration and regulate the timing of intracellular 
signaling of many G-protein mediated receptors [305]. The expression of the 
RGS gene family is widespread through the human body. Many of them 
show a distinct expression pattern in the rodent brain [313].  
 RGS4 mRNA has its highest levels of expression in frontal cortical 
regions, while subcortical sites (e. g. thalamus, striatum) manifest the lowest 
expression levels in normal postmortem human brain samples [314]. The 
regional density pattern in rodents seems to differ from that observed in 
humans [313]. It has been reported that RGS4 is linked to dopamine receptor 
D2 functions [315, 316] and inhibits signaling of metabotrobic glutamate 
receptors [317].  
 Concerning implication in neurocognitive functions, altered expression 
of RGS4 mRNA in the superior temporal gyrus (STG) in brains of 
schizophrenic patients has been documented [318]. The STG is believed to be 
a key region for speech and communication. Furthermore, it is connected to 
limbic regions, associated with schizophrenia pathology, and has been 
reported to be involved in the emergence of auditory hallucinations [319]. 
Another study demonstrated the impact of a variation at a RGS4 SNP, 
associated previously with psychosis (rs951436), on frontoparietal and 
frontotemporal regions during a working memory task and on grey matter 
structural connectivity as well as on white matter volume in healthy 
volunteers [320].  
 Concerning mouse behavioral data, RGS4 deficient mice did not display 
deficits in PPI [321]. RGS4 mutants also failed to show abnormalities in 
locomotor activity in open field, working memory in T-maze or Pavlovian 
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fear conditioning [321]. Again, as noted previously, genetic variation in a 
specific gene in humans does not inevitably lead to comparable behavioral 
and clinical manifestations in mice. Nevertheless, the potential contribution 
of this gene to the evolvement of the schizophrenic phenotype is worthwhile 
further investigating. Regarding validity issues of the RGS4 mouse model, 
the construct validity might be considered satisfying due to aspects 
mentioned above. However, further research is needed for clarifying face and 
predictive validity issues.  
 Table 3 contains an overview summarizing the behavioral phenotype of 
mice mutant for the here discussed genes. As noted previously, we have only 
included studies yielding positive results regarding schizophrenia-related 
symptoms. There is an enormous amount of studies addressing various 
genetic alterations in the mentioned genes. However, the number of 
schizophrenia-relevant phenotypes is still limited.  
 
4.2. Present genetic animal models: Promises and problems 
 Based on human data and experimental results with rodents, evidence is 
available for a role in schizophrenia of all the genes discussed here, be it as 
disease co-causing or as modifying factor. This holds true despite of the 
somewhat discouraging recent reports, raising doubts as to the significance of 
any of the candidate genes for schizophrenia [322]. Especially, strongest 
evidence remains for NRG1 and DTNBP1 [323-325].  
 The previous sections tried to illustrate different approaches in modeling 
schizophrenia in rodents. By means of clinical as well as basic research it has 
become apparent, that schizophrenia is not a monofactorial mental disorder, 
which affects a single physiologic system or specific brain region with its 
interconnected functional circuits. Rather it is a complex and polygenetic 
disease, which might be triggered by different environmental influences. 
Twin studies have taught us, that heritability has a crucial impact on the 
evolution of the disease. However, it is not sufficient for triggering 
schizophrenia since heritability even in monocygotic twins amounts to only 
50% [238, 239]. Logically, the other 50% stem from environmental 
influences. Although research in this category is still nascent, we have to put 
all efforts into creating models that unify multiple causative factors, genetic 
and environmental, to give rise to the disease. 
 
5. “Future” 
 As noted previously, the prevailing notion is that an early developmental 
deficit alone may not be sufficient to cause the disease. However, an early 
predisposing factor may increase disease vulnerability. On basis of this 
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increased vulnerability – might it be due to genetic predisposition or early 
brain injury – the illness is believed to be triggered by later life events (e.g. 
severe stress caused by extreme social isolation, psychotrauma, neurotrauma, 
drug abuse to just name a few). This interaction of (genetic) vulnerability and 
additional triggering events has been called the “two-hit” hypothesis of 
schizophrenia [326, 327]. The basic requirement is believed to be a perhaps 
minimally dysfunctional genetic background, affecting neuronal development 
and plasticity, which is fully compensated for in the absence of additional 
triggers.  
 There is in fact a growing number of studies combining two or more 
predisposing and triggering factors. For example, the effects of neonatal 
ventral hippocampal lesion is modified according to genetic strain [181]. 
Repeated PCP administration induced a more pronounced hyperlocomotion 
pattern in rats with neonatal ventral hippocampal lesion [328]. Furthermore, a 
recent study using different behavioral tasks has demonstrated that 
heterozygous NRG1 mutant mice are more sensitive to the effects of delta-9-
tetrahydrocannabinol (THC) administration [329]. Surprisingly, NRG1 
mutant mice acutely treated with THC had an enhanced PPI compared with 
wild type mice. The locomotion suppressant effect of THC was also more 
pronounced in the NRG1 mutant mice. Despite these rather atypical findings, 
a rodent model combining two different vulnerability factors seems to be a 
promising approach for more adequately mimicking the etiology and 
pathogenesis of schizophrenia. Table 4 gives an overview on the various 
rodent models discussed in this chapter.   
 In recent work, the onset of schizophrenia-associated cortical grey matter 
loss in the parietal lobe [100] was modeled by inducing a small standardized 
unilateral parietal cold-lesion through the intact skull of 28 day old mice. 
This lesion, triggering from the outside as yet unknown internal processes 
that lead to progressive brain atrophy in schizophrenia, led to a similar type 
of cortical grey matter loss in mice, when applied at the vulnerable age 
around puberty. Applied at later age, no such changes were observed 
anymore [330]. Presently, we are combining this model of subtle progressive 
brain atrophy with genetic and other environmental factors in order to create 
a “several hit model” of schizophrenia. 
 The prevailing amount of studies containing multiple vulnerability 
factors does not intensively focus on assessing the behavioral domains 
affected in schizophrenia. Moreover, various studies use locomotion as the 
only behavioral schizophrenia-relevant phenotype. This is not only the case 
in “multiple-hit” studies. It also holds true for monofactorial designs. Since 
diagnosing schizophrenia in man relies primarily, if not exclusively, on      
the behavioral phenotype,  an assessment procedure         which addresses relevant 
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domains also in rodents is indispensable. One potentially promising approach 
is adapting the diagnostic practice of mental disorders in humans to rodents. 
Compared with physical diseases, mental disorders lack thus far specific 
cellular indicators. Thus, the process of diagnosis is heavily based on 
objective and communicable classification systems. The most famous and 
widely used diagnosis system for mental health professionals is the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) of the 
American Psychiatric Association [4]. The DSM, since 1994 in its 4th 
revision, is a categorical classification system for various mental disorders. It 
enables making a diagnosis of the mental functioning of patients by means of 
using different branches of clinical information. The DSM-IV includes 
criteria for diagnosing a mental disorder. Symptoms listed there are grouped 
into clusters. Patients do not have to fulfill all points in all criteria to be given 
the corresponding diagnosis. Rather, these categories have to be seen as 
prototypes for the disease and patients showing a high degree of 
approximation with a given prototype get the corresponding diagnosis.  
DSM-IV criteria for schizophrenia are summarized in Table 5. For example, 
according to DSM-IV criteria for schizophrenia, it is necessary to show at 
least two symptoms of criterion A for the period of one month (or less if 
successfully treated). Additionally, the patient has to meet criteria B, C and 
D, while other potential confounding disorders have to be excluded (criteria 
E and F). However, only one symptom in criterion A is required, if delusions 
are bizarre or hallucinations consist of a monologue commenting the 
behavior of the patient. Despite these objective classification systems, 
making a diagnosis of schizophrenia in humans is often challenged by 
various pitfalls. Nevertheless, intensive efforts are made on validating 
diagnostic methods, e.g. by continuous updates and revisions of DSM and 
similar classification systems.  
 Similarly to diagnostic practice in humans, such an objective 
classification system is desperately needed in rodent models of 
schizophrenia. As was shown in this chapter, rodents demonstrate various 
behavioral features analogous to humans. Thus, the formulation of objective 
diagnostic criteria for “rodent schizophrenia” seems to have a factual basis.  
 In the following section, we offer a preliminary step towards defining 
communicable criteria for the diagnosis of schizophrenia in rodent models. 
As stated previously, the diagnostic process should account for the mainly 
behavioral phenotype of the disease. For the sake of simplicity, we will call 
these criteria “rodent DSM criteria”, pointing to our intention of having 
analogous conditions to human diagnostic standards. The key principle which 
is implicated in these criteria is that the diagnosis is made on the basis of 
constellation of specific symptoms, rather than of the presence of single 
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features of the disease. In analogy with the human diagnostic manual, a 
rodent diagnostic system has to include the combination of sufficient disease-
related symptoms in different behavioral domains. It has to be stated at this 
point, that the formulation of such diagnostic criteria is dependent on current 
knowledge of disease symptomatology and underlying mechanisms. The state 
of knowledge is target of steadily growing developments and achievements in 
science. Thus, the criteria we propose here for rodents will be as much 
subject to future revisions as the DSM criteria in humans. 
  
Table 5. Diagnostic criteria for schizophrenia according to DSM-IV (American-
Psychiatric-Association 2000). 
 
A Characteristic symptoms: Two (or more) of the following, each present for a significant 
portion of time during a 1-month period (or less if successfully treated):  
 
1. delusions  
2. hallucinations  
3. disorganized speech (e.g., frequent derailment or incoherence)  
4. grossly disorganized or catatonic behavior 
5. negative symptoms, i.e., affective flattening, alogia, or avolition  
 
Note: Only one Criterion A symptom is required if delusions are bizarre or 
hallucinations consist of a voice keeping up a running commentary on the person's 
behavior or thoughts, or two or more voices conversing with each other.  
B Social/occupational dysfunction: For a significant portion of the time since the onset 
of the disturbance, one or more major areas of functioning such as work, interpersonal 
relations, or self-care are markedly below the level achieved prior to the onset (or when 
the onset is in childhood or adolescence, failure to achieve expected level of 
interpersonal, academic, or occupational achievement).  
C Duration: Continuous signs of the disturbance persist for at least 6 months. This 6-
month period must include at least 1 month of symptoms (or less if successfully 
treated) that meet Criterion A (i.e., active-phase symptoms) and may include periods of 
prodromal or residual symptoms. During these prodromal or residual periods, the signs 
of the disturbance may be manifested by only negative symptoms or two or more 
symptoms listed in Criterion A present in an attenuated form (e.g., odd beliefs, unusual 
perceptual experiences). 
D Schizoaffective and Mood Disorder exclusion: Schizoaffective Disorder and Mood 
Disorder With Psychotic Features have been ruled out because either (1) no Major 
Depressive, Manic, or Mixed Episodes have occurred concurrently with the active-
phase symptoms; or (2) if mood episodes have occurred during active-phase symptoms, 
their total duration has been brief relative to the duration of the active and residual 
periods.  
E Substance/general medical condition exclusion: The disturbance is not due to the 
direct physiological effects of a substance (e.g., a drug of abuse, a medication) or a 
general medical condition.  
F Relationship to a Pervasive Developmental Disorder: If there is a history of Autistic 
Disorder or another Pervasive Developmental Disorder, the additional diagnosis of 
Schizophrenia is made only if prominent delusions or hallucinations are also present 
for at least a month (or less if successfully treated). 
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5.1. DSM criteria for rodent schizophrenia 
 As discussed at the beginning of this chapter, animal models of psychiatric 
disorders have to meet some validity requirements to be regarded as scientifically 
beneficial. Consequently, we are convinced that good construct validity of a 
potential model should be regarded as the first criterion, delivering category A 
which has to be met in a diagnostic system for rodent schizophrenia (Table 6). 
Thus, a potential experimental intervention should meet this key prerequisite. For 
example, animal models based on the “two-hit” hypothesis implicating 
combinations of candidate genes and environmental factors fulfill this 
requirement at best. However, the assessment of construct validity heavily 
depends on the growing understanding of the disease. Thus, this point has to be 
evaluated according to the contemporary disease knowledge.  
 Furthermore, we suggest to group different schizophrenia symptoms into 
classes according to domains (compare also Table 1). This approach 
addresses the face validity issue and puts positive and negative symptoms 
together in category B. As mentioned previously, there are almost no reliable 
behavioral features in rodents, which are homologous to human positive 
symptoms (e.g. hallucinations and delusions). Nevertheless, it is widely 
believed, that hyperlocomotion/hyperactivity and stereotypy are to some 
extent related to positive symptomatology. One important feature of negative 
symptoms is social withdrawal, which can be assessed in rodents. Similarly, 
some aspects of affective loss/anhedonia can be modeled. Consequently, a 
potential rodent model of schizophrenia should fulfill at least one of the 
characteristic features listed in category B.  
 As cognitive symptoms are believed to be a core feature of the disease 
[2], we suggest to include them in rodent DSM, even though very 
surprisingly they were not addressed (forgotten?) in the current version      
(4th ed.) of human DSM. Cognitive functions have been intensively studied in 
rodents, with various well-established and reliable tests available. Based on 
that, we include readouts for working memory, attention, executive functions 
and sensorimotor gating in category C. A potential “schizophrenic” rodent 
should show deficits in at least two characteristic features listed in this 
category. It has to be noted here, that rodents showing a global cognitive 
deficit with very low learning ability have to be excluded. Schizophrenia is 
not comparable with mental retardation or debility. 
 Concerning predictive validity, we suggest to include the reversal of 
symptoms by antipsychotics as part of an optional, supporting category D. 
We feel that it should be optional since not all schizophrenic patients benefit 
from antipsychotic medication [68]. However, a putative rodent model 
showing reversal of symptoms after antipsychotic medication should be 
regarded as most reliable. 
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Table 6. Rodent DSM-like criteria for modelling schizophrenia. 
 
Validity 
aspects 
Category Domain Characteristic features Rodent phenotype 
Construct 
validity 
A  The means of modeling applied in rodents should stay in 
conceptual correspondence with human disease  
B Positive 
symptoms 
 
 
 
 
 
 
 
Negative 
symptoms 
 
 
 
Psychomotor 
agitation 
 
 
 
 
 
Stereotypy 
 
Anhedonia 
 
Social 
withdrawal 
Spontaneous hyperlocomotion 
Increase in PCP- and MK801-induced 
hyperlocomotion 
Increase in amphetamine induced 
hyperlocomotion 
Increase in stress induced 
hyperlocomotion 
Circling movements 
Repetitive behaviors 
Decrease in sucrose preference 
 
Decreased preference to social novelty
Decreased social interaction 
Decreased or disturbed nesting in the 
home cage 
Decreased huddling in the home cage 
 
Face 
validity 
C Cognitive 
symptoms 
 
 
 
 
 
 
 
Working 
memory deficits 
 
Deficit of attention
 
 
Executive 
function deficits 
 
 
 
Deficit of 
sensorimotor 
gating 
Impaired performance in T-maze 
Impaired performance in 8-arm maze 
 
Impaired latent inhibition 
Decreased sustained attention in 
5CSRTT 
Increased distractibility in 5CSRTT 
Increased reaction time in 5CSRTT 
Increased premature responses in 
5CSRTT 
Decreased set-shifting ability 
Diminished PPI 
Deficit of startle habituation 
  Note: A global cognitive deficient phenotype with very low learning 
ability has to be excluded. 
                                                           Optional, supporting categories 
Predictive 
validity 
D  Improvement of some deficits from categories B and C 
after treatment with known antipsychotic drugs 
 E Non-
behavioral 
traits  
Findings in neuroimaging, neuropathology, pathophysiology 
and gene expression comparable to schizophrenia patients 
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 In contrast to diagnostic criteria in humans, we propose several 
additional invasive assessment methods for detecting morphological, cellular 
and physiological abnormalities shown in schizophrenic patients. Even 
though these findings are not consistent in all affected human individuals, 
they might ultimately help to formulate and detect subtypes of the disease in 
humans as well as rodents. These diagnostic means are considered in the 
second optional, supporting category E.  
 The here proposed criteria should be regarded as an attempt to guide the 
modeling of such complex biological disease phenomena as schizophrenia. 
The steadily growing advances in translational neuroscience and biological 
psychiatry will hopefully help to revise and modify the above mentioned 
categories for classification of rodent schizophrenia. Rigorous scientific 
efforts are desperately required in order to fulfill the substantial need for 
valid animal models of schizophrenia. We are convinced that further 
developments in this field will lead to deeper understanding of the underlying 
disease mechanisms as well as to advances in therapeutic and preventive 
approaches. 
 
References  
1. Wong, A.H. and Van Tol, H.H. 2003, Neurosci Biobehav Rev, 27, 269. 
2. Elvevag, B. and Goldberg, T.E. 2000, Crit Rev Neurobiol, 14, 1. 
3. Lewis, D.A. and Lieberman, J.A. 2000, Neuron, 28, 325. 
4. American-Psychiatric-Association 2000, Diagnostic and Statistical Manual of 
Mental Disorders. 4th ed. American Psychiatric Association, Washington, DC. 
5. Adityanjee, Aderibigbe, Y.A., Theodoridis, D. and Vieweg, V.R. 1999, 
Psychiatry Clin Neurosci, 53, 437. 
6. Ross, C.A., Margolis, R.L., Reading, S.A., Pletnikov, M. and Coyle, J.T. 2006, 
Neuron, 52, 139. 
7. Ellenbroek, B.A. and Cools, A.R. 1990, Behav Pharmacol, 1, 469. 
8. Kornetsky, C. and Markowitz, R. 1975,  Model Systems in Biological Psychiatry. 
Ingle, D.J. and Shein, H.M. (Ed.). MIT Press, Cambridge, Massachusetts, 26. 
9. McKinney, W.T. and Moran, E.C. 1981, Am J Psychiatry, 138, 478. 
10. Marcotte, E.R., Pearson, D.M. and Srivastava, L.K. 2001, J Psychiatry Neurosci, 
26, 395. 
11. Lipska, B.K. and Weinberger, D.R. 2000, Neuropsychopharmacology, 23, 223. 
12. McKinney, W.T., Jr. and Bunney, W.E., Jr. 1969, Arch Gen Psychiatry, 21, 240. 
13. Willner, P. 1986, Prog Neuropsychopharmacol Biol Psychiatry, 10, 677. 
14. van der Staay, F.J. 2006, Brain Res Rev, 52, 131. 
15. Matthysse, S. 1986, Prog Brain Res, 65, 259. 
16. Kornetsky, C. and Markowitz, R. 1978,  Psychopharmacology: A Generation of 
Progress. Lipton, M., DiMascio, A. and Killam, K. (Ed.). Raven Press, New 
York, 583. 
Rodent models of schizophrenia 253 
17. Matthysse, S. and Haber, S. 1975,  Model Systems in Biological Psychiatry. 
Ingle, D.J. and Shein, H.M. (Ed.). MIT Press, Cambridge, Massachusetts, 4. 
18. Willner, P. 1984, Psychopharmacology (Berl), 83, 1. 
19. Powell, C.M. and Miyakawa, T. 2006, Biol Psychiatry, 59, 1198. 
20. Gogos, J.A., Morgan, M., Luine, V., Santha, M., Ogawa, S., Pfaff, D. and 
Karayiorgou, M. 1998, Proc Natl Acad Sci U S A, 95, 9991. 
21. Clapcote, S.J., Lipina, T.V., Millar, J.K., Mackie, S., Christie, S., Ogawa, F., 
Lerch, J.P., Trimble, K., Uchiyama, M., Sakuraba, Y. et al. 2007, Neuron, 54, 
387. 
22. Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., 
Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., 
Chou, T.T. et al. 2002, Am J Hum Genet, 71, 877. 
23. Borison, R.L., Havdala, H.S. and Diamond, B.I. 1977, Life Sci, 21, 117. 
24. Lipska, B.K., Jaskiw, G.E. and Weinberger, D.R. 1991, Pharmacol Biochem 
Behav, 40, 169. 
25. Ridley, R.M. 1994, Prog Neurobiol, 44, 221. 
26. Iversen, S.D. and Koob, G.F. 1977, Adv Biochem Psychopharmacol, 16, 209. 
27. Vickery, S.S. and Mason, G.J. 2005, Applied Animal Behaviour Science, 91, 
247. 
28. Garner, J.P. and Mason, G.J. 2002, Behav Brain Res, 136, 83. 
29. Ellenbroek, B.A. and Cools, A.R. 2002, Behav Genet, 32, 349. 
30. Bellack, A.S., Morrison, R.L., Wixted, J.T. and Mueser, K.T. 1990, Br J 
Psychiatry, 156, 809. 
31. Couture, S.M., Penn, D.L. and Roberts, D.L. 2006, Schizophr Bull, 32 Suppl 1, 
S44. 
32. Portfors, C.V. 2007, J Am Assoc Lab Anim Sci, 46, 28. 
33. Jamain, S., Radyushkin, K., Hammerschmidt, K., Granon, S., Boretius, S., 
Varoqueaux, F., Ramanantsoa, N., Gallego, J., Ronnenberg, A., Winter, D. et al. 
2008, Proc Natl Acad Sci U S A, 105, 1710. 
34. Ellenbroek, B.A. and Cools, A.R. 2000, Behav Pharmacol, 11, 223. 
35. Braff, D.L., Geyer, M.A. and Swerdlow, N.R. 2001, Psychopharmacology (Berl), 
156, 234. 
36. Braff, D.L. and Light, G.A. 2004, Psychopharmacology (Berl), 174, 75. 
37. Swerdlow, N.R., Braff, D.L. and Geyer, M.A. 2000, Behav Pharmacol, 11, 185. 
38. Geyer, M.A., Krebs-Thomson, K., Braff, D.L. and Swerdlow, N.R. 2001, 
Psychopharmacology (Berl), 156, 117. 
39. Lubow, R.E. 2005, Schizophr Bull, 31, 139. 
40. Swerdlow, N.R., Braff, D.L., Hartston, H., Perry, W. and Geyer, M.A. 1996, 
Schizophr Res, 20, 91. 
41. Weiner, I., Lubow, R.E. and Feldon, J. 1988, Pharmacol Biochem Behav, 30, 
871. 
42. Moser, P.C., Hitchcock, J.M., Lister, S. and Moran, P.M. 2000, Brain Res Brain 
Res Rev, 33, 275. 
43. Weiner, I., Shadach, E., Tarrasch, R., Kidron, R. and Feldon, J. 1996, Biol 
Psychiatry, 40, 834. 
 Ahmed El-Kordi et al. 254
44. Barch, D.M. 2005, Annu Rev Clin Psychol, 1, 321. 
45. Perlstein, W.M., Carter, C.S., Noll, D.C. and Cohen, J.D. 2001, Am J Psychiatry, 
158, 1105. 
46. Barch, D.M. and Csernansky, J.G. 2007, Am J Psychiatry, 164, 1090. 
47. Barch, D.M., Sheline, Y.I., Csernansky, J.G. and Snyder, A.Z. 2003, Biol 
Psychiatry, 53, 376. 
48. Baddeley, A. 1996, Proc Natl Acad Sci U S A, 93, 13468. 
49. Dudchenko, P.A. 2004, Neurosci Biobehav Rev, 28, 699. 
50. Pontecorvo, M.J., Sahgal, A. and Steckler, T. 1996, Brain Res Cogn Brain Res, 3, 
205. 
51. Weiss, I.C. and Feldon, J. 2001, Psychopharmacology (Berl), 156, 305. 
52. Carlsson, A. 1977, Psychol Med, 7, 583. 
53. van Kammen, D.P. 1979, Psychoneuroendocrinology, 4, 37. 
54. Davis, J.M. 1974, J Psychiatr Res, 11, 25. 
55. Davis, K.L., Kahn, R.S., Ko, G. and Davidson, M. 1991, Am J Psychiatry, 148, 
1474. 
56. Abi-Dargham, A. 2004, Int J Neuropsychopharmacol, 7 Suppl 1, S1. 
57. Griffith, J.J., Oates, J. and Cavanaugh, J. 1968, J. Am. Med. Ass., 205. 
58. Connell, P.H. 1958, Amphetamine Psychosis. Oxford University Press Oxford. 
59. Hutchison, K.E. and Swift, R. 1999, Psychopharmacology (Berl), 143, 394. 
60. Swerdlow, N.R., Braff, D.L., Taaid, N. and Geyer, M.A. 1994, Arch Gen 
Psychiatry, 51, 139. 
61. Parwani, A., Duncan, E.J., Bartlett, E., Madonick, S.H., Efferen, T.R., Rajan, R., 
Sanfilipo, M., Chappell, P.B., Chakravorty, S., Gonzenbach, S. et al. 2000, Biol 
Psychiatry, 47, 662. 
62. Braff, D.L. and Geyer, M.A. 1990, Arch Gen Psychiatry, 47, 181. 
63. Hamm, A.O., Weike, A.I. and Schupp, H.T. 2001, Psychopharmacology (Berl), 
156, 259. 
64. Swerdlow, N.R., Talledo, J., Sutherland, A.N., Nagy, D. and Shoemaker, J.M. 
2006, Neuropsychopharmacology, 31, 2011. 
65. Klaning, U., Mortensen, P.B. and Kyvik, K.O. 1996, Br J Psychiatry, 168, 688. 
66. Angrist, B., Sathananthan, G., Wilk, S. and Gershon, S. 1974, J Psychiatr Res, 
11, 13. 
67. Mackeprang, T., Kristiansen, K.T. and Glenthoj, B.Y. 2002, Biol Psychiatry, 52, 
863. 
68. Conley, R.R. and Kelly, D.L. 2001, Biol Psychiatry, 50, 898. 
69. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, 
J.D., Heninger, G.R., Bowers, M.B., Jr. and Charney, D.S. 1994, Arch Gen 
Psychiatry, 51, 199. 
70. Meyer, J.S., Greifenstein, F. and Devault, M. 1959, Journal of Nervous and 
Mental Disease, 129, 54. 
71. Kim, J.S., Kornhuber, H.H., Schmid-Burgk, W. and Holzmuller, B. 1980, 
Neurosci Lett, 20, 379. 
72. Bakshi, V.P., Swerdlow, N.R. and Geyer, M.A. 1994, J Pharmacol Exp Ther, 
271, 787. 
Rodent models of schizophrenia 255 
73. Bakshi, V.P. and Geyer, M.A. 1995, Psychopharmacology (Berl), 122, 198. 
74. Moghaddam, B. and Jackson, M.E. 2003, Ann N Y Acad Sci, 1003, 131. 
75. Jentsch, J.D. and Roth, R.H. 1999, Neuropsychopharmacology, 20, 201. 
76. Hauber, W. and Schmidt, W.J. 1989, J Neural Transm Gen Sect, 78, 29. 
77. Mansbach, R.S. and Geyer, M.A. 1989, Neuropsychopharmacology, 2, 299. 
78. Steinpreis, R.E., Sokolowski, J.D., Papanikolaou, A. and Salamone, J.D. 1994, 
Pharmacol Biochem Behav, 47, 579. 
79. Duncan, E.J., Madonick, S.H., Parwani, A., Angrist, B., Rajan, R., Chakravorty, 
S., Efferen, T.R., Szilagyi, S., Stephanides, M., Chappell, P.B. et al. 2001, 
Neuropsychopharmacology, 25, 72. 
80. Carlsson, M. and Carlsson, A. 1990, Trends Neurosci, 13, 272. 
81. McCarley, R.W., Wible, C.G., Frumin, M., Hirayasu, Y., Levitt, J.J., Fischer, I.A. 
and Shenton, M.E. 1999, Biol Psychiatry, 45, 1099. 
82. Staal, W.G., Hulshoff Pol, H.E., Schnack, H.G., Hoogendoorn, M.L., Jellema, K. 
and Kahn, R.S. 2000, Am J Psychiatry, 157, 416. 
83. Hughes, C., Kumari, V., Das, M., Zachariah, E., Ettinger, U., Sumich, A. and 
Sharma, T. 2005, Acta Psychiatr Scand, 111, 185. 
84. Barrantes-Vidal, N., Aguilera, M., Campanera, S., Fatjo-Vilas, M., Guitart, M., 
Miret, S., Valero, S. and Fananas, L. 2007, Schizophr Res, 95, 70. 
85. Weinberger, D.R., Berman, K.F. and Zec, R.F. 1986, Arch Gen Psychiatry, 43, 
114. 
86. Suddath, R.L., Christison, G.W., Torrey, E.F., Casanova, M.F. and Weinberger, 
D.R. 1990, N Engl J Med, 322, 789. 
87. Cannon, T.D., van Erp, T.G., Huttunen, M., Lonnqvist, J., Salonen, O., Valanne, 
L., Poutanen, V.P., Standertskjold-Nordenstam, C.G., Gur, R.E. and Yan, M. 
1998, Arch Gen Psychiatry, 55, 1084. 
88. Goldstein, J.M., Goodman, J.M., Seidman, L.J., Kennedy, D.N., Makris, N., Lee, 
H., Tourville, J., Caviness, V.S., Jr., Faraone, S.V. and Tsuang, M.T. 1999, Arch 
Gen Psychiatry, 56, 537. 
89. Hirayasu, Y., Tanaka, S., Shenton, M.E., Salisbury, D.F., DeSantis, M.A., Levitt, 
J.J., Wible, C., Yurgelun-Todd, D., Kikinis, R., Jolesz, F.A. et al. 2001, Cereb 
Cortex, 11, 374. 
90. Wible, C.G., Shenton, M.E., Hokama, H., Kikinis, R., Jolesz, F.A., Metcalf, D. 
and McCarley, R.W. 1995, Arch Gen Psychiatry, 52, 279. 
91. Weinberger, D.R. 1991, Biol Psychiatry, 29, 509. 
92. Heckers, S., Rauch, S.L., Goff, D., Savage, C.R., Schacter, D.L., Fischman, A.J. 
and Alpert, N.M. 1998, Nat Neurosci, 1, 318. 
93. Weinberger, D.R., Berman, K.F. and Illowsky, B.P. 1988, Arch Gen Psychiatry, 
45, 609. 
94. Pycock, C.J., Kerwin, R.W. and Carter, C.J. 1980, Nature, 286, 74. 
95. Falkai, P. and Bogerts, B. 1986, Eur Arch Psychiatry Neurol Sci, 236, 154. 
96. Harrison, P.J. 1999, Brain, 122, 593. 
97. Church, S.M., Cotter, D., Bramon, E. and Murray, R.M. 2002, J Neural Transm 
Suppl, 129. 
98. Lieberman, J.A. 1999, Biol Psychiatry, 46, 729. 
 Ahmed El-Kordi et al. 256
99. Ojeda, N., Sanchez, P., Elizagarate, E., Yoller, A.B., Ezcurra, J., Ramirez, I. and 
Ballesteros, J. 2007, Actas Esp Psiquiatr, 35, 263. 
100. Thompson, P.M., Vidal, C., Giedd, J.N., Gochman, P., Blumenthal, J., Nicolson, 
R., Toga, A.W. and Rapoport, J.L. 2001, Proc Natl Acad Sci U S A, 98, 11650. 
101. Hoff, A.L., Sakuma, M., Razi, K., Heydebrand, G., Csernansky, J.G. and DeLisi, 
L.E. 2000, Am J Psychiatry, 157, 1824. 
102. Bogerts, B. 1993, Schizophr Bull, 19, 431. 
103. Croisier, E. and Graeber, M.B. 2006, Acta Neuropathol, 112, 517. 
104. Jarskog, L.F., Gilmore, J.H., Selinger, E.S. and Lieberman, J.A. 2000, Biol 
Psychiatry, 48, 641. 
105. Jarskog, L.F. 2006, Curr Opin Psychiatry, 19, 307. 
106. Purohit, D.P., Perl, D.P., Haroutunian, V., Powchik, P., Davidson, M. and Davis, 
K.L. 1998, Arch Gen Psychiatry, 55, 205. 
107. Mockler, D., Riordan, J. and Sharma, T. 1997, Schizophr Res, 26, 1. 
108. Lipska, B.K. 2004, J Psychiatry Neurosci, 29, 282. 
109. Harms, L.R., Eyles, D.W., McGrath, J.J., Mackay-Sim, A. and Burne, T.H. 2008, 
Behav Brain Res, 187, 343. 
110. Cintra, L., Granados, L., Aguilar, A., Kemper, T., DeBassio, W., Galler, J., 
Morgane, P., Duran, P. and Diaz-Cintra, S. 1997, Hippocampus, 7, 184. 
111. Cotter, D., Takei, N., Farrell, M., Sham, P., Quinn, P., Larkin, C., Oxford, J., 
Murray, R.M. and O'Callaghan, E. 1995, Schizophr Res, 16, 233. 
112. Brake, W.G., Boksa, P. and Gratton, A. 1997, Psychopharmacology (Berl), 133, 
389. 
113. Black, M.D., Selk, D.E., Hitchcock, J.M., Wettstein, J.G. and Sorensen, S.M. 
1999, Neuropharmacology, 38, 1299. 
114. Liu, D., Diorio, J., Tannenbaum, B., Caldji, C., Francis, D., Freedman, A., 
Sharma, S., Pearson, D., Plotsky, P.M. and Meaney, M.J. 1997, Science, 277, 
1659. 
115. Coyle, J.T. and Schwarcz, R. 1983,  Methods in Chemical Neuroanatomy. 
Björklund, A. and Hökfelt, T. (Ed.). Elsevier, New York, 508. 
116. Breese, G.R. and Traylor, T.D. 1970, J Pharmacol Exp Ther, 174, 413. 
117. Breese, G.R., Knapp, D.J., Criswell, H.E., Moy, S.S., Papadeas, S.T. and Blake, 
B.L. 2005, Brain Res Brain Res Rev, 48, 57. 
118. Lipska, B.K., Halim, N.D., Segal, P.N. and Weinberger, D.R. 2002, J Neurosci, 
22, 2835. 
119. Suzuki, M., Nohara, S., Hagino, H., Takahashi, T., Kawasaki, Y., Yamashita, I., 
Watanabe, N., Seto, H. and Kurachi, M. 2005, Psychiatry Res, 140, 157. 
120. Yoon, T., Okada, J., Jung, M.W. and Kim, J.J. 2008, Learn Mem, 15, 97. 
121. Braun, A.R., Jaskiw, G.E., Vladar, K., Sexton, R.H., Kolachana, B.S. and 
Weinberger, D.R. 1993, Pharmacol Biochem Behav, 46, 51. 
122. Lipska, B.K., Jaskiw, G.E., Braun, A.R. and Weinberger, D.R. 1995, Biol 
Psychiatry, 38, 255. 
123. Swerdlow, N.R., Lipska, B.K., Weinberger, D.R., Braff, D.L., Jaskiw, G.E. and 
Geyer, M.A. 1995, Psychopharmacology (Berl), 122, 27. 
124. Jaskiw, G.E., Karoum, F.K. and Weinberger, D.R. 1990, Brain Res, 534, 321. 
Rodent models of schizophrenia 257 
125. Miner, L.A., Ostrander, M. and Sarter, M. 1997, J Psychopharmacol, 11, 169. 
126. Joel, D., Weiner, I. and Feldon, J. 1997, Behav Brain Res, 85, 187. 
127. Lacroix, L., Spinelli, S., White, W. and Feldon, J. 2000, Neuroscience, 97, 459. 
128. Jaskiw, G.E., Karoum, F., Freed, W.J., Phillips, I., Kleinman, J.E. and 
Weinberger, D.R. 1990, Brain Res, 534, 263. 
129. Harden, D.G., King, D., Finlay, J.M. and Grace, A.A. 1998, Brain Res, 794, 96. 
130. King, D., Zigmond, M.J. and Finlay, J.M. 1997, Neuroscience, 77, 141. 
131. Wise, R.A. 2000, Prog Brain Res, 126, 255. 
132. Bordi, F. and Meller, E. 1989, Brain Res, 504, 276. 
133. Delfs, J.M. and Kelley, A.E. 1990, Neuroscience, 39, 59. 
134. LaHoste, G.J. and Marshall, J.F. 1990, Behav Brain Res, 38, 233. 
135. Subramaniam, S., Lucki, I. and McGonigle, P. 1992, Brain Res, 571, 313. 
136. Herrero, M.T., Barcia, C. and Navarro, J.M. 2002, Childs Nerv Syst, 18, 386. 
137. Swerdlow, N.R., Geyer, M.A. and Braff, D.L. 2001, Psychopharmacology (Berl), 
156, 194. 
138. Hazlett, E.A., Buchsbaum, M.S., Kemether, E., Bloom, R., Platholi, J., Brickman, 
A.M., Shihabuddin, L., Tang, C. and Byne, W. 2004, Am J Psychiatry, 161, 305. 
139. Buchsbaum, M.S., Someya, T., Teng, C.Y., Abel, L., Chin, S., Najafi, A., Haier, 
R.J., Wu, J. and Bunney, W.E., Jr. 1996, Am J Psychiatry, 153, 191. 
140. Andrews, J., Wang, L., Csernansky, J.G., Gado, M.H. and Barch, D.M. 2006, Am 
J Psychiatry, 163, 463. 
141. Andreasen, N.C., Arndt, S., Swayze, V., 2nd, Cizadlo, T., Flaum, M., O'Leary, 
D., Ehrhardt, J.C. and Yuh, W.T. 1994, Science, 266, 294. 
142. Arciniegas, D., Rojas, D.C., Teale, P., Sheeder, J., Sandberg, E. and Reite, M. 
1999, Biol Psychiatry, 45, 1329. 
143. Sutherland, R.J. 1982, Neurosci Biobehav Rev, 6, 1. 
144. Sandyk, R. 1991, Int J Neurosci, 61, 189. 
145. Sandyk, R. 1992, Int J Neurosci, 67, 19. 
146. Ellison, G. 1994, Brain Res Brain Res Rev, 19, 223. 
147. Lecourtier, L. and Kelly, P.H. 2005, Neuropsychopharmacology, 30, 484. 
148. Harms, M.P., Wang, L., Mamah, D., Barch, D.M., Thompson, P.A. and 
Csernansky, J.G. 2007, J Neurosci, 27, 13835. 
149. Mathalon, D.H., Heinks, T. and Ford, J.M. 2004, Am J Psychiatry, 161, 872. 
150. Schmahmann, J.D. 2003, Stroke, 34, 2264. 
151. Bardgett, M.E., Jackson, J.L., Taylor, G.T. and Csernansky, J.G. 1995, Behav 
Brain Res, 70, 153. 
152. Bardgett, M.E., Jacobs, P.S., Jackson, J.L. and Csernansky, J.G. 1997, Behav 
Brain Res, 84, 47. 
153. Csernansky, J.G., Csernansky, C.A., Kogelman, L., Montgomery, E.M. and 
Bardgett, M.E. 1998, Biol Psychiatry, 44, 1143. 
154. Goldman, M.B. and Mitchell, C.P. 2004, Schizophr Bull, 30, 367. 
155. Tierney, P.L., Degenetais, E., Thierry, A.M., Glowinski, J. and Gioanni, Y. 2004, 
Eur J Neurosci, 20, 514. 
156. Thierry, A.M., Gioanni, Y., Degenetais, E. and Glowinski, J. 2000, 
Hippocampus, 10, 411. 
 Ahmed El-Kordi et al. 258
157. Kelley, A.E. and Domesick, V.B. 1982, Neuroscience, 7, 2321. 
158. Jay, T.M., Glowinski, J. and Thierry, A.M. 1989, Brain Res, 505, 337. 
159. Lipska, B.K., Jaskiw, G.E., Karoum, F., Phillips, I., Kleinman, J.E. and 
Weinberger, D.R. 1991, Pharmacol Biochem Behav, 40, 181. 
160. Lipska, B.K., Jaskiw, G.E., Chrapusta, S., Karoum, F. and Weinberger, D.R. 
1992, Brain Res, 585, 1. 
161. Lanier, L.P. and Isaacson, R.L. 1975, Behav Biol, 13, 59. 
162. Kelley, A.E., Domesick, V.B. and Nauta, W.J. 1982, Neuroscience, 7, 615. 
163. Swanson, L.W. and Cowan, W.M. 1977, J Comp Neurol, 172, 49. 
164. Weinberger, D.R. 1987, Arch Gen Psychiatry, 44, 660. 
165. Kennard, M. 1936, Am J Physiol, 115, 138. 
166. Lipska, B.K., Jaskiw, G.E. and Weinberger, D.R. 1993, Neuropsychopharma-
cology, 9, 67. 
167. Lipska, B.K. and Weinberger, D.R. 1993, Brain Res Dev Brain Res, 75, 213. 
168. Lipska, B.K. and Weinberger, D.R. 1994, Neuropsychopharmacology, 10, 199. 
169. Sams-Dodd, F., Lipska, B.K. and Weinberger, D.R. 1997, Psychopharmacology 
(Berl), 132, 303. 
170. Lipska, B.K., Chrapusta, S.J., Egan, M.F. and Weinberger, D.R. 1995, Synapse, 
20, 125. 
171. Chambers, R.A. and Self, D.W. 2002, Neuropsychopharmacology, 27, 889. 
172. Le Pen, G., Gaudet, L., Mortas, P., Mory, R. and Moreau, J.L. 2002, 
Psychopharmacology (Berl), 161, 434. 
173. Becker, A., Grecksch, G., Bernstein, H.G., Hollt, V. and Bogerts, B. 1999, 
Psychopharmacology (Berl), 144, 333. 
174. Becker, A. and Grecksch, G. 2003, Pharmacol Biochem Behav, 76, 1. 
175. Becker, A. and Grecksch, G. 2000, Behav Brain Res, 109, 137. 
176. Chambers, R.A., Moore, J., McEvoy, J.P. and Levin, E.D. 1996, 
Neuropsychopharmacology, 15, 587. 
177. Lipska, B.K., Aultman, J.M., Verma, A., Weinberger, D.R. and Moghaddam, B. 
2002, Neuropsychopharmacology, 27, 47. 
178. Grecksch, G., Bernstein, H.G., Becker, A., Hollt, V. and Bogerts, B. 1999, 
Neuropsychopharmacology, 20, 525. 
179. Le Pen, G. and Moreau, J.L. 2002, Neuropsychopharmacology, 27, 1. 
180. Lipska, B.K., Swerdlow, N.R., Geyer, M.A., Jaskiw, G.E., Braff, D.L. and 
Weinberger, D.R. 1995, Psychopharmacology (Berl), 122, 35. 
181. Lipska, B.K. and Weinberger, D.R. 1995, Proc Natl Acad Sci U S A, 92, 8906. 
182. Lipska, B.K. and Weinberger, D.R. 1994, Brain Res Dev Brain Res, 78, 253. 
183. Goto, Y. and O'Donnell, P. 2004, Biol Psychiatry, 55, 172. 
184. Akbarian, S. and Huang, H.S. 2006, Brain Res Rev, 52, 293. 
185. Angelucci, F., Brene, S. and Mathe, A.A. 2005, Mol Psychiatry, 10, 345. 
186. Khaing, Z.Z., Weickert, C.S., Weinberger, D.R. and Lipska, B.K. 2000, Eur J 
Neurosci, 12, 4424. 
187. Lipska, B.K. and Weinberger, D.R. 2002, Neurotox Res, 4, 469. 
188. Jablensky, A. 1997, Schizophr Res, 28, 111. 
Rodent models of schizophrenia 259 
189. Owen, M.J., O'Donovan, M.C. and Gottesman, I.I. 2002, Psychiatric Genetics & 
Genomics. McGuffin, P., Owen, M.J. and Gottesman, I.I. (Ed.). Oxford University 
Press, Oxford, 247. 
190. Gottesman, I.I. 1991, Schizophrenia Genesis: The Origins of Madness. Freeman, 
New York. 
191. Jablensky, A. and Sartorius, N. 1988, Acta Psychiatr Scand Suppl, 344, 65. 
192. Bromet, E.J. and Fennig, S. 1999, Biol Psychiatry, 46, 871. 
193. Waddington, J.L., Corvin, A.P., Donohoe, G., O'Tuathaigh, C.M., Mitchell, K.J. 
and Gill, M. 2007, Psychiatr Clin North Am, 30, 365. 
194. Badner, J.A. and Gershon, E.S. 2002, Mol Psychiatry, 7, 405. 
195. Lewis, C.M., Levinson, D.F., Wise, L.H., DeLisi, L.E., Straub, R.E., Hovatta, I., 
Williams, N.M., Schwab, S.G., Pulver, A.E., Faraone, S.V. et al. 2003, Am J 
Hum Genet, 73, 34. 
196. Tecott, L.H. 2003, Am J Psychiatry, 160, 646. 
197. Pennacchio, L.A. 2003, Mamm Genome, 14, 429. 
198. Ryding, A.D., Sharp, M.G. and Mullins, J.J. 2001, J Endocrinol, 171, 1. 
199. Bucan, M. and Abel, T. 2002, Nat Rev Genet, 3, 114. 
200. Muller, M.B. and Keck, M.E. 2002, J Psychiatr Res, 36, 53. 
201. Bult, C.J., Eppig, J.T., Kadin, J.A., Richardson, J.E. and Blake, J.A. 2008, 
Nucleic Acids Res, 36, D724. 
202. Waterston, R.H. and Lindblad-Toh, K. and Birney, E. and Rogers, J. and Abril, 
J.F. and Agarwal, P. and Agarwala, R. and Ainscough, R. and Alexandersson, M. 
and An, P. et al. 2002, Nature, 420, 520. 
203. Gould, T.D. and Gottesman, II 2006, Genes Brain Behav, 5, 113. 
204. Walters, J.T. and Owen, M.J. 2007, Mol Psychiatry, 12, 886. 
205. Gottesman, II and Gould, T.D. 2003, Am J Psychiatry, 160, 636. 
206. Bearden, C.E. and Freimer, N.B. 2006, Trends Genet, 22, 306. 
207. Winterer, G. and Goldman, D. 2003, Brain Res Brain Res Rev, 43, 134. 
208. Burdick, K.E., Lencz, T., Funke, B., Finn, C.T., Szeszko, P.R., Kane, J.M., 
Kucherlapati, R. and Malhotra, A.K. 2006, Hum Mol Genet, 15, 1563. 
209. Ellenbroek, B.A. 2003, Behav Pharmacol, 14, 409. 
210. Chen, J., Lipska, B.K. and Weinberger, D.R. 2006, Biol Psychiatry, 59, 1180. 
211. Brose, N. 2008, Mol Cells, 25, 7. 
212. Harrison, P.J. and Weinberger, D.R. 2005, Mol Psychiatry, 10, 40. 
213. O'Tuathaigh, C.M., Babovic, D., O'Meara, G., Clifford, J.J., Croke, D.T. and 
Waddington, J.L. 2007, Neurosci Biobehav Rev, 31, 60. 
214. Gogos, J.A. and Gerber, D.J. 2006, Trends Pharmacol Sci, 27, 226. 
215. Fukui, N., Muratake, T., Kaneko, N., Amagane, H. and Someya, T. 2006, 
Neurosci Lett, 396, 117. 
216. Gruber, O., Falkai, P., Schneider-Axmann, T., Schwab, S.G., Wagner, M. and 
Maier, W. 2008, J Psychiatr Res. 
217. Yang, J.Z., Si, T.M., Ruan, Y., Ling, Y.S., Han, Y.H., Wang, X.L., Zhou, M., 
Zhang, H.Y., Kong, Q.M., Liu, C. et al. 2003, Mol Psychiatry, 8, 706. 
218. Zhao, X., Shi, Y., Tang, J., Tang, R., Yu, L., Gu, N., Feng, G., Zhu, S., Liu, H., 
Xing, Y. et al. 2004, J Med Genet, 41, 31. 
 Ahmed El-Kordi et al. 260
219. Li, T., Stefansson, H., Gudfinnsson, E., Cai, G., Liu, X., Murray, R.M., 
Steinthorsdottir, V., Januel, D., Gudnadottir, V.G., Petursson, H. et al. 2004, Mol 
Psychiatry, 9, 698. 
220. Munafo, M.R., Thiselton, D.L., Clark, T.G. and Flint, J. 2006, Mol Psychiatry, 
11, 539. 
221. Munafo, M.R., Attwood, A.S. and Flint, J. 2008, Schizophr Bull, 34, 9. 
222. Li, D., Collier, D.A. and He, L. 2006, Hum Mol Genet, 15, 1995. 
223. Tosato, S., Dazzan, P. and Collier, D. 2005, Schizophr Bull, 31, 613. 
224. Ikeda, M., Takahashi, N., Saito, S., Aleksic, B., Watanabe, Y., Nunokawa, A., 
Yamanouchi, Y., Kitajima, T., Kinoshita, Y., Kishi, T. et al. 2008, Schizophr Res. 
225. Duan, J., Martinez, M., Sanders, A.R., Hou, C., Krasner, A.J., Schwartz, D.B. 
and Gejman, P.V. 2005, Psychol Med, 35, 1599. 
226. Thiselton, D.L., Webb, B.T., Neale, B.M., Ribble, R.C., O'Neill, F.A., Walsh, D., 
Riley, B.P. and Kendler, K.S. 2004, Mol Psychiatry, 9, 777. 
227. Gardner, M., Gonzalez-Neira, A., Lao, O., Calafell, F., Bertranpetit, J. and 
Comas, D. 2006, Mol Psychiatry, 11, 66. 
228. Corfas, G., Roy, K. and Buxbaum, J.D. 2004, Nat Neurosci, 7, 575. 
229. Harrison, P.J. and Law, A.J. 2006, Biol Psychiatry, 60, 132. 
230. Falls, D.L. 2003, Exp Cell Res, 284, 14. 
231. Falls, D.L. 2003, J Neurocytol, 32, 619. 
232. Gu, Z., Jiang, Q., Fu, A.K., Ip, N.Y. and Yan, Z. 2005, J Neurosci, 25, 4974. 
233. Woo, R.S., Li, X.M., Tao, Y., Carpenter-Hyland, E., Huang, Y.Z., Weber, J., 
Neiswender, H., Dong, X.P., Wu, J., Gassmann, M. et al. 2007, Neuron, 54, 599. 
234. Hahn, C.G., Wang, H.Y., Cho, D.S., Talbot, K., Gur, R.E., Berrettini, W.H., 
Bakshi, K., Kamins, J., Borgmann-Winter, K.E., Siegel, S.J. et al. 2006, Nat 
Med, 12, 824. 
235. Li, B., Woo, R.S., Mei, L. and Malinow, R. 2007, Neuron, 54, 583. 
236. Hall, J., Whalley, H.C., Job, D.E., Baig, B.J., McIntosh, A.M., Evans, K.L., 
Thomson, P.A., Porteous, D.J., Cunningham-Owens, D.G., Johnstone, E.C. et al. 
2006, Nat Neurosci, 9, 1477. 
237. Stefansson, H., Sarginson, J., Kong, A., Yates, P., Steinthorsdottir, V., 
Gudfinnsson, E., Gunnarsdottir, S., Walker, N., Petursson, H., Crombie, C. et al. 
2003, Am J Hum Genet, 72, 83. 
238. van Erp, T.G., Saleh, P.A., Huttunen, M., Lonnqvist, J., Kaprio, J., Salonen, O., 
Valanne, L., Poutanen, V.P., Standertskjold-Nordenstam, C.G. and Cannon, T.D. 
2004, Arch Gen Psychiatry, 61, 346. 
239. van Haren, N.E., Picchioni, M.M., McDonald, C., Marshall, N., Davis, N., 
Ribchester, T., Hulshoff Pol, H.E., Sharma, T., Sham, P., Kahn, R.S. et al. 2004, 
Biol Psychiatry, 56, 454. 
240. Addington, A.M., Gornick, M.C., Shaw, P., Seal, J., Gogtay, N., Greenstein, D., 
Clasen, L., Coffey, M., Gochman, P., Long, R. et al. 2007, Mol Psychiatry, 12, 195. 
241. Gerlai, R., Pisacane, P. and Erickson, S. 2000, Behav Brain Res, 109, 219. 
242. O'Tuathaigh, C.M., Babovic, D., O'Sullivan, G.J., Clifford, J.J., Tighe, O., Croke, 
D.T., Harvey, R. and Waddington, J.L. 2007, Neuroscience, 147, 18. 
Rodent models of schizophrenia 261 
243. Rimer, M., Barrett, D.W., Maldonado, M.A., Vock, V.M. and Gonzalez-Lima, F. 
2005, Neuroreport, 16, 271. 
244. Reim, K., Wegmeyer, H., Brandstatter, J.H., Xue, M., Rosenmund, C., Dresbach, 
T., Hofmann, K. and Brose, N. 2005, J Cell Biol, 169, 669. 
245. McMahon, H.T., Missler, M., Li, C. and Sudhof, T.C. 1995, Cell, 83, 111. 
246. Harrison, P.J. and Eastwood, S.L. 1998, Lancet, 352, 1669. 
247. Eastwood, S.L. and Harrison, P.J. 2005, Schizophr Res, 73, 159. 
248. Yamauchi, Y., Qin, L.H., Nishihara, M., Sawada, K., Kato, K. and Inoue, S. 
2005, Brain Res, 1056, 59. 
249. Takahashi, S., Ujihara, H., Huang, G.Z., Yagyu, K.I., Sanbo, M., Kaba, H. and 
Yagi, T. 1999, Eur J Neurosci, 11, 2359. 
250. Chubb, J.E., Bradshaw, N.J., Soares, D.C., Porteous, D.J. and Millar, J.K. 2008, 
Mol Psychiatry, 13, 36. 
251. Hennah, W., Thomson, P., McQuillin, A., Bass, N., Loukola, A., Anjorin, A., 
Blackwood, D., Curtis, D., Deary, I.J., Harris, S.E. et al. 2008, Mol Psychiatry. 
252. Kilpinen, H., Ylisaukko-Oja, T., Hennah, W., Palo, O.M., Varilo, T., Vanhala, 
R., Nieminen-von Wendt, T., von Wendt, L., Paunio, T. and Peltonen, L. 2008, 
Mol Psychiatry, 13, 187. 
253. St Clair, D., Blackwood, D., Muir, W., Carothers, A., Walker, M., Spowart, G., 
Gosden, C. and Evans, H.J. 1990, Lancet, 336, 13. 
254. Millar, J.K., Wilson-Annan, J.C., Anderson, S., Christie, S., Taylor, M.S., 
Semple, C.A., Devon, R.S., Clair, D.M., Muir, W.J., Blackwood, D.H. et al. 
2000, Hum Mol Genet, 9, 1415. 
255. Hennah, W., Varilo, T., Kestila, M., Paunio, T., Arajarvi, R., Haukka, J., Parker, 
A., Martin, R., Levitzky, S., Partonen, T. et al. 2003, Hum Mol Genet, 12, 3151. 
256. Hodgkinson, C.A., Goldman, D., Jaeger, J., Persaud, S., Kane, J.M., Lipsky, R.H. 
and Malhotra, A.K. 2004, Am J Hum Genet, 75, 862. 
257. Porteous, D.J., Thomson, P., Brandon, N.J. and Millar, J.K. 2006, Biol 
Psychiatry, 60, 123. 
258. Duan, X., Chang, J.H., Ge, S., Faulkner, R.L., Kim, J.Y., Kitabatake, Y., Liu, 
X.B., Yang, C.H., Jordan, J.D., Ma, D.K. et al. 2007, Cell, 130, 1146. 
259. Millar, J.K., James, R., Brandon, N.J. and Thomson, P.A. 2004, Ann Med, 36, 
367. 
260. Schurov, I.L., Handford, E.J., Brandon, N.J. and Whiting, P.J. 2004, Mol 
Psychiatry, 9, 1100. 
261. Lipska, B.K., Peters, T., Hyde, T.M., Halim, N., Horowitz, C., Mitkus, S., 
Weickert, C.S., Matsumoto, M., Sawa, A., Straub, R.E. et al. 2006, Hum Mol 
Genet, 15, 1245. 
262. Burdick, K.E., Hodgkinson, C.A., Szeszko, P.R., Lencz, T., Ekholm, J.M., Kane, 
J.M., Goldman, D. and Malhotra, A.K. 2005, Neuroreport, 16, 1399. 
263. Millar, J.K., Pickard, B.S., Mackie, S., James, R., Christie, S., Buchanan, S.R., 
Malloy, M.P., Chubb, J.E., Huston, E., Baillie, G.S. et al. 2005, Science, 310, 
1187. 
264. Davis, R.L., Cherry, J., Dauwalder, B., Han, P.L. and Skoulakis, E. 1995, Mol 
Cell Biochem, 149-150, 271. 
 Ahmed El-Kordi et al. 262
265. Alberini, C.M., Ghirardi, M., Huang, Y.Y., Nguyen, P.V. and Kandel, E.R. 1995, 
Ann N Y Acad Sci, 758, 261. 
266. Porteous, D.J. and Millar, J.K. 2006, Trends Mol Med, 12, 255. 
267. Samochowiec, J., Hajduk, A., Samochowiec, A., Horodnicki, J., Stepien, G., 
Grzywacz, A. and Kucharska-Mazur, J. 2004, Psychiatry Res, 128, 21. 
268. Hosak, L. 2007, Eur Psychiatry, 22, 276. 
269. Murphy, K.C., Jones, L.A. and Owen, M.J. 1999, Arch Gen Psychiatry, 56, 940. 
270. Blasi, G., Mattay, V.S., Bertolino, A., Elvevag, B., Callicott, J.H., Das, S., 
Kolachana, B.S., Egan, M.F., Goldberg, T.E. and Weinberger, D.R. 2005, J 
Neurosci, 25, 5038. 
271. Egan, M.F., Goldberg, T.E., Kolachana, B.S., Callicott, J.H., Mazzanti, C.M., 
Straub, R.E., Goldman, D. and Weinberger, D.R. 2001, Proc Natl Acad Sci U S 
A, 98, 6917. 
272. Bilder, R.M., Volavka, J., Czobor, P., Malhotra, A.K., Kennedy, J.L., Ni, X., 
Goldman, R.S., Hoptman, M.J., Sheitman, B., Lindenmayer, J.P. et al. 2002, Biol 
Psychiatry, 52, 701. 
273. Chen, X., Wang, X., O'Neill, A.F., Walsh, D. and Kendler, K.S. 2004, Mol 
Psychiatry, 9, 962. 
274. Shifman, S., Bronstein, M., Sternfeld, M., Pisante-Shalom, A., Lev-Lehman, E., 
Weizman, A., Reznik, I., Spivak, B., Grisaru, N., Karp, L. et al. 2002, Am J Hum 
Genet, 71, 1296. 
275. Wei, J. and Hemmings, G.P. 1999, Psychiatr Genet, 9, 183. 
276. Joo, E.J., Jeong, S.H., Ahn, Y.M., Lee, K.Y., Chang Yoon, S., Kim, E.J., Kim, 
S.U., Cho, S.C. and Sik Kim, Y. 2005, Psychiatry Res, 136, 83. 
277. Munafo, M.R., Bowes, L., Clark, T.G. and Flint, J. 2005, Mol Psychiatry, 10, 
765. 
278. Glatt, S.J., Faraone, S.V. and Tsuang, M.T. 2003, Am J Psychiatry, 160, 469. 
279. Goldberg, T.E., Egan, M.F., Gscheidle, T., Coppola, R., Weickert, T., Kolachana, 
B.S., Goldman, D. and Weinberger, D.R. 2003, Arch Gen Psychiatry, 60, 889. 
280. Apud, J.A., Mattay, V., Chen, J., Kolachana, B.S., Callicott, J.H., Rasetti, R., 
Alce, G., Iudicello, J.E., Akbar, N., Egan, M.F. et al. 2007, 
Neuropsychopharmacology, 32, 1011. 
281. Meyer-Lindenberg, A. and Weinberger, D.R. 2006, Nat Rev Neurosci, 7, 818. 
282. Tunbridge, E.M., Harrison, P.J. and Weinberger, D.R. 2006, Biol Psychiatry, 60, 
141. 
283. Craddock, N., O'Donovan, M.C. and Owen, M.J. 2006, Schizophr Bull, 32, 9. 
284. Straub, R.E., Jiang, Y., MacLean, C.J., Ma, Y., Webb, B.T., Myakishev, M.V., 
Harris-Kerr, C., Wormley, B., Sadek, H., Kadambi, B. et al. 2002, Am J Hum 
Genet, 71, 337. 
285. Schwab, S.G., Knapp, M., Mondabon, S., Hallmayer, J., Borrmann-Hassenbach, 
M., Albus, M., Lerer, B., Rietschel, M., Trixler, M., Maier, W. et al. 2003, Am J 
Hum Genet, 72, 185. 
286. Kirov, G., Ivanov, D., Williams, N.M., Preece, A., Nikolov, I., Milev, R., Koleva, 
S., Dimitrova, A., Toncheva, D., O'Donovan, M.C. et al. 2004, Biol Psychiatry, 
55, 971. 
Rodent models of schizophrenia 263 
287. Liu, C.M., Liu, Y.L., Fann, C.S., Yang, W.C., Wu, J.Y., Hung, S.I., Chen, W.J., 
Chueh, C.M., Liu, W.M., Liu, C.C. et al. 2007, Schizophr Res, 93, 391. 
288. Joo, E.J., Lee, K.Y., Jeong, S.H., Ahn, Y.M., Koo, Y.J. and Kim, Y.S. 2006, 
Neurosci Lett, 407, 101. 
289. Datta, S.R., McQuillin, A., Puri, V., Choudhury, K., Thirumalai, S., Lawrence, J., 
Pimm, J., Bass, N., Lamb, G., Moorey, H. et al. 2007, Behav Brain Funct, 3, 50. 
290. Benson, M.A., Newey, S.E., Martin-Rendon, E., Hawkes, R. and Blake, D.J. 
2001, J Biol Chem, 276, 24232. 
291. Weickert, C.S., Straub, R.E., McClintock, B.W., Matsumoto, M., Hashimoto, R., 
Hyde, T.M., Herman, M.M., Weinberger, D.R. and Kleinman, J.E. 2004, Arch 
Gen Psychiatry, 61, 544. 
292. Talbot, K., Eidem, W.L., Tinsley, C.L., Benson, M.A., Thompson, E.W., Smith, 
R.J., Hahn, C.G., Siegel, S.J., Trojanowski, J.Q., Gur, R.E. et al. 2004, J Clin 
Invest, 113, 1353. 
293. Olney, J.W., Newcomer, J.W. and Farber, N.B. 1999, J Psychiatr Res, 33, 523. 
294. Williams, N.M., Preece, A., Morris, D.W., Spurlock, G., Bray, N.J., Stephens, 
M., Norton, N., Williams, H., Clement, M., Dwyer, S. et al. 2004, Arch Gen 
Psychiatry, 61, 336. 
295. van den Oord, E.J., Sullivan, P.F., Jiang, Y., Walsh, D., O'Neill, F.A., Kendler, 
K.S. and Riley, B.P. 2003, Mol Psychiatry, 8, 499. 
296. Fanous, A.H., van den Oord, E.J., Riley, B.P., Aggen, S.H., Neale, M.C., O'Neill, 
F.A., Walsh, D. and Kendler, K.S. 2005, Am J Psychiatry, 162, 1824. 
297. DeRosse, P., Funke, B., Burdick, K.E., Lencz, T., Ekholm, J.M., Kane, J.M., 
Kucherlapati, R. and Malhotra, A.K. 2006, Am J Psychiatry, 163, 532. 
298. Gornick, M.C., Addington, A.M., Sporn, A., Gogtay, N., Greenstein, D., Lenane, 
M., Gochman, P., Ordonez, A., Balkissoon, R., Vakkalanka, R. et al. 2005, J 
Autism Dev Disord, 35, 831. 
299. Burdick, K.E., Goldberg, T.E., Funke, B., Bates, J.A., Lencz, T., Kucherlapati, R. 
and Malhotra, A.K. 2007, Schizophr Res, 89, 169. 
300. Donohoe, G., Morris, D.W., De Sanctis, P., Magno, E., Montesi, J.L., Garavan, 
H.P., Robertson, I.H., Javitt, D.C., Gill, M., Corvin, A.P. et al. 2008, Biol 
Psychiatry, 63, 484. 
301. Fallgatter, A.J., Herrmann, M.J., Hohoff, C., Ehlis, A.C., Jarczok, T.A., Freitag, 
C.M. and Deckert, J. 2006, Neuropsychopharmacology, 31, 2002. 
302. Sillitoe, R.V., Benson, M.A., Blake, D.J. and Hawkes, R. 2003, J Neurosci, 23, 
6576. 
303. Li, W., Zhang, Q., Oiso, N., Novak, E.K., Gautam, R., O'Brien, E.P., Tinsley, 
C.L., Blake, D.J., Spritz, R.A., Copeland, N.G. et al. 2003, Nat Genet, 35, 84. 
304. Levitt, P., Ebert, P., Mirnics, K., Nimgaonkar, V.L. and Lewis, D.A. 2006, Biol 
Psychiatry, 60, 534. 
305. Talkowski, M.E., Chowdari, K., Lewis, D.A. and Nimgaonkar, V.L. 2006, 
Schizophr Bull, 32, 203. 
306. Talkowski, M.E., Seltman, H., Bassett, A.S., Brzustowicz, L.M., Chen, X., 
Chowdari, K.V., Collier, D.A., Cordeiro, Q., Corvin, A.P., Deshpande, S.N. et al. 
2006, Biol Psychiatry, 60, 152. 
 Ahmed El-Kordi et al. 264
307. Chen, X., Dunham, C., Kendler, S., Wang, X., O'Neill, F.A., Walsh, D. and 
Kendler, K.S. 2004, Am J Med Genet B Neuropsychiatr Genet, 129, 23. 
308. Mirnics, K., Middleton, F.A., Stanwood, G.D., Lewis, D.A. and Levitt, P. 2001, 
Mol Psychiatry, 6, 293. 
309. Ni, Y.G., Gold, S.J., Iredale, P.A., Terwilliger, R.Z., Duman, R.S. and Nestler, 
E.J. 1999, J Neurosci, 19, 3674. 
310. Sobell, J.L., Richard, C., Wirshing, D.A. and Heston, L.L. 2005, Am J Med 
Genet B Neuropsychiatr Genet, 139, 23. 
311. Ishiguro, H., Horiuchi, Y., Koga, M., Inada, T., Iwata, N., Ozaki, N., Ujike, H., 
Muratake, T., Someya, T. and Arinami, T. 2007, Schizophr Res, 89, 161. 
312. Zhang, F., St Clair, D., Liu, X., Sun, X., Sham, P.C., Crombie, C., Ma, X., Wang, 
Q., Meng, H., Deng, W. et al. 2005, Genes Brain Behav, 4, 444. 
313. Gold, S.J., Ni, Y.G., Dohlman, H.G. and Nestler, E.J. 1997, J Neurosci, 17, 8024. 
314. Erdely, H.A., Lahti, R.A., Lopez, M.B., Myers, C.S., Roberts, R.C., Tamminga, 
C.A. and Vogel, M.W. 2004, Eur J Neurosci, 19, 3125. 
315. Taymans, J.M., Leysen, J.E. and Langlois, X. 2003, J Neurochem, 84, 1118. 
316. Geurts, M., Hermans, E. and Maloteaux, J.M. 2002, Neurosci Lett, 333, 146. 
317. Saugstad, J.A., Marino, M.J., Folk, J.A., Hepler, J.R. and Conn, P.J. 1998, J 
Neurosci, 18, 905. 
318. Bowden, N.A., Scott, R.J. and Tooney, P.A. 2007, Schizophr Res, 89, 165. 
319. Cleghorn, J.M., Garnett, E.S., Nahmias, C., Brown, G.M., Kaplan, R.D., 
Szechtman, H., Szechtman, B., Franco, S., Dermer, S.W. and Cook, P. 1990, Br J 
Psychiatry, 157, 562. 
320. Buckholtz, J.W., Meyer-Lindenberg, A., Honea, R.A., Straub, R.E., Pezawas, L., 
Egan, M.F., Vakkalanka, R., Kolachana, B., Verchinski, B.A., Sust, S. et al. 
2007, J Neurosci, 27, 1584. 
321. Grillet, N., Pattyn, A., Contet, C., Kieffer, B.L., Goridis, C. and Brunet, J.F. 
2005, Mol Cell Biol, 25, 4221. 
322. Sanders, A.R., Duan, J., Levinson, D.F., Shi, J., He, D., Hou, C., Burrell, G.J., 
Rice, J.P., Nertney, D.A., Olincy, A. et al. 2008, Am J Psychiatry. 
323. Riley, B. and Kendler, K.S. 2006, Eur J Hum Genet, 14, 669. 
324. Shirts, B.H. and Nimgaonkar, V. 2004, Curr Psychiatry Rep, 6, 303. 
325. Sullivan, P.F. 2005, PLoS Med, 2, e212. 
326. Bayer, T.A., Falkai, P. and Maier, W. 1999, J Psychiatr Res, 33, 543. 
327. Maynard, T.M., Sikich, L., Lieberman, J.A. and LaMantia, A.S. 2001, Schizophr 
Bull, 27, 457. 
328. Hori, T., Subramaniam, S., Srivastava, L.K. and Quirion, R. 2000, 
Neuropharmacology, 39, 2478. 
329. Boucher, A.A., Arnold, J.C., Duffy, L., Schofield, P.R., Micheau, J. and Karl, T. 
2007, Psychopharmacology (Berl), 192, 325. 
330. Siren, A.L., Radyushkin, K., Boretius, S., Kammer, D., Riechers, C.C., Natt, O., 
Sargin, D., Watanabe, T., Sperling, S., Michaelis, T. et al. 2006, Brain, 129, 480. 
 
3.3. ORIGINAL PUBLICATION 
 
Radyushkin K, El-Kordi A*, Boretius S, Castaneda S, Ronnenberg A, Reim K, 
Bickeböller H, Frahm J, Brose N and Ehrenreich H (2010). Complexin2 null mutation 
requires a ‘second hit’ for induction of phenotypic changes relevant to schizophrenia. 
Genes, Brain and Behavior, 9:592-602. 
 
*Equally contributing first author 
 
 
 
Personal contribution 
I was involved in the design of the study, conduction of behavioral and 
psychopharmacological experiments, analysis and interpretation of behavioral data, 
analysis and supervision of analysis of MRI data, and preparing the manuscript.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70
Genes, Brain and Behavior (2010) 9: 592–602 © 2010 The Authors
Journal compilation © 2010 Blackwell Publishing Ltd/International Behavioural and Neural Genetics Society
Complexin2 null mutation requires a ‘second hit’
for induction of phenotypic changes relevant
to schizophrenia
K. Radyushkin†,∗∗,1, A. El-Kordi†,∗∗,1,
S. Boretius‡,∗∗, S. Castaneda†, A. Ronnenberg†,
K. Reim§, H. Bickebo¨ller¶, J. Frahm‡,∗∗,
N. Brose§,∗∗,∗ and H. Ehrenreich†,∗∗,∗
†Division of Clinical Neuroscience, Max Planck Institute of
Experimental Medicine, ‡Biomedizinische NMR Forschungs
GmbH, Max Planck Institute for Biophysical Chemistry,
§Department of Molecular Neurobiology, Max Planck Institute
of Experimental Medicine, ¶Department of Genetic
Epidemiology, Georg August University, and **DFG Center for
Molecular Physiology of the Brain (CMPB), Go¨ttingen, Germany
1These authors contributed equally to this work.
*Corresponding authors: Professor Hannelore Ehrenreich, MD,
DVM, Division of Clinical Neuroscience, Max Planck Institute of
Experimental Medicine, Hermann-Rein-Str. 3, 37075 Go¨ttingen,
Germany. E-mail: ehrenreich@em.mpg.de
Professor Nils Brose, PhD, Department of Molecular Neu-
robiology, Max Planck Institute of Experimental Medicine,
Hermann-Rein-Str. 3, 37075 Go¨ttingen, Germany. E-mail:
brose@em.mpg.de
Schizophrenia is a devastating disease that affects
approximately 1% of the population across cultures.
Its neurobiological underpinnings are still unknown.
Accordingly, animal models of schizophrenia often lack
construct validity. As concordance rate in monozy-
gotic twins amounts to only 50%, environmental risk
factors (e.g. neurotrauma, drug abuse, psychotrauma)
likely act as necessary ‘second hit’ to trigger/drive
the disease process in a genetically predisposed indi-
vidual. Valid animal models would have to consider
this genetic–environmental interaction. Based on this
concept, we designed an experimental approach for
modeling a schizophrenia-like phenotype in mice. As
dysfunction in synaptic transmission plays a key role in
schizophrenia, and complexin2 (CPLX2) gene expression
is reduced in hippocampus of schizophrenic patients, we
developed a mouse model with Cplx2 null mutation
as genetic risk factor and a mild parietal neurotrauma,
applied during puberty, as environmental ‘second hit’.
Several months after lesion, Cplx2 null mutants showed
reduced pre-pulse inhibition, deficit of spatial learning
and loss of inhibition after MK-801 challenge. These
abnormalities were largely absent in lesioned wild-type
mice and non-lesioned Cplx2 null mutants. Forced alter-
nation in T-maze, object recognition, social interaction
and elevated plus maze tests were unaltered in all
groups. The previously reported mild motor phenotype
of Cplx2 null mutants was accentuated upon lesion. MRI
volumetrical analysis showed a decrease of hippocampal
volume exclusively in lesioned Cplx2 null mutants. These
findings provide suggestive evidence for the ‘second hit’
hypothesis of schizophrenia and may offer new tools for
the development of advanced treatment strategies.
Keywords: Animal model, cryolesion, etiology, MK-
801, mouse model, neurotrauma, parietal cortex, PPI,
schizophrenia
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Schizophrenia is a frequent, debilitating, complex disease
phenotype, characterized by positive, negative and cognitive
symptoms (American Psychiatric Association 2000; van Os &
Kapur 2009; Wong & Van Tol 2003) with still obscure etiology
(Sawa & Snyder, 2002). As it is debatable which constructs
are central in the pathophysiology of schizophrenia, animal
models with convincing construct validity (e.g. Willner
1986) have been sparse. In contrast, models with face
validity, where immature rodents are exposed to lesions
or pharmacological interventions, have been used for many
years (for review see, e.g. Lipska 2004).
A genetic root of schizophrenia is indisputable but
concordance rate in monozygotic twins is only 50%
(Gottesman & Shields 1976), pointing to additional, epige-
netic/environmental risk factors (Anderson et al. 1998; Bayer
et al. 1999). The ‘second hit hypothesis’ proposes a non-
genetic risk factor (‘environmental or second hit’) triggering
schizophrenia in predisposed individuals (‘genetic or first hit’).
Consequently, recent animal models unite genetic with envi-
ronmental factors (for review see, e.g. Ayhan et al. 2009).
Based on this ‘second hit hypothesis’, we designed an experi-
mental approach for modeling schizophrenia which combines
a genetic [Complexin2 (Cplx2) null mutation] and an environ-
mental factor (mild parietal cortical lesion during puberty) to
induce schizophrenia-like features in mice.
Schizophrenia is seen as a ‘disease of the synapse’
(Harrison & Weinberger 2005) bringing synaptic molecules
into research focus. Among these are complexins (CPLX),
presynaptic proteins that modulate neuronal exocytosis (for
review see Brose 2008). They form a family of four small
(134–160 residues) charged proteins, subdivided into two
subfamilies: Cplx1/2 expressed in central nervous system
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and Cplx3/4 mainly in retinal ribbon synapses (McMahon
et al. 1995; Reim et al. 2005). In schizophrenic post-
mortem brains, hippocampal CPLX2/CPLX2 expression is
decreased (Harrison & Eastwood 1998; Sawada et al. 2002).
Association of single nucleotide polymorphisms in CPLX2
with schizophrenia was shown in a Korean population, adding
this gene to potential risk genes (Lee et al. 2005). In Cplx2−/−
mice, a mild behavioral phenotype consists of slight motor
deficit and, inconsistently, impaired learning in Morris water
maze (Glynn et al. 2003, 2007; Yamauchi et al. 2005).
Neurotrauma is one potential risk factor for schizophrenia
(Malaspina et al. 2001; McAllister 1998), and particularly
lesions affecting the right parietal lobe have been associated
with schizophrenia-like psychosis (Sachdev et al. 2001;
Zhang & Sachdev 2003). As in a pivotal longitudinal study
on patients with childhood onset schizophrenia, again the
parietal cortex evolved as starting point of cortical gray matter
loss (Thompson et al. 2001), we developed a mouse model,
where a small standardized lesion is set during puberty
onto the right parietal cortex. This mild cryolesion is applied
stereotactically through the intact skull (no fractures) and
does not cause any obvious immediate symptoms. It leaves
only a very tiny, barely visible scar but initiates a bilateral
neurodegenerative process very similar to that occurring
endogenously in schizophrenia for as yet unknown reasons
(Sargin et al. 2009; Sire´n et al. 2006). Importantly, mice
lesioned at a later age or in another location of the brain do not
develop comparable global brain atrophy/neurodegeneration
(Sire´n et al. 2006). The lesion alone does not create a
schizophrenic phenotype even though mild features of it are
showed with careful behavioral/morphological testing, e.g.
hyperactivity, cognitive dysfunction upon aging and global
brain atrophy (Sargin et al. 2009; Sire´n et al. 2006).
By combining Cplx2 null mutation with neurotrauma,
we provide further experimental proof-of-principle that a
genetic predisposition (affecting neurodevelopment) plus an
environmental risk factor (inducing neurodegeneration) can
give rise to prominent schizophrenia-like alterations in mouse
behavior and brain morphology.
Materials and methods
Animals
All experiments were permitted by the local Animal Care and Use
Committee.
CPLX2 mutant mice of mixed 129Sv-C57Bl/6 background were
generated by homologous recombination in embryonic stem cells
as described previously (Reim et al. 2001). Behavioral experiments
were performed after 10 backcrosses to the C57BL/6NCrl (Charles
River Laboratories, Sulzfeld, Germany) mouse strain and employed
age-matched male wild-type (WT or Cplx+/+; n = 53) and Cplx2
null mutant [knockout (KO) or Cplx2−/−; n = 65] littermates. Two
cohorts of mice were used: ‘cohort 1’ – WT n = 25, KO n = 36;
‘cohort 2’ (mice were born 6 weeks later) – WT n = 28, KO n = 29.
Mice were housed at 4–5 per cage in a room with 12 h light/dark
cycle (lights on at 0900 h) and ad libitum access to food/water
(except for the forced alternation in T-maze period; see below). The
order of testing was as follows: elevated plus maze, open field,
rotarod, grip strength, hind-limb clasping, social interaction, sucrose
preference, pre-pulse inhibition, novel object recognition test, forced
alternation in the T-maze and Morris water maze, pharmacological
challenge with MK-801. All mice were used for all behavioral tests
with the following exceptions: (1) for the pharmacological challenge
with MK-801, a subset of mice (n = 12) of cohort 1 was used;
(2) forced alternation in T-maze was only performed by cohort
2; (3) water maze was applied on cohort 1 and on a randomly
selected subset of mice (n = 5–8) from cohort 2. Finally, a subset
of mice (n = 11–12, balanced between cohorts) was examined by
magnetic resonance imaging (MRI) volumetry. The order of testing
was designed according to increasing invasiveness to minimize a
possible influence of experimental history (McIlwain et al. 2001).
Age of mice at the beginning of testing was 16 weeks, i.e. 3 months
after surgery (see below). Inter-test interval was at least 1–2 days
(for timetable and illustration of the barely visible scar remaining from
the cryolesion see Fig. 1a). Behavioral tests were performed in a blind
fashion during the light phase of the day from 1000 until 1700 h.
Surgery
At the age of 28 days (mouse puberty), mice were anaesthetized
with an intraperitoneal injection of 0.25% tribromoethanol (Avertin)
(0.125 mg/g). The parietal skull was exposed through a scalp
incision and a freezing lesion was placed on the right parietal
cortex (coordinates from bregma: 1.5 mm posterior, 1.5 mm lateral;
Franklin & Paxinos 1997). A cone-shaped copper cylinder with flat
round tip diameter of 1 mm was cooled with liquid nitrogen (−183◦C).
Its tip was stereotactically placed in direct contact with the exposed
parietal skull and kept in a place for 60 seconds. Sham-operated
animals went through the same procedure without cooling the metal
cone. After that, the scalp was sutured and mice were kept on a
heating plate (37◦C) until waking-up. The number of animals which
was assigned to either lesion or sham-lesion was balanced between
genotypes within each cohort.
Behavioral testing
Elevated plus maze
In this test of anxiety, mice were placed in the central platform, facing
an open arm of the plus maze (made of gray plastic with a 5 × 5 cm
central platform, 30 × 5 cm open arms and 30 × 5 × 15 cm closed
arms; illumination 120 lx). The behavior was recorded for 5 min by an
overhead video camera and a PC equipped with ‘Viewer 2’ software
(Biobserve GmbH, Bonn, Germany) to calculate the time spent in
open or closed arms, distance traveled, number of arm visits and
velocity. The proportion of time spent in open arms was used to
estimate open arm aversion (fear equivalent).
Open field
Spontaneous activity in the open field was tested in a gray Perspex
arena (120 cm in diameter, 25 cm high; illumination 120 lx). Mice
were placed in the center and allowed to explore the open field for
7 min. The behavior was recorded by a PC-linked overhead video
camera. ‘Viewer 2’ software was used to calculate velocity, distance
traveled and time spent in central, intermediate or peripheral zones
of the open field.
Rotarod
The rotarod test examines motor function, balance and coordination.
It comprised a rotating drum (Ugo Basile, Comerio, Varese, Italy),
which was accelerated from 4 to 40 r.p.m. over 5 min. Mice were
placed individually on the drum and the latency of falling off the drum
was recorded using a stop-watch. To assess motor learning, the
rotarod test was repeated 24 h later.
Grip strength
A grip strength meter (TSE GmbH, Bad Homburg, Germany) was
used to assess forelimb grip strength. Mice were lifted and held by
their tail so that their forepaws could grasp a wire grid. The mice were
then gently pulled backward by the tail with their posture parallel to
the surface of the table until they released the grid. The peak force
applied by the forelimbs of the mouse was recorded in Newton (N).
Each mouse performed the test three times (with 30-min interval),
and the greatest value measured was used for statistical analysis.
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Hind-limb clasping measurement
To measure hind-limb clasping, mice were suspended from the tail
for 1 min to elicit the clasping phenotype, which was scored on a
scale from 0 to 1, where 0 represented no clasping, 1 represented
hind paw or all paws clasping.
Social interaction
Sociability and social memory were tested as described earlier
(Radyushkin et al. 2009). The social testing arena was a rectangular,
three-chambered box. Each chamber was 20 × 40 × 22 cm in size.
Dividing walls were made from clear Plexiglas, with rectangular
openings (35 × 35 mm) allowing access into each chamber. The
chambers of the arena were cleaned, and fresh paper chip bedding
was added between trials. The test mouse was first placed in the
middle chamber and allowed to explore for 5 min. The openings
into the two-side chambers were obstructed by plastic boxes during
this habituation phase. After the habituation period, an unfamiliar
C57BL/6NCrl male mouse (stranger 1) without prior contact with the
subject mouse was placed in one of the side chambers. The location
of stranger 1 in the left vs. right side chamber was systematically
alternated between trials. The stranger mouse was enclosed in a
small (60 × 60 × 100 mm), rectangular wire cage, which allowed
nose contact through the bars but prevented fighting. The animals
serving as strangers had previously been habituated to placement
in the small cage. An identical empty wire cage was placed in the
opposite chamber. A heavy cup was placed on the top of each
of the small wire cages to prevent climbing by the test mice.
Both openings to the side chambers were then unblocked, and the
subject mouse was allowed to explore the entire social test arena
for a 10-min session. The amount of time spent in each chamber
and the number of entries into each chamber were recorded by
the video-tracking system ‘Viewer 2’ (Biobserve GmbH). An entry
was defined as all four paws in one chamber. At the end of
the first 10-min trial, each mouse was tested in a second 10-min
session to quantify social preference for a new stranger. A second,
unfamiliar mouse (stranger 2) was placed into the previously empty
wire cage. The test mouse had a choice between the first, already
explored mouse (familiar stranger 1), and the novel unfamiliar mouse
(new stranger 2). As described above, measures were taken of
the amount of time spent in each chamber and the number of
transitions between chambers of the apparatus during the second
10-min session. Based on the amount of time spent in each chamber,
a ‘sociability index’ and a ‘social memory index’ (with a value of 0
meaning no preference) were calculated according to the following
formulas:
Sociability index =
{[
Timestranger
(Timestranger + Timeempty)
]
× 100
}
− 50
Memory index =
{[
Timenovel mouse
(Timenovel mouse + Timefamiliar mouse)
]
×100
}
− 50.
Sucrose preference
The sucrose preference test was performed as described earlier
(Jamain et al. 2008) using a two-bottle procedure, during which mice
had free access to both water and a sucrose solution. Animals
were first habituated for 48 h to consume water from the two small
(100 ml) bottles. After habituation, mice were deprived of water, and
the sucrose preference was measured during the next 3 days. The
first 2 days served as a habituation to sucrose solution. The results
of day 3 were used for the evaluation of sucrose preference. Each
day, group-housed mice were placed individually into small plastic
cages and two bottles were presented to them for 60 min – one
with tap water and one with a 2% sucrose solution. Consumption
of water or sucrose solution was measured by weighing the bottles
before and after the session. Bottles were counterbalanced across
the left and the right sides of the cage, and their position was
alternated from test to test. Sucrose preference (%) was calculated as
follows: preference = [sucrose solution intake (ml)/total fluid intake
(ml)] × 100.
Pre-pulse inhibition test
In this test of sensorimotor gating, individual mice were placed in
small metal cages (90 × 40 × 40 mm) to restrict major movements
and exploratory behavior. The cages were equipped with a movable
platform floor attached to a sensor that records vertical movements
of the floor. The cages were placed in four sound-attenuating isolation
cabinets (TSE GmbH, Bad Homburg, Germany). Startle reflexes
were evoked by acoustic stimuli delivered from a loudspeaker
that was suspended above the cage and connected to an acoustic
generator. The startle reaction to an acoustic stimulus, which evokes
a movement of the platform and a transient force resulting from this
movement of the platform, was recorded with a computer during a
recording window of 260 milliseconds (beginning with the onset of
pre-pulse) and stored for further evaluation. The recording window
was defined from the onset of the acoustic stimulus. An experimental
session consisted of a 2-min habituation to 65 dB background white
noise (continuous throughout the session), followed by a baseline
recording for 1 min at background noise. After baseline recording,
six pulse-alone trials using startle stimuli of 120 dB intensity and 40
milliseconds duration were applied in order to decrease the influence
of within-session habituation. These data were not included in the
analysis of the pre-pulse inhibition. For tests of pre-pulse inhibition,
the 120 dB/40 milliseconds startle pulse was applied either alone
or preceded by a pre-pulse stimulus of 70, 75 or 80 dB intensity
and 20 milliseconds duration. An interval of 100 milliseconds with
background white noise was employed between each pre-pulse
and pulse stimulus. The trials were presented in a pseudorandom
order with an interval ranging from 8 to 22 seconds. The amplitude
of the startle response (expressed in arbitrary units) was defined
as the difference between the maximum force detected during a
recording window and the force measured immediately before the
stimulus onset. Amplitudes were averaged for each individual animal,
separately for both types of trials (i.e. stimulus alone or stimulus
preceded by a pre-pulse). Pre-pulse inhibition was calculated as the
percentage of the startle response using the following formula:
%pre-pulse inhibition
= 100 −
[
(startle amplitude after pre-pulse and pulse)
(startle amplitude after pulse only)
]
× 100].
Novel object recognition test
As a test for recognition memory, the novel object recognition test
consisted of a training phase and a testing phase. First, mice were
habituated to the experimental apparatus for 10 min in the absence
of any objects. The experimental apparatus was a rectangular open
field (40 × 40 × 40 cm) made of gray plastic. During the training
phase, mice were placed in the experimental apparatus with one
object and allowed to explore for 10 min. The object was thoroughly
cleaned between trials to make sure no olfactory cues were present.
Retention was tested immediately after training and 1 h later.
During these retention tests, the mouse explored the experimental
apparatus for 10 min in the presence of one familiar andone novel
object. An independent set of objects was used for training and
testing of each retention interval. The location of the object was
counterbalanced so that one-half of the animals in each group saw
the novel object on the left side of the apparatus, and the other half
saw the novel object on the right side of the apparatus. A mouse was
scored as exploring an object when its head was oriented toward the
object within a distance of 1 cm or closer. Preference index, a ratio
of the amount of time spent exploring the new object over the total
time spent exploring both objects during the retention test was used
as a measure of recognition memory.
Forced alternation in T-maze
This test is used for the assessment of major deficits in working
memory. The gray plastic floors of the T-maze were 5 cm wide. The
stem of the T-maze was 35 cm long with a guillotine door located
20 cm before the arm entries. Closure of this door forms the start
box. The cross-piece of the T-maze was 70 cm long, and at each
end, there was a water well 2 cm in diameter and 0.75 cm deep. The
clear Perspex walls of the maze were 15 cm high. For performance
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Figure 1: Experimental design (a) and effects of Cplx2−/− genotype alone and in combination with juvenile parietal
neurotrauma (barely visible scar indicated by an arrow in a representative coronal MRI section in (a) as ‘second hit’ on
readouts of general activity (b, c), anxiety (b, d), motor strength (e–g) and pathological reflexes (h). The mild activity/motor
phenotype of Cplx2−/− mice is slightly accentuated upon lesion, obvious through increased incidence of pathological reflexes.
Abbreviations used in (a): OP = cryolesion; behavior 1 = battery of tests including elevated plus maze, open field, rotarod, grip strength,
hind-limb clasping, pre-pulse inhibition, social interaction, novel object recognition, forced alternation; behavior 2 = battery of tests
including water maze and challenge with MK-801. Abbreviations used in (b–h): KO = knockout; WT = wild-type; S = sham; L = lesion;
n = 26–32 per group; mean ± SEM presented; *P < 0.05; **P < 0.001.
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of this test, mice were kept water deprived with 1 h access to water
per day. Habituation to the T-maze was performed over 3 days with
1 daily 5 min session during which drops of water were scattered
throughout the maze. Animals were allowed to explore freely to
reach the point where, at the end of habituation, they would reliably
run down the stem of the maze to find water rewards in both
arms. Following habituation, the animals received a total of 20 daily
sessions of training. During each training session, two trials were
presented with an inter-trial interval (ITI) of approximately 10 min.
Each trial consisted of twos runs. In the first run (‘sample run’), liquid
rewards (0.1 ml 4% sucrose solution) were placed in each well, and
a wooden barrier was used to restrict access to one of the arms. As
a consequence, the animal was forced to enter a pre-selected arm
on each ‘sample run’ and then allowed to drink the reward there.
The animal was then picked up and confined in the start box for a
specific delay. Two delays were used: 10 sessions with no delay,
followed by 10 sessions with 20 seconds delay. During the second
run (‘test run’), the door to the start box was opened and the animal
offered a free choice between the two arms of the T-maze. The
criteria for selecting an arm consisted of the mouse placing a back
foot in one of the arms. No retracing by the mouse was permitted.
If the mouse had alternated (i.e. had entered the arm not previously
visited on the ‘sample run’), it was allowed to drink reward before
being returned to its cage. If the other arm was chosen (i.e. the
same arm as visited on the ‘sample run’), the mouse was confined
to that arm for approximately 10 seconds and then returned to its
cage. Left and right arms were used as ‘sample’ and ‘test’ arms
in a counterbalanced manner. Data from five sessions were pooled
together, and the percentage of correct runs was calculated and
presented in graphs.
Morris water maze
Spatial learning and memory was assessed in a water maze (Morris
1984). A large circular tank (diameter 1.2 m, depth 0.4 m) was filled
with opaque water (25 ± 1◦C, depth 0.3 m) and the escape platform
(10 × 10 cm) was submerged 1 cm below the surface. The swim
patterns were monitored by a computer and the video-tracking
system ‘Viewer 2’. The escape latency, swim speed, path length and
trajectory of swimming were recorded for each mouse. During the
first 2 days, mice were trained to swim to a clearly visible platform
(visible platform task) that was marked with a 15-cm high black
flag and placed pseudo-randomly in different locations across trials
(non-spatial training). The extra-maze cues were hidden during these
trials. After 2 days of visible platform training, hidden platform training
(spatial training) was performed. For 8 days, mice were trained to
find a hidden platform (i.e. the flag was removed) that was located
at the center of one of the four quadrants of the pool. The location
of the platform was fixed throughout testing. Mice had to navigate
using extra-maze cues that were placed on the walls of the testing
room. Every day, mice went through four trials with an inter-trial
interval of 5 min. The mice were placed into the pool facing the side
wall randomly at one of four start locations and allowed to swim until
they find the platform, or for a maximum of 90 seconds. Any mouse
that failed to find the platform within 90 seconds was guided to the
platform. The animal then remained on the platform for 20 seconds
before being removed from the pool. The next day after completion
of the hidden platform training, a probe trial was conducted in order to
determine whether mice used a spatial strategy to find the platform
or not. The platform was removed from the pool and the mice were
allowed to swim freely for 90 seconds. The percentage of time spent
in each quadrant of the pool as well as the number of times the mice
crossed the former position of the hidden platform were recorded.
Measurement of MK-801 induced hyperactivity
in the open field
Baseline motor activity of each mouse in open field was registered for
20 min as described above. Then mice were injected intraperitoneally
with MK-801 (Sigma–Aldrich Chemie GmbH, Munich, Germany) in a
volume of 10 ml/kg body weight and tested for 120 min. We chose a
dose of 0.3 mg/kg, because our pilot experiments showed that this
was the lowest dose causing detectable and consistent hyperactivity
in non-mutant C57BL/6N mice. Right after injection, the mouse was
placed into an open field and its movements were recorded for
120 min. Cumulative distance traveled over 4-min intervals was used
as readout of activity.
MRI volumetry
Upon completion of the behavioral analysis, mice (aged 11–12
months, Cplx2−/− sham n = 12; Cplx2−/− lesion as well as WT
sham/lesion n = 11) were anesthetized in a chamber with 5%
isofluorane, intubated and kept under anesthesia with 1–1.5%
isofluorane in O2 and room air (1:1.5). In vivo brain volumetry was
performed by MRI at a field strength of 2.35 T (Bruker Biospin,
Ettlingen, Germany) using a T1-weighted three-dimensional FLASH
sequence as described (Natt et al. 2002), reaching an isotropic
resolution of 117 μm. Total brain volume (excluding olfactory bulb,
cerebellum and brainstem) and, separately, the size of lateral and
third ventricles, cerebellum, hippocampus and brainstem were
determined by manually drawing respective regions-of-interest on
up to 50 contiguous horizontal MRI sections. The experimenter
performing volumetrical analyses was not aware of any group
assignment of individual mice (‘completely blinded’).
Statistical analysis
Unless stated otherwise, the data given in figures and text are
expressed as mean ± SEM. Data were compared by either three-
way analysis of variance (ANOVA) for repeated measures followed by
post hoc subgroup tests (two-way ANOVAs for repeated measures for
defined subgroups or, as non-parametric test, Mann–Whitney U-test
to make the results even more robust against small deviations from
normality) or two-way ANOVA where appropriate. As an interaction
between genotype and lesion was our prior hypothesis, an interaction
term was usually included in the models. Irrespective of the
significance of the interaction effect, the data were further explored
by separate analysis of the lesion effect within the two genotypes
and of the genotype effect within the two treatment (lesion) groups.
Significance obtained through this post hoc procedure was regarded
as suggestive evidence for a ‘second hit’ in the absence of a
significant genotype × lesion interaction. For analysis, SPSS v.14
software (SPSS Inc., Chicago, IL, USA) was used. Data of clasping
measures were analyzed by Chi-square test. A P-value below
0.05 was considered to be significant. Multiple testing adjustment
(Bonferroni) was applied, where indicated.
Results
Accentuation of the Cplx2−/− motor phenotype upon
standardized parietal cortical neurotrauma
We first compared basic behavioral functions such as
locomotor activity, anxiety and motor performance in Cplx2
null mutant vs. WT mice with or without standardized
neurotrauma.
In the open field (evaluated for 7 min), Cplx2−/− in
comparison with WT mice spent less time in central and
intermediate zones but more in the periphery, independently
of neurotrauma (two-way ANOVAs (with Bonferroni correction)
for each zone: significant effect of genotype, no effect of
lesion and no interaction effect; for center: F1,109 = 19.25,
P < 0.0001; for intermediate: F1,109 = 40.27, P < 0.0001;
for periphery: F1,109 = 37.49, P < 0.0001; Fig. 1b). This
behavior was associated with reduced distance traveled of
the Cplx2−/−, i.e. a somewhat lower motor activity (two-
way ANOVA: significant effect of genotype, F1,112 = 21.93,
P < 0.001; no effects of lesion and interaction; Fig. 1c).
Additional analysis of long-term open field activity obtained
596 Genes, Brain and Behavior (2010) 9: 592–602
Cplx2 null mutation and neurotrauma: a two-hit schizophrenia model
during the MK-801 challenge test (total distance traveled
during the 20 min baseline evaluation before administration
of MK-801) essentially confirmed these results (see below
MK-801 test and Fig. 3a). The two-way ANOVA showed a
significant effect of genotype (F1,44 = 14.62, P < 0.0001)
and no effect of lesion or interaction. Anxiety as potential
explanation of the open field pattern may be excluded,
because comparable levels of anxiety in all groups were
found in elevated plus maze with no significant effects of
genotype or lesion on the time spent in different zones
(even though the amount of time spent in open arms was
surprisingly large in this series of experiments, making it
difficult to decisively interpret this experiment) (Fig. 1d).
In agreement with an altered motor phenotype, Cplx2−/−
mice, independently of lesion, showed a significant decrease
of their falling latency in the rotarod test for motor balance
and coordination (two-way ANOVA: significant effect of
genotype, F1,113 = 21.91, P < 0.0001; no effects of lesion
and no interaction effect; Fig. 1e). A potential interfering
effect of body weight with this readout could be excluded
because there was no weight difference between the
groups (Fig. 1f). In addition, grip strength measurements
yielded no significant differences (Fig. 1g). In contrast,
only in Cplx2−/− mice, neurotrauma led to a significant
increase in the proportion of animals with abnormal hind-limb
clasping reflex, indicating a ‘second hit’ effect of lesion on
motor functions (P = 0.035, Chi-square test; Fig. 1h). Social
interaction and sucrose preference test for anhedonia did not
yield differences between the groups (data not shown).
Cognitive testing suggests ‘second hit’ effects
in lesioned Cplx2−/− mice
Neither forced alternation in T-maze nor novel object
recognition tests showed any differences in performance
between the groups (Fig. 2a–d). Both the tests are relatively
insensitive, requiring strong deficits to show appreciable
effects. In contrast, Morris water maze, a sensitive
test for hippocampus-dependent learning and memory,
showed a significant effect of trials (three-way ANOVA for
repeated measures, F7,546 = 40.305, P < 0.001) as well as a
significantly longer escape latency, particularly of Cplx2−/−
mice (effect of genotype, F1,78 = 29.570, P < 0.001) with
neither effect of lesion (F1,78 = 3.335, P = 0.72) nor of
interaction (F1,78 = 2.779, P = 0.1). The plot is suggestive
of a selective performance deficit of lesioned null mutants at
late stages of training. Interestingly, this suggestive deficit
of lesioned Cplx2−/− mice only is evident in trials 6–8,
reflecting a learning impairment in the period of spatial
memory formation (Fig. 2e) (Janus 2004; Wolfer et al. 1998).
Importantly, the results of the probe trial, particularly in
the absence of differences at the beginning of training,
provide even better support for our ‘dual hit hypothesis’.
Here, only lesioned Cplx2−/− mice showed a decrease in
preference for the target quadrant (Mann–Whitney U-test,
P = 0.0071; Fig. 2f). To exclude a potential influence of the
Cplx2−/− motor deficit on swimming speed (and therefore on
escape latency), we analyzed the distance traveled by each
mouse until reaching the platform, a parameter independent
of swimming performance. The pattern of results was similar
to the findings regarding escape latency (data not shown).
Analysis of an alternative readout for spatial memory, i.e. the
number of crossings of the platform site in the probe trial,
yielded again the clearest defect in lesioned Cplx2−/− mice
(Mann–Whitney U-test, P = 0.0356; data not shown).
Pre-pulse inhibition analysis showed a significant effect of
stimulus intensity (three-way ANOVA for repeated measures,
F2,220 = 136.292, P < 0.001) but no effect of genotype,
lesion or interaction. There was a tendency for lesion
(P = 0.1). Guided by our hypothesis of a ‘dual hit’ effect
(genotype plus lesion), we compared in two separate two-
way ANOVAs for repeated measures (including two groups of
the same genotype each) the effect of lesion vs. sham and
obtained nominal significance exclusively for the combination
of mutant genotype and lesion: (1) KO sham vs. KO lesion:
significant effect of lesion, F1,61 = 4.71, P = 0.03; (2) WT
sham vs. WT lesion: no effect of lesion, F1,49 = 0.01,
P = 0.91 (Fig. 2g). The startle response amplitude was
increased upon lesion only in Cplx2−/− (Mann–Whitney
U-test, P = 0.0007) but not in WT mice (Mann–Whitney
U-test, P = 0.19, Fig. 2h). Taken together, these data provide
suggestive evidence for the ‘second hit’ hypothesis regarding
higher brain functions.
Increased sensitivity to MK-801 treatment
in lesioned Cplx2−/− mice only
Using three-way ANOVA for repeated measures to evaluate
MK-801 results, we obtained a significant effect of time
(F29,1276 = 48.418, P < 0.001) as well as a significant
genotype × lesion interaction effect (F1,44 = 4.09, P = 0.049)
but no significant effect of genotype or lesion. These results
allowed us to go on with a post hoc test using two
separate two-way ANOVAs analyzing the effect of genotype
in the lesion vs. sham paradigm separately. Although sham-
operated Cplx2−/− mice showed no differences in MK-801
induced hyperlocomotion in comparison to sham-operated
WT mice (Fig. 3b), there was a clear ‘second hit’ effect
detectable in lesioned Cplx2−/− mice. This group showed
a relative increase in hyperlocomotion in comparison with
lesioned WT mice (two-way ANOVA for repeated measures:
significant effect of genotype, F1,22 = 5.79, P = 0.024;
significant effect of interaction, F29,638 = 3.29, P < 0.0001;
Fig. 3c). When looking at sham vs. lesion groups of each
genotype separately, it becomes obvious that MK-801 leads
to reduced hyperactivity in lesioned wild-types while in
lesioned mutants, this effect is absent, explaining the relative
hyperactivity (‘loss of inhibition’) seen in Fig. 3.
Decrease of total hippocampal volume exclusively
in lesioned Cplx2−/− mice
MRI volumetrical analyses failed to uncover significant
differences between genotypes, independent of lesion,
regarding whole brain, lateral and third ventricles, brainstem
and cerebellum. The results on total brain matter (total brain
circumference minus cerebellum, olfactory bulb, brain stem
and ventricles) are shown in Fig. 3d. In agreement with our
previously published data (Sire´n et al., 2006) there is a strong
tendency of a reduction in brain matter in lesioned wild-type
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Figure 2: Effects of Cplx2−/− genotype alone and in combination with juvenile parietal neurotrauma as ‘second hit’ on
readouts of cognitive performance (a–f) and sensorimotor gating (g, h). Whereas the relatively insensitive tests, forced
alternation in T-maze (a, b) and object recognition (c, d), do not show differences between the groups, there is a remarkable deficit in
spatial learning and memory in Morris water maze as well as in PPI, particularly pronounced upon dual hit (e–h). Abbreviations: MWM
= Morris water maze; PPI = pre-pulse inhibition; KO = knockout; WT = wild-type; S = sham; L = lesion; n = 17–22 per group; mean
± SEM presented; *P < 0.05; **P < 0.01). Note that data similar to those shown in (e), obtained with a different cohort of mice, have
been included in a human genetic paper, dealing with the modifier role of CPLX2 on cognition in schizophrenia (Begemann et al. 2010).
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Figure 3: Effects of Cplx2−/− genotype alone and in combination with juvenile parietal neurotrauma as ‘second hit’ on
pharmacological challenge with the NMDA antagonist MK-801 (a–c), on total brain matter (d) and on hippocampal volume (e,
f). Cplx2−/− mice, regardless of lesion, show decreased activity during baseline evaluation (20 min) before administration of MK-801
(a). Only lesioned Cplx2−/− mice exhibit relative hyperactivity upon MK-801 (b, c). There is a strong tendency of a reduction in brain
matter in lesioned wild-type as compared with non-lesioned wild-type mice. In contrast, non-lesioned Cplx2−/− mice show a tendency
of decreased brain matter that is not further reduced by lesion (d). Exclusively lesioned Cplx2−/− mice have a decreased hippocampal
volume (e, f). Abbreviations: KO = knockout; WT = wild-type; S = sham; L = lesion; n = 11–12 per group; mean ± SEM presented;
*P < 0.05; **P < 0.0001.
as compared with non-lesioned wild-type mice. In contrast,
non-lesioned Cplx2−/− mice show a tendency of decreased
brain matter that is not further reduced by lesion. However,
using a two-way ANOVA, we obtained a significant effect of
lesion (F1,41 = 4.76, P < 0.03) on total hippocampal volume
(Fig. 3e,f). Post hoc tests showed that the hippocampal
volume was significantly reduced exclusively in lesioned
Cplx2−/− (Mann–Whitney U-test, P = 0.045, Fig. 3e) but
not in lesioned WT mice (Mann–Whitney U-test, P = 0.69).
Discussion
We report here that the exposure of juvenile mice, carrying a
null mutation of Cplx2, to a small parietal cortical lesion leads
to the development of a phenotype relevant to schizophrenia.
Cplx2 encodes a synaptic protein crucial for neurotransmitter
release and may represent a probable schizophrenia risk
gene. Mild parietal neurotrauma around puberty is one
of the several potential environmental factors, acting as
‘second hit’. The phenotype resulting from the combination
of these two ‘hits’ includes alterations in sensorimotor gating,
selective deficiency in learning and memory functions,
a slight accentuation of the genotype-associated motor
symptoms, loss of inhibition/relative hyperactivity upon
NMDA receptor antagonism and a reduction in total
hippocampal volume. Although the phenotype effects are
mostly small and statistical support for a genotype × lesion
interaction is suggestive rather than conclusive despite large
group sizes, chance effects are very unlikely because all
observed effects point in the same direction.
A mild behavioral phenotype in Cplx2−/− mice has
been reported earlier, comparable with the sham-operated
Cplx2−/− group in the present work, comprising mainly a
motor deficit in rotarod and open field and, inconsistently,
a somewhat impaired learning curve in Morris water
maze (Glynn et al. 2003, 2007; Yamauchi et al. 2005).
In more schizophrenia-relevant tests, such as pre-pulse
inhibition (PPI) of the startle response and pharmacological
challenge with the NMDA receptor antagonist MK-801, the
mutant genotype alone, i.e. sham-operated Cplx2−/− mice,
showed no alterations as compared with WT mice. As an
environmental ‘second hit’, we applied a small standardized
right parietal cortical neurotrauma to juvenile mice (Sargin
et al., 2009; Sire´n et al., 2006). Again, consequences of
this mild trauma alone, i.e. in the absence of a modifying
genotype, are minor (Sargin et al., 2009; Sire´n et al., 2006).
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This was also the case for lesioned WT mice in the present
study, reflected by a tendency of reduced startle amplitude
and number of visits to the former platform location in the
Morris water maze probe trial.
The most clear-cut results, collectively resembling phe-
notypic changes relevant to schizophrenia, were obtained
with the experimental group that combined effects of the
genetic factor (null mutation of the Cplx2 gene) and the envi-
ronmental factor (cryolesion as experimental neurotrauma)
in the sense of a ‘second hit’: (1) deficit in PPI, a widely
accepted readout of sensorimotor gating, frequently found
in schizophrenic patients (Braff & Geyer 1990; Swerdlow
& Geyer 1998), emerged in Cplx2−/− mice only upon neu-
rotrauma. (2) Similarly, the most prominent phenotype in
learning and memory functions was observed upon dual hit.
Although crude learning and memory tests, i.e. forced alter-
nation in T-maze and novel object recognition, did not yield
differences between the groups, only Morris water maze
performance showed the predicted deficit in lesioned null
mutant Cplx2 mice. (3) Lesioned Cplx2−/− mice displayed an
exacerbation of their motor phenotype, reflected by a signifi-
cantly higher incidence of abnormal hind-limb clasping. Even
though pathological motor reflexes do not belong to the core
symptoms of schizophrenia, they are among the so-called
‘neurological soft signs’ of the disease (Chan & Gottes-
man 2008; Heinrichs & Buchanan 1988). (4) Only lesioned
Cplx2−/− mice responded to the NMDA receptor antagonist
MK-801 with a relative hyperactivity (‘loss of inhibition’) in
the open field. This pharmacological challenge is regarded as
another schizophrenia-related readout (Carlsson et al., 1999;
Geyer & Markou, 1995; O’Neill & Bolger 1989). In fact, NMDA
receptor antagonists such as phencyclidine or ketamine
induce transient schizophrenia-like cognitive dysfunctions
and perceptual alterations in healthy volunteers (Adler et al.
1999; Lahti et al. 2001; Malhotra et al. 1996), and exacerbate
symptoms of schizophrenia in patients (Lahti et al. 2001; Mal-
hotra et al. 1997). Among others, these findings gave rise to
the NMDA receptor hypofunction hypothesis of schizophre-
nia (e.g. reviewed by Gunduz-Bruce 2009; Olney et al. 1999).
This hypothesis proposes that NMDA receptor blockade dis-
rupts NMDA receptor-mediated stimulation of GABAergic,
serotonergic and noradrenergic inhibitory neurons, leading to
‘loss of inhibition’ in major excitatory pathways (Coyle 2004;
Olney et al. 1999). (5) A significant increase of the baseline
startle response was only found in Cplx2−/− mice after juve-
nile lesion. Although there is accumulating evidence (Csomor
et al. 2008; Yee et al. 2005) assuming a dependency of %PPI
from baseline startle response, there is a wealth of literature
that argues against such a dependency (Blumenthal et al.
2004; Ison et al. 1997; Yee et al. 2004). Whether baseline
startle response determines %PPI or not, together with the
relative hyperactivity to a subthreshold dose of MK-801 in
the open field, the significant increase in the baseline startle
amplitude in Cplx2−/− mice after juvenile lesion additionally
supports the idea of ‘loss of inhibition’ in these animals.
In fact, compounds assumed to produce positive-like symp-
toms in mice (e.g. MK-801, PCP) have also been reported
to increase the baseline startle response (Geyer et al. 1984;
Karl et al. 2010). (6) Finally, the reduction in hippocampal vol-
ume, a typical finding in schizophrenia (Hyde & Weinberger
1990; Shenton et al. 2001) is found exclusively in the dual
hit group. Only readouts of negative symptoms (social with-
drawal, anhedonia) were not observed in any of the groups.
It should clearly be noted; however, that even the leading
disease classification system (DSM-IV-TR, American Psychi-
atric Association 2000) does not require the presence of all
symptom complexes for diagnosing schizophrenia.
In an experimental attempt similar to the one presented
here, Inoue and colleagues had combined early maternal
stress with Cplx2 null mutation, in order to investigate the
gene × environment interaction hypothesis of schizophrenia
(Yamauchi et al. 2005). They found that after early maternal
deprivation, Cplx2 null mutant mice developed a decrease
in hippocampal long-term potentiation (LTP) and a spatial
learning deficit in Morris water maze. Other schizophrenia
typical readouts, supporting the validity of the model for this
disease, however, were not reported in this study.
Taken together, the model of a gene × environment inter-
action presented here results in the development of three
of four lead symptom complexes of schizophrenia: posi-
tive symptoms, cognitive symptoms and brain morphology
changes. The findings (1) suggest that the combination of a
Cplx2−/− mutation with juvenile parietal neurotrauma may
represent a novel animal model for schizophrenia with higher
construct validity than most related models tested so far and
(2) provide experimental support for the ‘second hit’ hypoth-
esis of schizophrenia etiology. Although the mechanisms
underlying the gene × environment interactions observed
here are unclear at present, this novel mouse model offers an
important conceptual basis for further studies on the biolog-
ical processes involved in these interactions that ultimately
cause schizophrenia-related brain dysfunctions.
Likely, there are many different other ways of combining
genetic and environmental risk in mice to create phenotypic
changes relevant for schizophrenia (for review, see, e.g.
Ayhan et al. 2009). This is obviously what happens
in the human population and explains why no major
disease genes have been identified in schizophrenia. The
gene × environment approach; however, will be pivotal
for understanding the pathophysiology of the disease.
Different gene × environment interactions, resulting in a
schizophrenia-like phenotype, will ultimately have to be
compared to allow extracting common denominators of
disease onset/progression.
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4. EFFECT OF EPO ON HIGHER BRAIN FUNCTIONS IN MICE 
 
4.1. OVERVIEW OF PROJECT II 
Since the introduction of the hematopoietic growth factor erythropoietin (EPO) to 
clinical use – over 20 years ago – to treat patients suffering from anemic conditions, 
reports have been accumulating stating improvement of cognitive performance of the 
treated individuals. Initially, this improvement was attributed to anemia correction with 
subsequently enhanced tissue oxygenation also in the central nervous system 
(Jelkmann, 2005). However, after discovering that EPO and its receptor (EPOR) are 
produced by and act on cells of the nervous system (Masuda et al., 1993; Masuda et 
al., 1994) several reports on neuroprotective and neuroregenerative effects of EPO in 
rodent models of neurological diseases followed (for review, see Brines and Cerami, 
2005; Juul, 2004; Sirén et al., 2009). Importantly, many recent human studies in 
schizophrenia and multiple sclerosis convincingly demonstrated EPO effects on 
cognition (Ehrenreich, Fischer et al., 2007; Ehrenreich, Hinze-Selch et al., 2007). 
Finally, the hematopoiesis-independent effect of EPO on the nervous system has 
been proven by slight modification of the EPO molecule, rendering it non-
hematopoietic but still tissue-protective (Sirén et al., 2009). 
 
Our previous work in healthy young mice treated for 3 weeks with EPO revealed 
improvement of hippocampal memory. At the time of improved memory, an increase 
in short-term and long-term potentiation was documented in hippocampal slices 
(Adamcio et al., 2008). Along the same lines, application of a single high intravenous 
dose of EPO in healthy human subjects enhanced the hippocampal response during 
memory retrieval measured by functional magnetic resonance imaging one week 
later (Miskowiak et al., 2007). However, some preclinical studies using disease 
models failed to show effects of EPO treatment on cognition in their respective 
healthy control groups (Mala et al., 2005; Mogensen et al., 2008). This might be 
explained by the use of tests (e.g. T-maze, 8-arm radial maze), well suited to 
measure pathology but less sensitive for detecting fine improvements in cognitive 
performance in healthy individuals.  
 
To further delineate EPO-mediated improvement of cognition in healthy mice, where 
no disease-associated variables interfere, we aimed in project II at investigating the 
spectrum of cognitive functions potentially influenced by EPO. Therefore, we 
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employed a sensitive assay for sequentially detecting cognitive performance, the Five 
Choice Serial Reaction Time Task (5CSRTT), originally developed for rats by Carli 
and colleagues  (Carli et al., 1983) and adapted for mice by Humby and co-workers 
(Humby, 2005). The 5CSRTT has been used to study attention and executive 
functions in different rodent models of neuropsychiatric diseases, including attention 
deficit / hyperactivity disorder (ADHD) (Blondeau and Dellu-Hagedorn, 2007), 
schizophrenia (Lecourtier and Kelly, 2005) and impulsivity disorders (Isles et al., 
2004; Robbins, 2002). With 5CSRTT, we systematically investigated the effect of 
EPO on different types of learning, memory and attention in healthy young mice.  
In this study, 45 C57BL/6NCrl male mice (randomly assigned to one of three groups: 
EPO, placebo or “no-inject”, 15 mice/group) were treated for 3 weeks with EPO 
(5000IU/kg) versus placebo intraperitoneally every other day, beginning at postnatal 
day 28. After termination of treatment, mice were started on the 5CSRTT, with daily 
training and testing extending to about 3 months. Overall, a significantly higher 
proportion of EPO treated mice finished the task, i.e. reached the criteria of 
adequately reacting to a 1.0sec flash light out of five arbitrarily appearing choices. 
During acquisition of this capability, i.e. over almost all sequential training phases, 
learning readouts (magazine training, operant and discriminant learning, stability of 
performance) were superior in EPO versus control mice. 
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4.2. ORIGINAL PUBLICATION 
 
El-Kordi A, Radyushkin K and Ehrenreich H (2009). Erythropoietin improves operant 
conditioning and stability of performance in mice. BMC Biology, 7:37. 
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Abstract
Background: Executive functions, learning and attention are imperative facets of cognitive
performance, affected in many neuropsychiatric disorders. Recently, we have shown that
recombinant human erythropoietin improves cognitive functions in patients with chronic
schizophrenia, and that it leads in healthy mice to enhanced hippocampal long-term potentiation,
an electrophysiological correlate of learning and memory. To create an experimental basis for
further mechanistic insight into erythropoietin-modulated cognitive processes, we employed the
Five Choice Serial Reaction Time Task. This procedure allows the study of the effects of
erythropoietin on discrete processes of learning and attention in a sequential fashion.
Results: Male mice were treated for 3 weeks with erythropoietin (5,000 IU/kg) versus placebo
intraperitoneally every other day, beginning at postnatal day 28. After termination of treatment,
mice were started on the Five Choice Serial Reaction Time Task, with daily training and testing
extending to about 3 months.
Overall, a significantly higher proportion of erythropoietin-treated mice finished the task, that is,
reached the criteria of adequately reacting to a 1.0 sec flash light out of five arbitrarily appearing
choices. During acquisition of this capability, that is, over almost all sequential training phases,
learning readouts (magazine training, operant and discriminant learning, stability of performance)
were superior in erythropoietin-treated versus control mice.
Conclusion: Early erythropoietin treatment leads to lasting improvement of cognitive
performance in healthy mice. This finding should be exploited in novel treatment strategies for
brain diseases.
Background
The haematopoietic growth factor erythropoietin (EPO)
has been in clinical use for over 20 years to treat patients
with anaemic conditions, ranging from renal failure to
cancer. Upon introduction of EPO to the clinic, it was
observed that cognitive performance of treated individu-
als also improved. This improvement was essentially
attributed to anaemia correction with subsequently
enhanced tissue oxygenation also in the brain [1]. Much
later, EPO and its receptor were found to be produced by
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BMC Biology 2009, 7:37 http://www.biomedcentral.com/1741-7007/7/37and act on cells of the nervous system [2,3]. Many reports
on neuroprotective and neuroregenerative effects of EPO
in rodent models of neurological diseases followed [4]
(for review see [5,6]). Our recent human studies in schiz-
ophrenia and multiple sclerosis revealed profound EPO
effects on cognitive performance [7,8]. The separation of
haematopoietic and neuroprotective properties upon
slight modification of the EPO molecule ultimately
proved the haematopoiesis-independent effect of EPO on
the nervous system [6].
To investigate, in the absence of interfering disease varia-
bles, the physiological role of the brain EPO system
regarding cognition, we performed a series of studies in
healthy young mice where we found hippocampal mem-
ory, measured by classical fear conditioning, improved
after 3 weeks of EPO treatment. At the time of improved
memory, an increase in short-term and long-term poten-
tiation was documented in hippocampal slices [9]. Along
the same lines, application of a single high intravenous
dose of EPO in healthy human volunteers enhanced the
hippocampal response during memory retrieval measured
by functional magnetic resonance imaging one week later
[10]. It should, however, be also mentioned that preclini-
cal studies using disease models failed to show effects of
EPO treatment on cognition in their respective healthy
control groups (for example, [11,12]). This is most likely
explained by the application of tests (for example, T-
maze, 8-arm radial maze), well suited to measure pathol-
ogy but less sensitive for assessing subtle improvements in
cognitive performance in healthy individuals.
Since the development of new therapies, targeting cogni-
tive performance is of major interest for clinical neuro-
science, and EPO might here be a promising candidate;
thus the spectrum of cognitive functions potentially influ-
enced by EPO has to be better defined. For this purpose,
we employed the Five Choice Serial Reaction Time Task
(5CSRTT), originally developed for rats by Carli and col-
leagues [13] and adapted for mice by Humby and co-
workers [14]. The 5CSRTT has been used to analyse atten-
tion and executive functions in different rodent models of
neuropsychiatric diseases, including attention-deficit/
hyperactivity disorder [15], schizophrenia [16] and
impulsivity disorders [17] (for review, see [18]). With
5CSRTT, we systematically studied the effect of EPO on
different types of learning, memory and attention in
healthy young mice. We note that obtaining cognitive
results in healthy young individuals cannot automatically
be translated to disease situations or aged mice. Neverthe-
less, this approach is the simplest first step to providing a
foundation for mechanistic insight. We report here that
early EPO treatment indeed improves most of the sequen-
tial learning and memory components of a complex long-
term cognitive task, ultimately leading to better and more
stable cognitive achievements.
Results
Erythropoietin increases overall performance in 5CSRTT
First, we compared the overall performance of EPO, pla-
cebo, or no-inject groups in 5CSRTT. Kaplan-Meier analy-
sis revealed that the proportion of mice that finished
training in the 5CSRTT (that is, reached criteria of stably
responding to a 1.0-sec stimulus duration on three con-
secutive days) up to day 94 after cessation of treatment
was significantly higher in the EPO-treated group as com-
pared with placebo and no-inject groups (Log-Rank test, P
= 0.02). There were no differences between placebo and
no-inject groups (Figure 1). Taken as a group, EPO-treated
mice learn faster.
Erythropoietin accelerates associative, operant and 
discriminant learning in 5CSRTT
Since different types of learning determine performance
in the 5CSRTT, we asked whether the superiority of EPO-
treated mice is reflected in initial learning parameters.
Indeed, the number of head entries during habituation
and magazine training appeared higher throughout all
phases (M1–M4) in EPO-treated mice compared with the
Kaplan-Meier presentation of overall group performance in miceFigure 1
Kaplan-Meier presentation of overall group perform-
ance in mice. Curves represent group performance (n = 
13–15 per group). They indicate the cumulative probability of 
members of each group not to finish the task (that is, not to 
reach performance criteria in the 1.0-sec stimulus duration 
phase). EPO-treated mice are superior, that is, have a lower 
probability not to finish the task as compared with no-inject 
and placebo groups. On day 59 after cessation of treatment, 
the first mouse reached criteria in the 1.0-sec phase. This 
mouse belonged to the EPO group. Day 94 is the time point 
on which > 60% of one experimental group (here the EPO 
group) had finished the task.
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between groups in phases M1 and M4 of magazine train-
ing by Kruskal-Wallis test (P < 0.05 for each) could be
attributed to superior performance of the EPO versus pla-
cebo group following post hoc analysis (Dunn's multiple
comparison test, P < 0.01). During the operant learning
phase (S1), EPO-treated mice made more nose pokes
(ANOVA: F(1,41) = 8.81, P = 0.005) on days 2 and 3 (post
hoc P < 0.001 and P < 0.01, respectively) (Figure 2B).
Additionally, there was a significant group effect in the
discriminant learning phase (S2), with EPO-treated mice
demonstrating higher choice accuracy (ANOVA: F(1,41) =
5.35, P = 0.026) (Figure 2C).
We wondered whether the improvement in operant and
discriminant learning parameters would continue in face
of more complex conditions and thus enhanced cognitive
challenge during the 5CSRTT training. In fact, the 5CSRTT
procedure is much more complex than the preceding
shaping phases and consists of more parallel stimuli in
addition to stimulus duration (for example, number of
stimulus lights, more restricted time-out period). We ana-
lysed accuracy in the consecutive stimulus duration
phases: 16 sec, 8 sec and 4 sec. The percentage of correct
responses over the first 3 days of each phase served as rea-
dout of initial learning capabilities in the 5CSRTT training
(Figure 2D, E and 2F). EPO-treated mice performed better
in 16-sec and 8-sec phases (ANOVA F(1,41) = 7.21; P = 0.01
and F(1,39) = 4.87; P = 0.03, respectively, Figure 2D and
2E), but no longer in the following ones, from 4 sec (Fig-
ure 2F) to 2 sec, 1.8 sec, 1.4 sec, 1.2 sec and 1.0 sec (data
not shown). Overall accuracy increased over consecutive
phases until reaching a plateau at 4 sec for both groups,
which then stayed essentially stable over the following
Analysis of distinct sequential learning phasesFigure 2
Analysis of distinct sequential learning phases. (A) Number of head entries as indicators of associative learning in maga-
zine training (M1–4) show an overall significant effect of EPO treatment compared with placebo. (B) Number of nose pokes in 
the operant learning phase (S1) as well as (C) percentage of correct nose pokes in the discriminant learning phase (S2) were 
higher in the EPO-treated compared with the control group (placebo plus no-inject). (D, E) Initial cognitive performance in 
the 5CSRTT was better upon EPO treatment in the 16-sec and 8-sec stimulus duration phases, but no longer in the 4-sec 
phase (F); n = 14–28 per group; data presented as mean ± S.E.M.; all significance values refer to post hoc tests which were only 
significant if ANOVA was also significant; in (E), only ANOVA was significant (P = 0.03).
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BMC Biology 2009, 7:37 http://www.biomedcentral.com/1741-7007/7/37shorter-duration phases (data not shown). There was no
consistent difference in accuracy (nor amount of omis-
sions) during the attentional challenge phase of 0.8 sec
(F(1,18) = 0.49, P = 0.5 and F(1,18) = 1.45, P = 0.24, respec-
tively).
Erythropoietin improves task adaptation and stabilizes 
performance in 5CSRTT
We next analysed the number of training days required to
reach performance criteria in 5CSRTT for each stimulus
duration, that is, acquisition days (Figure 3A). There was
a significant effect of stimulus duration on the number of
training days needed, independent of treatment (F(7,126) =
8.24, P < 0.0001). Starting immediately from 2 sec, mice
required more days to reach criteria compared with previ-
ous phases. To further address the phenomenon of an
abrupt increase of training days in the 2-sec phase (inde-
pendently of treatment), we analysed omissions more
closely. In fact, omissions in all training phases from 16
sec to 1 sec were comparable between the two experimen-
tal groups, and rates were low up to the switch from the 4-
sec to the 2-sec phase (for illustration, data of the respec-
tive first training day of each stimulus duration are given
as an example: range of omissions on day 1 of 16 sec: 6.55
± 4.28 EPO versus 5.83 ± 4.17 control; on day 1 of 8 sec:
9.45 ± 13.09 EPO versus 8.93 ± 8.99 control; on day 1 of
4 sec: 16.90 ± 9.94 EPO versus 16.90 ± 9.81 control; on
day 1 of 2 sec: 29.78 ± 12.86 EPO versus 35.89 ± 10.27
control; on day 1 of 1.8 sec 22.11 ± 7.46 EPO versus 21.96
± 8.75 control; on day 1 of 1.4 sec: 27.00 ± 7.58 EPO ver-
sus 28.93 ± 11.12 control; on day 1 of 1.2 sec: 24.67 ±
8.21 EPO versus 24.1 ± 8.77 control; on day 1 of 1.0 sec:
24.7 ± 5.72 EPO versus 29.06 ± 10.29 control). It turned
out that from the 4-sec phase to the 2-sec phase, omis-
sions promptly doubled and stayed at a high level up to
the end of 5CSRTT training (1 sec), independent of treat-
ment group. This may explain the prominent increase in
training day requirement starting from 2 sec.
We next averaged omitted trials in each of the six 10-trial
blocks over the first 10 days of this 2-sec phase (Figure
3B). There was no significant overall effect of treatment;
however, there was a significant interaction between trial
block and treatment (F(5,130) = 2.37, P = 0.04). Post hoc
analysis revealed that EPO-treated mice had significantly
fewer omissions in the first trial block compared with con-
trols (P < 0.05), pointing to a faster adaptation to the task.
As fluctuations in performance may increase the number
of days needed for reaching performance criteria, we ana-
lysed the magnitude of fluctuation ('relapsing back from
already achieved criteria') in the 2-sec phase. Here, the
control group had significantly more relapses compared
with the EPO group, pointing to more stable performance
upon EPO (Chi2 test, P = 0.04) (Figure 3C). To further
explore the effect of EPO on stability of performance, we
analysed total omissions after reaching criteria (1.0 sec)
over additional 4 days. EPO-treated mice were superior (P
= 0.04) as compared with the control group (Figure 3D).
Erythropoietin does not affect locomotor activity in 
5CSRTT
To clarify whether increased locomotion has contributed
to the superior performance of EPO-treated mice in
Analysis of selected readouts of cognitive performance in high-performer miceFigure 3
Analysis of selected readouts of cognitive performance in high-performer mice. (A) Number of acquisition days 
required for reaching performance criteria at each stimulus duration phase shows no group differences but a sharp increase in 
the transition from 4 sec to 2 sec. (B) The EPO-treated group showed faster task adaptation: The proportion of omissions in 
the first of six 10-trial blocks collapsed across the first 10 days of the 2-sec phase was significantly lower. Post hoc test. (C) The 
EPO-treated group showed higher stability of performance: the proportion of mice that relapsed from already reached per-
formance criteria in the 2-sec stimulus duration phase was smaller. Chi2 test. (D) EPO improves performance stability even in 
the 1-sec phase: Proportion of total omissions over 4 days after reaching performance criteria was significantly lower in the 
EPO group. Mann-Whitney test. N = 7–28; data presented as mean ± S.E.M.
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BMC Biology 2009, 7:37 http://www.biomedcentral.com/1741-7007/7/37phases with 16-sec and 8-sec stimulus duration, we ana-
lysed the average of reward latency (that is, the time
between responding correctly and collecting reward) as
well as the 'latency correct' (that is, the time between stim-
ulus presentation and responding correctly) in the corre-
sponding phases. There were no differences between
groups in either reward latency or in 'latency correct' in
any phase of the 5CSRTT training (data not shown).
Discussion
In the present study, a 3-week high-dose EPO treatment of
healthy young mice increased the probability of these ani-
mals finishing training in the 5CSRTT. While there were
no differences in the number of total days needed to ter-
minate the task among ultimately successful individual
mice, regardless of group assignment, the proportion per
group was different, with more successful mice in the
EPO-treated cohort. EPO-treated mice showed superior
performance in associative, operant and discriminant
learning as well as in initial 5CSRTT training phases.
Moreover, EPO-treated mice demonstrated better task
adaptation and higher performance stability. In contrast,
with the number of mice remaining in the task, there were
no clear effects with this particular EPO treatment sched-
ule (terminated more than 3 months before) on atten-
tional performance, as defined by response to the 0.8-sec
stimulus duration.
To gain an overall impression of the progress in cognitive
training of our mouse groups, we employed the survival
analysis of Kaplan-Meier. This methodological approach
was crucial for our purposes as it describes, over a long
testing period, the development of group performance in
a higher cognitive task, the 5CSRTT. By applying standard
statistical methods only, the clear superiority of the EPO
group would not have been detectable. In fact, the Kaplan-
Meier results inspired us to dissect out potential learning
processes contributing to the superior group performance
of EPO-treated mice. The success of this statistical
approach would suggest the usefulness of this method for
future group analysis in the 5CSRTT.
While clear benefits of EPO treatment could easily be
demonstrated throughout all initial learning phases
including the 5CSRTT training up to 8-sec stimulus dura-
tion, we did not find differences in accuracy in phases
with stimulus durations of 4 sec and below. This might be
due to a ceiling effect, as both groups had reached almost
maximal performance at this stage. Nevertheless, also in
these more progressed phases, EPO superiority was visible
when analysing more subtle readouts of cognitive per-
formance, for example, stability and task adaptation.
A particularly difficult 5CSRTT training step for mice is the
switching from the 4-sec to the 2-sec stimulus duration
phase. In this challenging phase, EPO-treated mice had
consistently lower omission rates when entering the task,
indicating immediate task adaptation. This improvement
just failed to translate into significant differences in acqui-
sition days. Interestingly, a previous study on galanin
transgenic mice, a model for impaired learning capacity,
reported for this critical 2-sec phase more than doubling
of required training days compared with controls, due to
more omissions [19]. In contrast to the improved task
adaptation shown in the present study, reflected by less
omissions in the first trial block, galanin transgenic mice
exhibited more omissions in the last two trial blocks,
pointing to deficiency of sustained attention [19]. In con-
trast to all other studies employing 5CSRTT, we have addi-
tionally analysed parameters representing stability of
Experimental designFigu e 4
Experimental design. Following 3 weeks of EPO (5,000 IU/kg body weight intraperitoneal) versus placebo (diluent control) 
treatment or handling only (no-inject group), 7-week-old mice go through habituation/magazine training (M1–M4) and shaping 
phases (S1–S2) before starting training in the 5CSRTT. Here they move from 16 sec to the respective next phase with lower 
stimulus duration (8 sec and so on) upon reaching fixed criteria. Having reached criteria in the 1.0-sec phase, their attention is 
challenged by further shortening stimulus duration (0.8 sec).
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BMC Biology 2009, 7:37 http://www.biomedcentral.com/1741-7007/7/37performance. The analysis of relapse frequency (that is,
dropping down from a once-acquired performance level)
in the challenging 2-sec stimulus duration phase with its
increasing attentional challenge again revealed a more
consistent performance by the EPO group.
An important limitation of the current study (and of
5CSRTT in general) has to be addressed: the strong selec-
tion bias of mice with higher cognitive abilities means
that mice that do not learn crucial steps of the task are
excluded from further testing (which is frequently not
mentioned in respective publications). This gradual
decrease of numbers in advanced training phases renders
statistical analysis increasingly difficult. For instance, in
the current study, there would not have been enough mice
in the placebo and the no-inject group for separate analy-
sis in the attentional phase with stimulus duration of 0.8
sec, despite starting out with 15 mice per group. A total of
45 mice to be run simultaneously in this task already
reaches the limits of a generous set-up of five chambers
and more than a full working day of the investigator. Since
performance of placebo and no-inject groups did not dif-
fer much in the early phases, pooling of both groups to
obtain a 'control cohort' was possible.
Conclusion
The findings of the present study, that is, improved
sequential learning and memory components of a com-
plex long-term cognitive task upon EPO treatment, will
provide the basis for further work targeting molecular fac-
ets of these critical phases. Such studies will include quan-
titative and qualitative evaluation of neurogenesis and
synapse formation in respective brain regions, for exam-
ple, cingulate cortex and hippocampus. In the latter, we
recently detected increased long-term potentiation after
EPO treatment [9]. In addition, future work will have to
assess whether the effects of EPO obtained here are
restricted to the use of very young and healthy animals, or
would be similarly strong in older mice and/or disease
conditions. Further untangling of molecular mechanisms
of EPO action on higher cognitive functions may then
ultimately open new avenues for prevention strategies and
therapeutic interventions in neuropsychiatric diseases.
Methods
Animals
Forty-five male C57BL/6NCrl mice (Charles River,
Sulzfeld, Germany), 3 weeks old upon arrival, were
housed in groups of five in standard plastic cages, with
food and water ad libitum. The temperature in the colony
room was maintained at 20–22°C, the light-dark cycle at
12 h (light on at 0400 hrs). After 7 days of acclimatising
to the new environment, injections were started at the age
of 28 days and were always performed in the first half of
the light phase. Behavioural experiments were conducted
by an investigator, blinded to treatment condition, during
the second half of the light phase (between 1000 hrs and
1500 hrs). All experiments were approved by the local
Animal Care and Use Committee in accordance with the
German Animal Protection Law.
Injection protocol
Mice were randomly assigned to one of three groups: EPO,
placebo or 'no-inject' (to uncover potential effects of
repeated injection stress), each consisting of 15 mice.
Mice were intraperitoneally injected every other day for 21
days (11 injections in total) either with EPO (5,000 IU/kg,
Epoetin-alpha, Janssen-Cilag, Neuss, Germany) or with
placebo (diluent buffer) in a volume of 0.01 ml/g body
weight. Mice from the no-inject group were just weighed
every other day (in order to keep handling similar to the
injected mice) with no additional manipulations. Train-
ing started 1 day after cessation of injections.
5CSRTT apparatus
Mice were trained in an operant chamber (height 18 cm,
width 15.5 cm, depth 20 cm, Med Associates Inc, St.
Albans, USA), enclosed in a sound-attenuating box and
connected to a Fujitsu Siemens PC. One wall of the oper-
ant chamber had a curved shape and carried an array of
five stimulus holes. The stimulus holes were 1.2 cm in
diameter and contained an LED stimulus light (depth 1
cm) in the rear. Infrared photocell pairs were located at 4
mm from the entrance of the stimulus holes and detected
nose pokes of mice into the holes. The wall opposite to
the stimulus holes contained a magazine cup, also with a
photocell detector of head entries, in which liquid reward
(4% sucrose solution) was delivered always simultane-
ously with illumination of the magazine. The house light
was located 32 cm above the magazine.
Habituation and magazine training
Two days before starting training, mice were habituated to
the liquid reward of 4% sucrose solution in their home
cages overnight. The day before starting magazine train-
ing, sucrose bottles were removed and mice were water-
deprived. Water deprivation was applied during the whole
experimental period. Immediately after finishing the daily
test sessions, mice were given water in individual cages for
20 min. Magazine training consisted of four consecutive
phases (M1–M4), one phase per day, each lasting for 15
min, with all stimulus holes closed. In the first phase
(M1), liquid reward was delivered (10 μl) upon initiation
of the training session. In the second phase of magazine
training (M2), the number of potential rewards was
increased, with a fixed interval of 118 sec between reward
presentations. A head entry into the magazine was
required to collect the reward. In the third phase (M3), the
fixed interval was replaced by a head entry-dependent
interval of 100 sec to obtain reward. In the last phasePage 6 of 8
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BMC Biology 2009, 7:37 http://www.biomedcentral.com/1741-7007/7/37(M4), this interval was further reduced to 50 sec, ideally
yielding a consistently increasing number of head entries.
Head entries into the magazine together with reward con-
sumption were taken as indicators for associating the
magazine with reward delivery (see experimental design
Figure 4).
Shaping phases (operant and discriminant learning)
During shaping, mice were trained to perform a nose poke
into an illuminated stimulus hole in order to obtain
reward. The shaping procedure consisted of two phases
(each extending over several days, dependent on individ-
ual performance, and with a daily session duration of 30
min) where mice were taught to associate nose poking
into an illuminated hole with reward (phase S1), and then
trained to discriminate between those nose pokes that
lead to reward (illuminated holes) and those that do not
(unlit holes) (phase S2) (Figure 4). Throughout shaping
all stimulus holes were open. During S1, all stimulus
lights were on. Any nose poke in a stimulus hole was
rewarded. The inter-trial interval (time from pick-up of
reward to next stimulus hole illumination) was set to 8
sec. During S2, presentation of lit and unlit holes was con-
ducted in a pseudorandom manner. Mice were only
rewarded upon nose poking into a lit stimulus hole. Per-
forming a nose poke in an unlit hole led to switch-off of
the house light for 5 sec. Mice in S1 were moved to the
next training phase once they had reached 35–40 nose
pokes each on three consecutive days. S2 was terminated
when mice had arrived at a stable performance of ≥ 70%
correct responses. Starting from analysis of shaping
phases, placebo and no-inject groups were pooled, since
they no longer differed in any of the high-performing
tasks beyond habituation.
5CSRTT training
The training session started with illumination of maga-
zine light and presentation of 4% sucrose solution. Head
entry started the trial. At 8 sec after head entry, light (ini-
tially set to 16 sec) was randomly presented in one of the
five stimulus holes. A correct response, that is, nose pok-
ing into the lit hole, led to reward (6 μl) and next trial start
after 8 sec. Nose poking in an unlit stimulus hole, that is,
an incorrect response, led to extinguishing the house light
for 5 sec (time-out) and no reward. Further nose pokes
during time-out extended that period for additional 5 sec
each. If a mouse did not respond by nose poking into any
of the holes during stimulus presentation, an omission
was counted. As a consequence, no reward was presented.
Also omissions provoked time-out. A training session was
terminated after 30 min or upon performing 60 trials,
whichever came first. Mice were trained in the phase with
16-sec stimulus duration until they reached clearly
defined performance criteria (≥ 75% accuracy (correct
responses/correct + incorrect responses * 100), ≤ 20%
omissions and at least 50 trials performed over three con-
secutive days). Eight such phases followed with gradually
declining stimulus duration up to 1.0 sec (16, 8, 4, 2, 1.8,
1.4, 1.2, and 1.0 sec).
In the first phases, mice had time to respond as long as the
stimulus light was on. For phases with stimulus duration
below 5 sec, the response time (so-called limited hold)
was added up to 5 sec. Having 'finished the task' meant
having reached the above performance criteria for the 1.0
sec phase. Training sessions were performed every day,
including weekends. As soon as > 60% of the mice in one
of the three experimental groups had finished the task by
reaching performance criteria in the 1.0 sec phase, regular
5CSRTT training was stopped for all groups (day 94; Fig-
ure 1) and only high performers of all groups were carried
on with attention testing, that is, stimulus duration below
1.0 sec (0.8 sec). This resulted in EPO n = 10 versus con-
trol n = 10 (placebo n = 4 plus no-inject n = 6).
Overview on parameters of task acquisition
The following parameters were employed: (1) proportion
of mice that finished the task in all experimental groups;
(2) number of days until reaching performance criteria in
all phases (acquisition days); (3) proportion of omis-
sions, that is, number of omitted per total number of per-
formed trials within one training session; (4) number of
head entries during a magazine training session; (5)
number of nose pokes during an operant learning session;
(6) accuracy, that is, percentage of correct responses calcu-
lated as number of correct responses/correct + incorrect
responses*100; (7) sustained attention, that is, atten-
tional performance, expressed as omissions as a function
of time in session, evaluated over the first 10 days in the
2-sec phase (the most challenging training step). Data are
expressed in 10-trial blocks collapsed across all 10 days;
(8) newly introduced parameter: Stability of performance/
relapses, that is, the ability to maintain a high performance
with respect to omissions and accuracy for three consecu-
tive days. Mice that reached the above mentioned criteria
without keeping them for the required 3 days were consid-
ered relapsing. An additional measure of performance sta-
bility in high performers were omissions in the 1.0-sec
stimulus duration phase, as determined for 4 days after
reaching criteria.
Statistical analysis
Statistical analysis was performed using the statistical pro-
grams SPSS for windows, release 16 (SPSS Inc., Chicago,
USA) and GraphPad Prism version 4.00 for Windows,
(GraphPad Software, San Diego, USA). We applied two-
way ANOVA repeated measures, Kruskal-Wallis test, chi2-
test and Mann-Whitney test where indicated. Bonferroni
and Dunn's multiple comparison tests were used for post
hoc analysis. Threshold for significance was P < 0.05. Sur-Page 7 of 8
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vival analysis/Kaplan-Meier curves [20] were introduced
to demonstrate the proportion of mice per group finish-
ing the 5CSRTT training up to the 1.0-sec stimulus dura-
tion (task goal). Mice that did not reach the goal until day
94 were censored.
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5. EFFECT OF OVER-EXPRESSION OF EPOR IN THE FOREBRAIN 
AND HIPPOCAMPUS OF MICE ON COGNITIVE PERFORMANCE  
 
5.1. OVERVIEW OF PROJECT III 
Cognitive deficits are the core of many neuropsychiatric diseases. It has been shown 
in project II and in other studies that EPO improves cognitive performance in health 
and disease (Adamcio et al., 2008; Ehrenreich, Fischer et al., 2007; Ehrenreich, 
Hinze-Selch et al., 2007; El-Kordi, Radyushkin and Ehrenreich, 2009). In project III 
we aimed at gaining more mechanistic insight into the cellular contribution to these 
EPO effects on higher cognition in mice. For this purpose, we chose to target a 
particular subpopulation of neurons known to be involved in cognition. We developed 
a transgenic mouse model expressing EPO receptor (EPOR) under the α-
calcium/calmodulin-dependent protein kinase II (α-CaMKII) promoter, i.e. in pyramidal 
neurons of cortex and hippocampus. For that, we used a mutant form of the receptor  
with a point mutation at nucleotide 484 causing a substitution of arginine to cysteine 
at codon 129 of N terminus (R129C) leading to disulfide-linked homodimerization of 
EPOR and rendering it constitutively active. By over-expressing cEPOR, which has 
been shown to activate EPO-induced signaling without the requirement of its ligand 
(Fu et al., 2009; Moucadel and Constantinescu, 2005), in principal neurons of cortex 
and hippocampus, we achieved a reliable and permanent EPO-induced stimulation of 
a cell type, known to be involved in long-term potentiation and higher brain functions. 
Wildtype and transgenic mice were analyzed using a wide spectrum of behavioral 
tasks. Expression of cEPOR in cortical and hippocampal pyramidal neurons of 
transgenic mice resulted in better performance in Morris water maze compared to 
their wild type littermates. Moreover, transgenic mice showed increased cognitive 
flexibility, improved social memory and superior attentional capacities in 5CSRTT. 
Using electrophysiological techniques, we found that transgenic mice had enhanced 
synaptic plasticity (long-term potentiation, LTP). However, the superior cognitive 
performance was accompanied by signs of increased impulsivity under cognitive 
challenge and mild hyperactivity. 
Taken together, selective EPOR activity in pyramidal neurons of hippocampus and 
cortex prominently affects cognitive performance. These findings will help elucidate 
the cellular/molecular mechanisms involved in cognitive effects of the brain EPO 
system and ultimately open new avenues for treatment of neurological and 
psychiatric diseases. 
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ABSTRACT 
 
Erythropoietin (EPO) and its receptor (EPOR) are expressed in the 
developing brain and their transcription is upregulated in adult neurons and 
glia upon injury or neurodegeneration. We have shown neuroprotective 
effects and improved cognition in patients with neuropsychiatric diseases 
treated with EPO. However, the critical EPO targets in brain are unknown, 
and separation of direct and indirect effects has remained difficult, given the 
role of EPO in hematopoiesis and brain oxygen supply. Here we 
demonstrate that mice with transgenic expression of a constitutively active 
EPOR isoform (cEPOR) in pyramidal neurons of cortex and hippocampus 
exhibit enhancement of spatial learning, cognitive flexibility, social memory, 
and attentional capacities, accompanied by increased impulsivity. Superior 
cognitive performance is associated with augmented long-term potentiation 
of cEPOR expressing neurons in hippocampal slices. That endogenous 
EPOR activity stimulates plasticity of cortical neurons is unexpected, but 
functionally complements anti-apoptotic actions of EPO in the recovery from 
brain injury. 
 
 
 
INTRODUCTION 
 
The hematopoietic growth factor erythropoietin (EPO) expands erythrocytes by 
preventing apoptosis of erythroblasts in the bone marrow. Recombinant human 
EPO (rhEPO) is a clinically safe drug, applied for the treatment of anemia 
worldwide. The surprising clinical observation that rhEPO improves cognitive 
functions has always been attributed to the increase in hemoglobin levels and thus 
enhanced tissue oxygenation (e.g. Grimm et al. , 1990 ;Hengemihle et al. , 1996 
;Kramer et al. , 1996 ;Pickett et al. , 1999), (for review, see Ehrenreich et al. , 2008 
;Jelkmann, 2005, 1992). Even after the discovery of EPO and EPO receptor 
(EPOR) in the brain (Masuda et al. , 1993 ;Masuda et al. , 1994), it took years until 
direct EPO effects on the central nervous system were first explored by in vivo 
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experiments (Sadamoto et al. , 1998). In the following, EPO turned out to have 
potent antiapoptotic, antioxidative and anti-inflammatory properties in the brain (for 
review, see e.g. Brines and Cerami, 2005 ;Siren et al. , 2009). Downstream 
signaling pathways of EPO in cells of the nervous system were extensively 
explored, showing an involvement of signal transducers and activators of 
transcription (STATs), phosphatidylinositol-3 kinase (PI3K)/AKT, RAS/extracellular 
signal-regulated kinase (ERK1/2), nuclear factor kappa B (NF-kappa B) and calcium 
(Byts et al. , 2008 ;Digicaylioglu and Lipton, 2001 ;Siren et al. , 2001). A large 
number of preclinical studies followed, devoted to the employment of EPO as a 
neuroprotective agent (for review, see Sargin et al. , 2010). Recent clinical trials on 
patients with schizophrenia (Ehrenreich et al. , 2007b ;Wustenberg et al. , 2010) or 
chronic progressive multiple sclerosis (Ehrenreich et al. , 2007a) as well as a trial 
involving extremely preterm infants (Neubauer et al. , 2010), which all demonstrated 
improved cognitive outcome upon EPO treatment, strongly suggested that this 
growth factor should be considered as a candidate neuroprotective drug 
counteracting cognitive decline. Nevertheless, the relevant mechanisms of action 
remained unclear and difficult to formally separate from blood oxygenation effects. 
 
As compared to neuroprotection studies in disease models (for review, see Sargin 
et al. , 2010), work on the function of the EPO system in normal brain is scarce. 
Based on the prominent effects of EPO on cognition, we hypothesized that an 
important physiological role of EPO in postnatal life or adulthood might be the 
modulation of neuroplasticity and of higher cognitive functions. We showed 
previously that in healthy young mice high-dose EPO treatment over 3 weeks 
enhanced hippocampal long-term potentiation (LTP) and memory (Adamcio et al. , 
2008), as well as executive and attentional functions (El-Kordi et al. , 2009). A 
recent functional magnetic resonance imaging (fMRI) study on healthy volunteers 
reported enhancement of the hippocampal response during memory retrieval after 
only one high dose of EPO (Miskowiak et al. , 2007). In all of these cases, EPO was 
applied peripherally, penetrated an intact blood-brain-barrier (Banks et al. , 2004 
;Brines et al. , 2000 ;Ehrenreich et al. , 2004), and likely bound to all major classes 
of brain cells expressing EPOR, making it impossible to delineate the cell type(s) 
responsible for enhanced cognition. 
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To explore whether EPO-EPOR signaling in cortical neurons has a direct impact on 
cognitive functions in the non-injured brain, we chose a transgenic strategy. To be 
independent of rhEPO and to genetically define the neuronal target cells, we 
expressed a constitutively active form, EPORR129C in the postnatal mouse forebrain, 
using a transgene driven by the α-calcium/calmodulin-dependent protein kinase II (α-
CaMKII) promoter. The substitution in EPORR129C (cEPOR) confers growth factor-
independent survival and tumorigenicity to hematopoietic Ba/F3 cells that are 
normally dependent on interleukin-3 for growth and survival (Longmore et al. , 1994 
;Yoshimura et al. , 1990). The constitutive activity results from the formation of a 
disulfide-linked receptor homodimer, mimicking the EPO-bound form (Watowich et 
al. , 1992). Expression of cEPOR thus activates EPOR signaling without requirement 
of a ligand (Fu et al. , 2009 ;Moucadel and Constantinescu, 2005).  
 
We show here that cEPOR expression in pyramidal neurons of cortex and 
hippocampus of transgenic (TG) mice prominently enhances higher cognitive 
performance. Superior cognition is correlated with enhanced paired pulse facilitation 
and long-term potentiation at the Schaffer collateral CA1 synapse, indicative of 
increased short- and long-term plasticity. Cognitive augmentation in this genetic 
model is different from that observed in mice receiving rhEPO injections and comes 
at the price of higher impulsivity and reduced behavioral control under strong 
cognitive challenge. We conclude that EPO-EPOR signaling stimulates neuronal 
plasticity independent of any hematopoietic effects and in addition to its 
neuroprotective actions.  
 
 
 
RESULTS 
 
Transgenic cEPOR expression in cortical and hippocampal neurons 
To systematically investigate the role of the EPO system in learning, memory and 
attention, we generated a TG mouse line expressing a constitutively active form of 
EPOR (cEPOR) under control of the α-CaMKII promoter (Fig.1A), which restricts 
expression of cEPOR to forebrain pyramidal neurons of postnatal mice. A 
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hemagglutinin (HA) tag at the amino terminus of cEPOR allowed monitoring of 
transgene expression. Of 3 independent lines produced, we analyzed 2 (TG1 and 
TG2) in detail, which showed a similar spatio-temporal expression pattern of the 
mutant receptor (Fig.1B and Fig.S1). In fact, cEPOR expression was enriched in 
cortex and hippocampus (Fig.1B and C) but not in cerebellum and peripheral tissues 
(Fig.1C). Western blot analysis demonstrated the presence of a 64kDa mutant 
receptor in the brains of TG animals that was regulated developmentally over time 
and augmented in early postnatal days (Fig.1D). Mice lacked any signs of 
neuropathology, were long-lived, and reproduced well. Animals in both lines showed 
normal growth and development, body weight, mating behavior and gross brain 
morphology, virtually identical to that of WT mice (Fig.S2). Moreover, hematocrit 
levels were comparable between WT and TG mice (WT mice: 45.00±0.3162%, N=5; 
TG mice: 46.00±1.080%, p=0.36; N=4). Thus, behavioral differences would not be 
secondary to developmental changes of the brain or hyperoxygenation.  
 
Slight hyperactivity but normal basic behavior of cEPOR TG mice  
We first assessed basic behavioral functions, such as locomotor and exploratory 
activity, anxiety, and motor performance, in cEPOR TG mice in comparison to WT 
littermates. In the elevated plus maze, there was the expected significant effect of 
arms (2-way ANOVA, F(2,90)=66.70; p<0.0001), but neither a genotype (p=0.9997) 
nor an interaction effect (p=0.4748), indicating comparable anxiety levels between 
TG and WT mice (Fig.2A). In the open field test, mice did not differ with respect to 
the time spent in zones (2-way ANOVA, effect of genotype p=0.9996) (Fig.2B). 
However, TG mice showed increased velocity (Mann-Whitney U-test, p=0.003) 
(Fig.2B inset) as well as distance travelled (data not shown). There were no 
differences between groups in exploratory activity, locomotor coordination, motor 
learning and acoustic startle response (Fig.2C-E).  
 
Enhanced spatial learning and cognitive flexibility  
The novel object recognition test as a relatively crude readout of basic cognition did 
not reveal any differences between groups (data not shown). However, Morris water 
maze, a sensitive test for hippocampus-dependent learning/memory processes 
(Morris, 1984), yielded a significant effect of days (2-way ANOVA for repeated 
measures F(7,203)=24.66; p<0.0001) as well as a significant effect of genotype (2-
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way ANOVA for repeated measures, F(1,29)=8.863; p=0.006) and no interaction 
effect (p=0.87) (Fig.2F). To exclude hyperactivity as a potential confounding variable, 
we evaluated the distance travelled for locating the hidden platform – a parameter 
independent of swimming speed. Again, there was a significant effect of genotype 
(2-way ANOVA for repeated measures, F(1,29)=6.791; p=0.014) (Fig.2G) indicating 
enhanced hippocampus-dependent learning and memory function in cEPOR TG 
mice. The similar performance level of both groups on day 8 of the hidden platform 
paradigm (p=0.8) allowed us to further assess cognitive flexibility of cEPOR TG mice 
using the reversal paradigm. Again, 2-way ANOVA for repeated measures revealed 
a significant effect of days (F(7,196)=55.71, p<0.0001), significant effect of genotype 
(F(1,28)=5.090, p=0.03) and a significant interaction effect (F(7,196)=3.649, 
p=0.001). Post-hoc analysis indicated a significant difference on day 1 (Bonferroni 
post-hoc test, p<0.001). To further delineate performance of both groups on this 
critical day 1, we applied a 2-way ANOVA for repeated measures over the 4 trials of 
this day. Both groups significantly improved over time (F(3,84)=12.71, p<0.0001), 
however there was a significant genotype effect (F(1,28)=9.632, p=0.004), pointing 
to faster adaptation of cEPOR TG mice to the new platform position (Fig.2H and 
inset).  
 
Enhanced synaptic plasticity of the hippocampus 
We hypothesized that the improvements of hippocampal learning are associated with 
a higher degree of synaptic plasticity. To assess changes in synaptic function and 
plasticity at the Schaffer collateral-CA1 synapse, extracellular field potential 
recordings were performed in stratum radiatum of the CA1 subfield of acute 
hippocampal tissue slices. Basal synaptic function and neuronal excitability were 
judged on the basis of input-output curves and synaptic plasticity was tested by 
paired-pulse stimulation and long-term potentiation (LTP)-inducing trains of tetanic 
stimuli. The amplitude and slope of orthodromically evoked field excitatory 
postsynaptic potentials (fEPSPs) did not differ significantly among WT and TG mice, 
and the normalized input-output curves (10-150µA stimuli) were only slightly right-
shifted for cEPOR mice at low stimulation intensities (≤ 70µA, data not shown). On 
average, half maximum response amplitudes were obtained with 30µA and 50µA 
stimuli in WT (n=14 slices) and TG mice (n=12 slices), respectively. 
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Clear differences were observed, however, in response to twin-pulse stimulation. In 
cEPOR TG mice, paired-pulse facilitation with interpulse durations of up to 150ms 
was significantly increased as compared to WT mice (Fig.3A,B). At the shortest 
interpulse interval tested (25ms), the fEPSP amplitudes increased by 59.3±15.5% 
and 127.9±22.7% for WT (n=13 slices) and TG mice (n=12), respectively, and fEPSP 
slopes increased by 113.6±20.2% and 268.2±45.4%. 
 
LTP-inducing stimuli (3 trains of 100Hz, each lasting for 1s) also resulted in a more 
pronounced potentiation of fEPSPs in cEPOR mice, during both the early and the 
late phase of LTP (Fig.3C,D). Immediately after tetanic stimulation, i.e. the phase 
being referred to as post-tetanic potentiation (PTP), fEPSP amplitudes were 
increased by 68.6±9.4% and 190.5±22.4% for WT and TG mice, respectively, and 
fEPSP slopes increased by 133.3±16.0% and 283.3±47.9% (Fig.3D). This initial 
post-tetanic potentiation decayed over the course of 3-5min and the evoked 
responses stabilized. One hour after LTP induction, fEPSP amplitudes were still 
increased by 38.4±7.4% and 116.7±18.7% and fEPSP slopes were elevated by 
51.0±13.2% and 140.7±32.5% (Fig.3D).  
  
Social memory, attention and higher cognitive capacities 
Would EPO-EPOR signaling also affect higher cortical functions that cannot be 
easily correlated with electrophysiological readouts? We first addressed social 
functions in cEPOR TG mice. While there were no differences in social interaction 
and social approach (data not shown), cEPOR TG mice showed enhanced social 
memory (Fig.2I). This behavior was not due to increased exploratory activity, since 
performance in the hole board test did not differ between groups (Fig.2C). 
Additionally, no differences in olfaction were detected between groups (data not 
shown) indicating that this finding reflects improved memory function in the area of 
social interaction.  
 
We next assessed attention and behavioral control in these mice using the 5-choice 
serial reaction time task (5-CSRTT) (Fig.4A). In this test, mice are trained on an 
everyday basis over many months to adequately respond to a short (≤1.4sec) light 
stimulus. Light stimuli appear pseudorandomly in one of five equally distant stimulus 
holes. Mice are only rewarded if they make a nose poke in the location, where the 
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light shows up. To be considered correct, responses have to occur in a short limited 
time window after stimulus presentation. After reaching stable performance, this 
trained behavior is challenged via different interfering manipulations (e.g. sound 
distracters, changing stimulus durations etc). 
 
Training under baseline conditions for 21 days revealed enhanced attentional 
abilities in cEPOR mice demonstrated by significantly lower reaction times (2-way 
ANOVA for repeated measures, effect of genotype F(1,16)=6.649, p=0.005, Fig.4B). 
Post-hoc analysis indicated a significant difference in the first trial block (i.e. the first 
ten trials collapsed over 21 days) (p<0.001). This pattern remained robust even in 
face of higher cognitive challenges in INT2 (effect of genotype F(1,12)=8.09, 
p=0.015; effect of ITI F(3,36)=15.62, p<0.0001; effect of interaction F(3,36)=3.757), 
p=0.02, Fig.4C). Post-hoc evaluation revealed significantly lower reaction times in 
cEPOR TG mice in ITI5 and ITI6 (p<0.01 and p<0.05, respectively). Furthermore, 
cEPOR TG mice tended to show less premature responses in INT2 compared to WT 
littermates (effect of genotype F(1,14)=6.658, p=0.02, Fig.4D). Since progression 
until 'Recovery4' is performance-dependent, unifying various aspects of learning and 
cognitive control, we analyzed the proportion of mice finishing this phase until 
experimental day 250. Survival analysis showed a significant difference between 
groups (p=0.03), indicating overall faster task progression in cEPOR TG mice 
(Fig.4E). 
 
Resistance to behavioral distracters 
Having obtained a consistently superior performance of TG mice in the whole series 
of consecutive 5-CSRTT attentional challenges, we exposed the mice to interfering 
acoustic stimuli. In the intervention phase 5 (INT5), mice were randomly confronted 
either with trials, where a sound distracter was simultaneously applied with a short 
light stimulus, or with trials lacking such distracting auditory stimulus. The effect of 
the sound distracter on attentional accuracy was investigated. In cEPOR TG mice, 
the sound distracter did not affect attentional accuracy (Wilcoxon test, p=0.94) in 
contrast to WT littermates where sound distraction led to a decrease in accuracy 
(p=0.01, Fig.4F). Reaction times showed here only borderline significance (effect of 
genotype p=0.057). Sound distraction led to a similar increase in reaction times in 
both groups (effect of sound F(1,14)=6.572, p=0.023, Fig.4G). 
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Increased impulsivity and reduced behavioral control under challenge 
Experimental cEPOR transgene expression was not ubiquitous in all EPO 
responsive cells in the brain, but restricted to forebrain pyramidal neurons, 
suggesting that a natural balance of stimulatory and inhibitory circuits may have 
been perturbed. We therefore wondered whether overall superior cognitive 
performance would come at a 'price' and searched for subtle behavioral defects. 
Indeed, an interesting behavioral abnormality was impulsivity. Under conditions of 
long inter-trial intervals (11sec) cEPOR TG mice tended to have more omissions 
compared to WT littermates (Mann-Whitney U-test, p=0.02, Fig.5A). In contrast to 
their resistance towards attentional distractions, cEPOR TG mice had more 
premature responses in the task where they were confronted with sound distracters, 
i.e. responses that occurred before the light-coupled sound appeared (Mann-
Whitney U-test, p=0.03, Fig.5B). To address whether signs of increased impulsivity 
are also detectable in simpler readouts of this behavioral feature, we performed the 
marble burying test. Indeed, cEPOR TG mice buried more marbles compared to WT 
littermates (Mann-Whitney U-test, p=0.047, Fig.5C). Thus, confining enhanced 
EPOR activity to glutamatergic cortical projection neurons in the reported experiment 
may have specific disadvantages, and it will be interesting to compare the here 
obtained behavioral pattern with the in vivo effects of enhanced EPO-EPOR 
signaling in other neuronal subpopulations.  
 
 
  
DISCUSSION 
 
In order to investigate how the EPO system influences cognitive performance and 
synaptic plasticity, and to experimentally prove that previously reported effects of 
rhEPO on cognition in patients are independent of brain oxygen supply, we created a 
novel mouse model with constitutive EPOR signaling in cortical neurons that are 
defined by α-CaMKII promoter activity. This way, we were able to specifically mimic 
EPO system function independent of any ligand in pyramidal neurons of cortex and 
hippocampus, i.e. regions pivotal for learning and memory processes. In other 
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words, we 'over-accentuated' the endogenous action of the EPO system in specific 
cortical and hippocampal layers, particularly the CA1 subregion (Morishita et al. , 
1997), to delineate the contribution of these neuronal subpopulations to the EPO 
effects on cognition. We found that selective constitutive expression of EPOR in 
forebrain neurons leads to a phenotype with superior performance in higher cognitive 
tasks. Behaviorally, this phenotype is accompanied by slightly increased activity and 
impulsivity. Electrophysiologically, both short- and long-term plasticity at the Schaffer 
collateral CA1 synapses are significantly increased in cEPOR expressing TG mice.  
 
We performed a detailed and comprehensive behavioral-cognitive analysis of 
cEPOR TG mice to demonstrate that increased EPO signaling in cortex and 
hippocampus enhances a whole array of learning and memory processes, as well as 
cognitive flexibility and attentional capacities, reflected by shorter reaction times and 
reduced distractibility through competing irrelevant auditory stimuli. Very similar 
higher cognitive tasks were found improved in human patients upon several months 
of weekly high-dose intravenous EPO treatment (Ehrenreich et al. , 2007a 
;Ehrenreich et al. , 2007b ;Wustenberg et al. , 2010), pointing to specific targets of 
EPO action on cognition that are common to both mice and humans. Augmented 
EPOR signaling in cEPOR TG mice also improved social memory, which is partly 
dependent on hippocampal functions (Kogan et al. , 2000). We note that a recent 
study reported on better facial recognition performance in patients with major 
depression following high-dose EPO application (Miskowiak et al. , 2009), supporting 
social cognition as another selective target of EPO effects across species. 
 
It is important to point out that there are clear differences between EPO effects on 
higher cognition upon systemic administration to healthy mice (El-Kordi et al. , 2009) 
as compared to the selective and specific stimulation of the EPO system in forebrain 
pyramidal neurons reported here. In contrast to mice receiving intraperitoneal EPO 
injections (El-Kordi et al. , 2009), the cEPOR TG mice did not show improved 
performance in the (still relatively basic) initial 5-CSRTT training phases. Their 
superiority, however, was pronounced in the highest cognitive challenge tasks, 
demanding tremendous attentional capacities. 
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Surprisingly, under cognitively most challenging conditions, cEPOR TG mice 
demonstrated more premature responses as readout of impaired behavioral impulse 
control (Chudasama et al. , 2003). The slightly hyperactive and impulsive phenotype 
of cEPOR TG mice was further confirmed by a simple additional assay – the marble 
burying test. Behavioral consequences of this kind were not noted upon high-dose 
EPO treatment where the cellular target is defined by the almost ubiquitous presence 
of EPOR throughout the brain. A potential explanation for the cEPOR TG phenotype 
of impulsivity and hyperactivity might be the continuous stimulation of the EPO 
system exclusively in cortical projection neurons. Since the frontal cortex has 
reciprocal projections to subcortical and basal brain regions (e.g. Kuroda et al. , 1998 
;Rotaru et al. , 2005 ;Uylings et al. , 2003), responsible for locomotion, motivation 
and impulsivity (for review, see e.g. Berridge and Kringelbach, 2008 ;Chambers et al. 
, 2003 ;Takakusaki et al. , 2004), the excitation of frontal pyramidal neurons might 
lead to a relative deficit in the simultaneous inhibitory regulation of these areas, 
consistent with a disturbance of the homeostatic balance within neuronal networks, 
resulting in impulsivity and hyperactivity of TG mice. This hypothesis is presently 
under systematic investigation in our laboratory through selected cEPOR expression 
in subpopulations of inhibitory interneurons. 
 
EPO and EPOR are expressed at very high levels in the developing central nervous 
system (Digicaylioglu et al. , 1995 ;Knabe et al. , 2004 ;Knabe et al. , 2005 ;Liu et al. 
, 1996 ;Liu et al. , 1994). In contrast, their expression is markedly reduced 
postnatally and remains low in the normal adult brain (Ehrenreich et al. , 2005). Both 
genes are upregulated under disease conditions in various different cell types in the 
brain, possibly to exert neuroprotective effects (Bernaudin et al. , 1999 ;Bernaudin et 
al. , 2002). Our present data indicate that EPO-EPOR signaling serves a role in 
neuroplasticity, independent of and in addition to its anti-apoptotic neuroprotective 
tasks. Since the steady-state level of both receptor and ligand is nevertheless low in 
the uninjured brain, we suggest that this function may also be disease-relevant. We 
propose a model in which EPO-EPOR induction under disease conditions not only 
prevents neuronal cell death, but also triggers the enhanced neuronal plasticity that 
is required to functionally compensate for lost neuronal functions. It is intriguing that 
this could indicate the strategy of the neocortex, which is known to provide striking 
functional compensations after injury. This study, together with our previous work, 
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also supports a physiological role for EPO in cognitive processes. All this should be 
exploited to define novel strategies to therapeutically enhance brain plasticity and 
cognitive performance in disease conditions. 
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MATERIALS AND METHODS 
 
Generation and characterization of transgenic (TG) mice 
EPORR129C (cEPOR) bears a single point mutation at nucleotide 484, i.e. in the 
exoplasmic domain, causing a substitution of cysteine for arginine at codon 129 of 
the N terminus (R129C). The cDNA sequence of cEPOR, containing a hemagglutinin 
(HA; YPYDVPDY) tag inserted five residues downstream of the signal peptidase 
cleavage site (Constantinescu et al. , 2001), was excised with PacI and SalI from the 
pMX-HA-cEPOR plasmid. The HA-cEPOR cDNA was inserted into pNN265 plasmid, 
with a modified multiple cloning site, that carries a 5' hybrid intron and a 3' intron plus 
poly-A signal from SV40 through PacI and SalI sites. Finally, the entire DNA fragment 
of HA-cEPOR, flanked by a hybrid intron at the 5’ end and a polyadenylation signal 
from SV40 at the 3’ end was cut out from pNN265 vector using NotI and placed 
downstream of the 8.5kb α-CaMKII promoter.  
The TG founders were produced by pronuclear injection of the linearized DNA into 
C57BL6/N ('TG1') or FvB/N ('TG2') zygotes. The analysis of line TG1 mice was 
performed after (N=4-6) backcrosses with C57BL6/N wildtype mice. The TG1 line 
was used (because of its clean C57BL6/N background) for the behavioral 
experiments presented here. The analysis of line TG2 mice was performed after 
backcrossing (N=8-9) to C57BL6/N mice.  
The genotype of transgenic offspring was analyzed by PCR of tail genomic DNA 
using primers specific for the 3’ end of the α-CaMKII promoter sequence  
(5’-GGGAGGTAGGAAGAGCGATG-3’) and the 5’ end of the HA-cEPOR cDNA 
sequence (5’-CACCCTGAGTTTGTCCATCC-3’) yielding a 769 bp product. PCR 
amplification of the tail DNA was carried out with the following conditions: 2min, 94°C 
(1 cycle); 30s 94°C, 30s 60°C, 1min, 72°C (35 cycles), followed by final extension at 
72°C for 10min. 
 
Immunofluorescence  
Wildtype and TG male HA-cEPOR mice were transcardially perfused under deep 
anesthesia with saline followed by 4% paraformaldehyde in 0.1M sodium phosphate 
buffer (PBS) (pH 7.4). Brains were removed from the skulls, postfixed in 4% PFA 
overnight at 4˚C and subsequently cryoprotected in 30% sucrose/PBS solution. After 
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being frozen on dry ice, coronal cryosections (30µm) were collected, washed briefly 
with PBS and incubated for 40min at room temperature (RT) with 0.1% glycine 
(Merck, Darmstadt, Germany), 0.1% Triton X-100 in PBS. Sections were then 
immersed for 1h at RT in blocking solution [5% normal horse serum (NHS), 0.1% 
Triton X-100 in PBS] and incubated with mouse monoclonal anti-HA (1:500, 
Covance, Hiss Diagnostics, Freiburg, Germany) diluted in 3% NHS, 0.1% Triton X-
100/PBS overnight at 4°C. After washing with PBS, sections were treated with anti-
mouse Cy3-coupled secondary antibody (1:1000, Jackson ImmunoResearch 
Laboratories-Dianova, Hamburg, Germany) for 1h at RT. Following PBS washes, 
sections were mounted on Super Frost microscopic slides, air dried and coverslipped 
using Aqua-Poly/Mount (Polysciences, Eppelheim, Germany). Sections were imaged 
with a fluorescence stereomicroscope (Leica MZ16 FA, Wetzlar, Germany). 
 
Protein extraction and immunoblotting 
Wildtype and TG HA-cEPOR male mice were sacrificed by cervical dislocation. The 
tissue samples were dissected and immediately frozen on dry ice. For 
immunoblotting, tissue samples including hippocampus, cortex, cerebellum, liver and 
kidney, were homogenized in lysis buffer (50mM Tris HCL (pH 8.3), 150mM NaCl, 
40mM NaF, 5mM EDTA, 5mM EGTA, 1mM Na3VO4, 1% Igepal, 0.1% 
Natriumdesoxycholat, 0.1% SDS] containing 1mM phenylmethysulfonylfluoride, 
10µg/ml aprotinin and 0.1mg/ml leupeptin) using an Ultra-turrax homogenizer 
(Kinematica, Luzern, Switzerland). The lysates were centrifuged (1200rpm) for 
45min at 4°C. The supernatant was collected and mixed with 3 volumes of Laemmli 
buffer [250 mM Tris HCL (pH 8.3), 8% SDS, 40% glycerol, 20% 2-mercaptoethanol, 
0.04% pyronin Y], and boiled for 10min at 70°C for immunoblotting. The protein 
samples were run on NuPAGE 4-12% Bis-Tris Gel (Invitrogen, Karlsruhe, Germany) 
for 1h at 200V and transferred to a nitrocellulose membrane. After blocking with 5% 
milk in Tween 20-Tris-buffered saline (TTBS) for 1h at RT, membranes were 
incubated in primary antibodies for mouse rat monoclonal anti-HA (1:500, Roche, 
Mannheim, Germany) with mouse monoclonal anti-GAPDH (1:10000, Assay 
Designs/Stressgen, Ann Arbor, MI, USA) as an internal control. Immunoreactive 
bands were visualized using secondary antibodies coupled to horseradish 
peroxidase by enhanced chemoluminescence (Amersham, Freiburg, Germany).  
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RNA isolation and expression analysis by reverse transcriptase PCR (RT-PCR) 
Brains of E12, E17, P0, P14 and adult (2 months old) TG male HA-cEPOR mice 
were rapidly frozen after being sacrificed. Tissue was homogenized in Trizol using 
an Ultra-turrax homogenizer (Kinematica, Luzern, Switzerland). Total RNA was 
isolated by using the RNeasyPlus kit (Qiagen, Hilden, Germany). During RNA 
isolation, on-column DNase digestion was performed with the RNase-free DNase set 
(Qiagen, Hilden, Germany). cDNA was prepared using N9 random and Oligo(dT)18 
primers. HA-cEPOR expression was detected by PCR using the sense (5’ 
CTACCCATACGACGTCCCAG 3’) and antisense (5’ GCGTCCAGGAGCACTACTTC 
3’) primers specific for the transgene, yielding a 362bp product. GAPDH cDNA was 
amplified as internal control using the sense 5’ TGCCAAGGCTGTGGGCAAGG 3’ 
and antisense 5’ TGTTGGGGGCCGAGTTGGGA 3’ primers (431bp). PCR 
amplification was done with following conditions: 2min, 94°C (1 cycle); 45s 94°C, 45s 
58°C, 1min 72°C (30 cycles), followed by final extension at 72°C for 10min. 
 
Slice preparation and electrophysiological recordings 
Synaptic function and plasticity were assessed in acute brain tissue slices. Adult 
male wildtype and TG HA-cEPOR mice (3-4 months old) were decapitated under 
deep ether anesthesia, the brain was rapidly removed from the skull and placed in 
chilled artificial cerebrospinal fluid (ACSF) for 1-2min. Acute neocortical/hippocampal 
tissue slices (400µm thick transverse slices) were cut from the forebrain using a 
vibroslicer (752M Vibroslice, Campden Instruments, Loughborough, UK). The slices 
were then separated in the sagittal midline, transferred to an Oslo style interface 
recording chamber and left undisturbed for at least 90min to ensure recovery from 
surgical trauma. Recording chamber was kept at a temperature of 32-33oC, 
continuously aerated with 95% O2 - 5% CO2 (400ml/min), and perfused with 
oxygenated ACSF (3-4ml/min). The ACSF contained (in mM): 130 NaCl, 3.5 KCl, 
1.25 NaH2PO4, 24 NaHCO3, 1.2 CaCl2, 1.2 MgSO4, and 10 dextrose; aerated with 
95% O2 - 5% CO2 to adjust pH to 7.4.  
 
Orthodromically evoked field excitatory postsynaptic potentials (fEPSPs) were 
elicited by stimulation of Schaffer collaterals and recorded in stratum radiatum of the 
CA1 subfield with a locally constructed extracellular DC potential amplifier as 
described earlier (Adamcio et al. , 2008 ;Hepp et al. , 2005). Unipolar stimuli of 
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0.1ms duration, negative polarity and 10-150µA amplitude were generated by a 
stimulator (Grass S88 stimulator equipped with PSIU6 stimulus isolation units, Grass 
Instruments, Astro-Med Inc., Rodgau, Germany) and delivered via stimulation 
electrodes made from steel microwire (50µm diameter, AM-Systems, Carlsborg WA, 
USA; (Muller and Somjen, 1998)). Extracellular recording electrodes were pulled 
from thin-walled borosilicate glass capillaries (GC150TF-10, Harvard Apparatus, 
Holliston MA, USA) using a horizontal electrode puller (P-97 Flaming/Brown 
Micropipette Puller, Sutter Instruments, Novato CA, USA). They were filled with 
ACSF and their tips were trimmed to a final resistance of ~5MΩ. Evoked responses 
were sampled at an acquisition rate of 20kHz using an Axon Instruments Digitizer 
1322A and PClamp 9.2 software (Molecular Devices Corporation, Sunnyvale CA, 
USA). Synaptic function and neuronal excitability were assessed by recording input-
output curves (10-150µA stimulus intensity) and synaptic plasticity was tested by 
inducing paired-pulse facilitation (PPF) and long-term potentiation (LTP). For PPF 
and LTP-recordings, stimulation intensity was adjusted to obtain half-maximum 
response amplitudes. In PPF recordings, the inter-stimulus interval was varied in the 
range of 25-200ms. LTP was induced by three 1s lasting 100Hz trains, separated by 
20s each, and fEPSPs were then recorded for 60min. To improve the signal to noise 
ratio of the recordings, 4 consecutive sweeps were averaged online (Muller and 
Somjen, 1998); individual stimuli were delivered every 5s (input-output curves and 
PPF) or 15s (LTP). To quantify changes in synaptic function and plasticity, the 
amplitude of the EPSPs and their slope (within the 20-80% range of the falling 
phase) were analyzed using PClamp 9.2 software (Molecular Devices). 
 
Behavioral testing 
All experiments were approved by the local Animal Care and Use Committee in 
accordance with the German Animal Protection Law. For behavioral testing, mice 
were housed in groups of 3-5 in standard plastic cages, food and water ad libitum 
(except for the 5-choice training period, see below). The temperature in the colony 
room was maintained at 20-22°C, with a 12h light-dark cycle (light on at 7:00am). 
Behavioral experiments were conducted by an investigator, blinded to the genotype, 
during the light phase of the day (between 8:00am and 17:00pm). The order of 
testing was as follows: Elevated plus maze, open field, hole board, rotarod, pre-pulse 
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inhibition, social interaction, novel object recognition test, Morris water maze, the 5-
choice serial reaction time task and marble burying test. Age of mice at the 
beginning of testing was 11-12 weeks. Inter-test interval was at least 1-2 days.  
Elevated plus maze: In this test of anxiety, mice were placed in the central platform, 
facing an open arm of the plus-maze (made of grey plastic with a 5x5cm central 
platform, 30x5cm open arms and 30x5x15cm closed arms; illumination 120lx). The 
behavior was recorded for 5min by an overhead video camera and a PC equipped 
with “Viewer 2” software (Biobserve GmbH, Bonn, Germany) to calculate the time 
spent in open or closed arms, distance traveled, number of arm visits, and velocity. 
The proportion of time spent in open arms was used to estimate open arm aversion 
(fear equivalent). 
Open field: Spontaneous activity in the open field was tested in a grey Perspex 
arena (120cm in diameter, 25cm high; illumination 120lx). Mice were placed in the 
center and allowed to explore the open field for 7min. The behavior was recorded by 
a PC-linked overhead video camera. “Viewer 2” software was used to calculate 
velocity, distance traveled, and time spent in central, intermediate or peripheral 
zones of the open field. 
Hole board: The hole board test measures exploratory activity. The apparatus 
consisted of a 51×51×33cm transparent Perspex chamber with a non-transparent 
floor, with 16 equally spaced holes, 2cm in diameter, 2cm deep. Mice were allowed 
to explore the chamber for 5min and the number of explored holes (head dips) was 
registered by a computer software (TSE GmbH, Bad Homburg, Germany). The 
illumination in the testing room was 120lx.  
Rotarod: The rotarod test examines motor function, balance, and coordination. It 
comprised a rotating drum (Ugo Basile, Comerio, Varese, Italy), which was 
accelerated from 4 to 40rpm over 5min. Mice were placed individually on the drum 
and the latency of falling off the drum was recorded using a stop-watch. To assess 
motor learning, the rotarod test was repeated 24h later. 
Pre-pulse inhibition test: In this test of sensorimotor gating, individual mice were 
placed in small metal cages (90x40x40mm) to restrict major movements and 
exploratory behavior. The cages were equipped with a movable platform floor 
attached to a sensor that records vertical movements of the floor. The cages were 
placed in 4 sound-attenuating isolation cabinets (TSE GmbH, Bad Homburg, 
Germany). Startle reflexes were evoked by acoustic stimuli delivered from a 
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loudspeaker that was suspended above the cage and connected to an acoustic 
generator. The startle reaction to an acoustic stimulus, which evokes a movement of 
the platform and a transient force resulting from this movement of the platform, was 
recorded with a computer during a recording window of 260ms (beginning with the 
onset of pre-pulse) and stored for further evaluation. The recording window was 
defined from the onset of the acoustic stimulus. An experimental session consisted 
of a 2min habituation to 65dB background white noise (continuous throughout the 
session), followed by a baseline recording for 1min at background noise. After 
baseline recording, 6 pulse-alone trials using startle stimuli of 120dB intensity and 
40ms duration were applied in order to decrease influence of within-session 
habituation. These data were not included in the analysis of the pre-pulse inhibition. 
For tests of pre-pulse inhibition, the 120dB/40ms startle pulse was applied either 
alone or preceded by a pre-pulse stimulus of 70db, 75db, or 80dB sound pressure 
level and 20ms duration. An interval of 100ms with background white noise was 
employed between each pre-pulse and pulse stimulus. The trials were presented in a 
pseudorandom order with an interval ranging from 8 to 22s. The amplitude of the 
startle response (expressed in arbitrary units) was defined as the difference between 
the maximum force detected during a recording window and the force measured 
immediately before the stimulus onset. Amplitudes were averaged for each individual 
animal, separately for both types of trials (i.e. stimulus alone or stimulus preceded by 
a pre-pulse). Pre-pulse inhibition was calculated as the percentage of the startle 
response using the following formula: % pre-pulse inhibition = 100 – [(startle 
amplitude after pre-pulse and pulse) / (startle amplitude after pulse only) x 100]. 
Social interaction: Sociability and social memory were tested as described in detail 
elsewhere ((e.g. Moy et al. , 2004)). The social testing arena was a rectangular, 3-
chambered box. Each chamber was 20x40x22cm in size. Dividing walls were made 
from clear Plexiglas, with rectangular openings (35x35mm) allowing access into 
each chamber. The chambers of the arena were cleaned, and fresh paper chip 
bedding was added between trials. The test mouse was first placed in the middle 
chamber and allowed to explore for 5min. The openings into the two-side chambers 
were obstructed by plastic boxes during this habituation phase. After the habituation 
period, an unfamiliar C57BL/6NCrl male mouse (stranger 1) without prior contact 
with the subject mouse was placed in one of the side chambers. The location of 
stranger 1 in the left versus right side chamber was systematically alternated 
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between trials. The stranger mouse was enclosed in a small (60x60x100mm), 
rectangular wire cage, which allowed nose contact through the bars but prevented 
fighting. The animals serving as strangers had previously been habituated to 
placement in the small cage. An identical empty wire cage was placed in the 
opposite chamber. A heavy cup was placed on the top of each of the small wire 
cages to prevent climbing by the test mice. Both openings to the side chambers were 
then unblocked, and the subject mouse was allowed to explore the entire social test 
arena for a 10min-session. The amount of time spent in each chamber and the 
number of entries into each chamber were recorded by the video tracking system 
“Viewer 2” (Biobserve GmbH). An entry was defined as all 4 paws in one chamber. 
At the end of the first 10min-trial, each mouse was tested in a second 10min-session 
to quantify social preference for a new stranger. A second, unfamiliar mouse 
(stranger 2) was placed into the previously empty wire cage. The test mouse had a 
choice between the first, already explored mouse (familiar stranger 1), and the novel 
unfamiliar mouse (new stranger 2). As described above, measures were taken of the 
amount of time spent in each chamber and the number of transitions between 
chambers of the apparatus during the second 10min-session. Based on the amount 
of time spent in each chamber, a ‘sociability index’ and a ‘social memory index’ (with 
a value of 0 meaning no preference) were calculated according to the following 
formulas:  
Sociability index = ((Timestranger/(Timestranger + Timeempty)) x 100) – 50. 
Memory index = ((Timenovel mouse/(Timenovel mouse + Timefamiliar mouse)) x 100) – 50. 
Novel object recognition test: As a test for recognition memory, the novel object 
recognition test consisted of a training phase and a testing phase. First, mice were 
habituated to the experimental apparatus for 10min in the absence of any objects. 
The experimental apparatus was a rectangular open field (40x40x40cm) made of 
grey plastic. During the training phase, mice were placed in the experimental 
apparatus with 1 object and allowed to explore for 10min. The object was thoroughly 
cleaned between trials to make sure no olfactory cues were present. Retention was 
tested immediately after training and 30min later. During these retention tests, the 
mouse explored the experimental apparatus for 10min in the presence of 1 familiar 
and 1 novel object. An independent set of objects was used for training and testing 
of each retention interval. The location of the object was counterbalanced so that 
one-half of the animals in each group saw the novel object on the left side of the 
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apparatus, and the other half saw the novel object on the right side of the apparatus. 
A mouse was scored as exploring an object when its head was oriented toward the 
object within a distance of 1cm or closer. Preference index, a ratio of the amount of 
time spent exploring the new object over the total time spent exploring both objects 
during the retention test was used as a measure of recognition memory. 
Morris water maze: Spatial learning and memory was assessed in a water maze 
(Morris, 1984). A large circular tank (diameter 1.2m, depth 0.4m) was filled with 
opaque water (25±1˚C, depth 0.3m) and the escape platform (10x10cm) was 
submerged 1cm below the surface. The swim patterns were monitored by a 
computer and the video-tracking system “Viewer 2”. The escape latency, swim 
speed, path length, and trajectory of swimming were recorded for each mouse. 
During the first 2 days, mice were trained to swim to a clearly visible platform (visible 
platform task) that was marked with a 15cm high black flag and placed pseudo-
randomly in different locations across trials (non-spatial training). The extra-maze 
cues were hidden during these trials. After 2 days of visible platform training, hidden 
platform training (spatial training) was performed. For 8 days, mice were trained to 
find a hidden platform (i.e. the flag was removed) that was located in the center of 
one of the 4 quadrants of the pool. The location of the platform was fixed throughout 
testing. Mice had to navigate using extra-maze cues that were placed on the walls of 
the testing room. Every day, mice went through 4 trials with an inter-trial interval of 
5min. The mice were placed into the pool facing the side wall randomly at 1 of 4 start 
locations and allowed to swim until they found the platform, or for a maximum of 90s. 
Any mouse that failed to find the platform within 90s was guided to the platform. The 
animal then remained on the platform for 20s before being removed from the pool. 
The next day after completion of the hidden platform training, a probe trial was 
conducted in order to determine whether mice used a spatial strategy to find the 
platform or not. The platform was removed from the pool and the mice were allowed 
to swim freely for 90s. The percentage of time spent in each quadrant of the pool as 
well as the number of times the mice crossed the former position of the hidden 
platform were recorded. In order to investigate the flexibility of cognitive processes in 
mice, the reversal water maze test was performed. The experimental procedure was 
identical to the one used for the hidden platform training with the exception that the 
escape platform was moved from the original position to the neighbouring quadrant.  
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The 5-choice serial reaction time task (5-CSRTT) measures higher brain functions, 
ranging from various discrete learning/memory to attentional paradigms (Humby et 
al. , 2005 ;Robbins, 2002). Mice were trained in an operant chamber (width 15.5cm, 
depth 20cm, height 18cm; Med Associates Inc, St. Albans, USA), enclosed in a 
sound attenuating box and connected to a Fujitsu Siemens PC. One wall of the 
operant chamber had a curved shape and carried an array of five stimulus holes. 
The stimulus holes were 1.2cm in diameter and contained a LED stimulus light 
(depth 1cm) in the rear. Infrared photocell pairs were located at 4mm from the 
entrance of the stimulus holes and detected nose pokes of mice into the holes. The 
wall opposite to the stimulus holes contained a magazine cup, also with a photocell 
detector of head entries, in which liquid reward (4% sucrose solution) was delivered 
always simultaneously with illumination of the magazine. The house light was 
located 32cm above the magazine.  
Habituation and magazine training: Two days before starting training, mice were 
habituated to the liquid reward of 4% sucrose solution in their home cages over 
night. The day before starting magazine training, sucrose bottles were removed and 
mice were water deprived. Water deprivation was applied during the entire 
experimental period. Immediately after finishing the daily test sessions, mice were 
given water in individual cages for 20min. Magazine training consisted of four 
consecutive phases (M1-M4), 1 phase per day, each lasting for 15min, with all 
stimulus holes closed. In the first phase (M1), liquid reward was delivered (10µl) 
upon initiation of the training session. In the second phase of magazine training 
(M2), the number of potential rewards was increased, with a fixed interval of 118sec 
between reward presentations. A head entry into the magazine was required to 
collect the reward. In the third phase (M3), the fixed interval was replaced by a head 
entry-dependent interval of 100sec to obtain reward. In the last phase (M4), this 
interval was further reduced to 50sec, ideally yielding a consistently increasing 
number of head entries. Head entries into the magazine together with reward 
consumption were taken as indicators for associating the magazine with reward 
delivery. 
Shaping phases (operant and discriminant learning): During shaping, mice were 
trained to perform a nose poke into an illuminated stimulus hole in order to obtain 
reward. The shaping procedure consisted of two phases (each extending over 
several days, dependent on individual performance, and with a daily session 
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duration of 30min) where mice were taught to associate nose poking into an 
illuminated hole with reward (phase S1), and then trained to discriminate between 
those nose pokes that lead to reward (illuminated holes) and those that do not (unlit 
holes) (phase S2). Throughout shaping all stimulus holes were open. During S1, all 
stimulus lights were on. Any nose poke in a stimulus hole was rewarded. The inter-
trial interval (time from pick-up of reward to next stimulus hole illumination) was set 
to 8sec. During S2, presentation of lit and unlit holes was conducted in a 
pseudorandom manner. Mice were only rewarded upon nose poking into a lit 
stimulus hole. Performing a nose poke in an unlit hole led to switch-off of the house 
light for 5sec. Mice in S1 were moved to the next training phase once they had 
reached 35-40 nose pokes each on 3 consecutive days. The number of trials in S2 
was 60 per day and training in this phase was terminated when mice had arrived at a 
stable performance of ≥70% correct responses for three consecutive days.  
5-CSRTT training: The training session started with illumination of magazine light 
and presentation of 4% sucrose solution. Head entry started the trial. At 8sec after 
head entry, light (initially set to 16sec) was randomly presented in one of the 5 
stimulus holes. A correct response, i.e. nose poking into the lit hole, led to reward 
(6μl) and the next trial start after 8sec (inter-trial interval, ITI). Nose poking in an unlit 
stimulus hole, i.e. an incorrect response, led to extinguishing the house light for 5sec 
(time-out) and no reward. Further nose pokes during time-out extended that period 
for additional 5sec each. If a mouse did not respond by nose poking into any of the 
holes during stimulus presentation, an omission was counted. As a consequence, no 
reward was presented. Also omissions provoked time-out. A training session was 
terminated after 30min or upon performing 60 trials, whatever came first. Mice were 
trained in the phase with 16sec stimulus duration until they reached clearly defined 
performance criteria (≥75% accuracy [correct responses/correct + incorrect 
responses * 100], ≤20% omissions and at least 50 trials performed over 3 
consecutive days). Six such phases followed with gradually declining stimulus 
duration up to 1.4sec (16, 8, 4, 2, 1.8 and 1.4sec). In the first phases, mice had time 
to respond as long as the stimulus light was on. For phases with stimulus duration 
below 5sec, the response time (so called limited hold) was added up to 5sec.  
Baseline training and attentional manipulations 
After the acquisition phase, which was terminated by reaching stable performance 
criteria in the 1.4sec-phase (see above), mice were trained at ‘baseline parameters’, 
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i.e. stimulus duration of 1.4sec, an ITI of 8sec and a maximum of 60 trials. This 
training was performance-independent, lasted for 21 days (1 session/day) and was 
conducted to further stabilize performance of mice (Wrenn et al. , 2006). Immediately 
after baseline training, attentional intervention phases (INT1-5) succeeded in the 
following manner: (INT1) variable, long ITI (8, 9, 10 and 11sec); (INT2) variable, 
short ITI (5, 6, 7 and 8sec); (INT3) variable, short stimulus duration (1.4, 1.0, 0.6 and 
0.2sec); (INT4) variable long ITI (8, 9, 10 and 11sec) coupled with variable short 
stimulus duration (1.4, 1.0, 0.6 and 0.2sec) and (INT5) short stimulus duration 
(0.6sec) applied simultaneously with a sound distracter (80dB, white noise).  INT1, 
INT2, INT3 and INT5 lasted for 4 days (1 session/day), while INT4 was conducted 
for 15 days (1 session/day). Between 2 intervention phases, mice were kept in a 
‘recovery’ phase, consisting of baseline parameters, until they re-reached the above 
described baseline performance criteria. This was done to rule out the impact of 
motivational and learning factors resulting from the prior intervention phase (Humby 
et al. , 1999).  
Marble burying test: The marble burying test is used to assess stereotypies and 
obsessive-compulsive behaviors in mice (Deacon, 2006). Mice were tested in plastic 
cages (34.5x56.5x18cm) filled with 5cm deep wood chip bedding. 24 glass marbles 
evenly spaced (4cm apart) were placed on the surface. Individual mice were put in 
the cage and left there for 30min. Illumination was dimmed (6lx). The number of 
buried marbles (to 2/3 their depth) during this time was counted.   
 
Statistical analysis  
Statistical analysis was performed using the statistical programs SPSS for windows, 
release 16 (SPSS Inc., Chicago, USA) and GraphPad Prism version 4.00 for 
Windows, (GraphPad Software, San Diego, USA). We applied 2-way ANOVA for 
repeated measures, Kruskal-Wallis test, chi2-test, Mann-Whitney U-Test and survival 
analysis where indicated. Bonferroni and Dunn’s multiple comparison tests were 
used for post-hoc analysis. Threshold for significance was p<0.05. All data are 
presented as mean±SEM (standard error of the mean). 
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Figure Legends 
 
Figure 1: Construction and characterization of HA-cEPOR TG mice ('TG1'). 
(A) Construct HA-cEPOR used for production of HA-cEPOR TG mice. HA-cEPOR, 
flanked by a hybrid intron at the 5’ end and a polyadenylation signal at the 3’ end 
was placed under the control of the α-CaMKII promoter. (B) Forebrain-specific 
expression of HA-cEPOR transgene revealed by immunohistochemistry.  A 
monoclonal antibody against the HA-tag was used to stain coronal sections of the 
hippocampus. Expectedly, HA-cEPOR expression is absent in WT mice [(a) and (b) 
are magnifications of the respective regions of interest]. In TG mice, HA-cEPOR 
expression is restricted to pyramidal neurons of the cortex (c), CA1 (d) as well as 
CA3 subregions of the hippocampus and granular layer of the dentate gyrus. Scale 
bars; 100µm and 500µm. (C) Tissue-specific expression of HA-cEPOR mRNA (top) 
and protein (bottom) in TG mice. TG mRNA expression was detected by PCR using 
TG specific primers, yielding a 362bp product. Western blot analysis of HA-cEPOR 
using a monoclonal antibody against HA-tag revealed a 64kDa band. HA-cEPOR 
mRNA and protein were expressed in cortex (CX) and hippocampus (HP) of TG 
mice but not in cerebellum (CB) or in peripheral tissues (LIV: liver; KID: kidney). 
GAPDH was used as the internal control for both mRNA (431bp) and protein 
(36kDa) expression analysis. (D) Developmental regulation of the HA-cEPOR 
transgene. HA-cEPOR transgenic mRNA and protein expression was not seen in 
fetal tissue ('embryonic' day 12 and 17), but detected at early postnatal days (P0, 
P14) and remained constant until adulthood.  
 
 
Figure 2: Essentially normal basic behavior of cEPOR TG mice contrasts the 
distinctly superior cognitive performance. 
TG mice were normal in basic behavioral functions (A-E) except for slight 
hyperactivity, as demonstrated by increased velocity in the open field (B). In basic 
cognitive tasks, i.e. spatial learning/memory and cognitive flexibility as evaluated by 
Morris water maze (F-H) and social memory (I), cEPOR TG mice were significantly 
superior to WT. N=13-18 per group; mean±SEM presented. 
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Figure 3: cEPOR mice reveal improved synaptic short- and long-term plasticity 
(A,B) Short-term plasticity as tested by paired-pulse facilitation was markedly 
enhanced in cEPOR mice. The amplitude (A) and slope (B) of the second EPSP are 
normalized to the first EPSP of a given twin pulse. Plotted are the averages of 13 
(wildtype) and 12 slices (cEPOR TG). Error bars represent SEM and the level of 
significance of the changes observed is indicated. The sample responses shown in 
the inset were elicited by 30µA stimuli separated by 25ms; stimulation artefacts are 
truncated. (C,D) Also, post tetanic potentiation (PTP) as well as long-term 
potentiation (LTP) was more pronounced in cEPOR mice. LTP was induced at time 
0; plotted are the normalized averages of 11 slices for each genotype. The sample 
responses in the inset show EPSPs under baseline conditions, immediately after the 
LTP-inducing stimulus, i.e. the phase of PTP, and 60min after stimulation. 
Responses were elicited by 60µA stimuli, scaling is identical to panel B. 
 
 
Figure 4: cEPOR TG mice perform better in the attentional interventions of the 
5-choice serial reaction time task (5-CSRTT). 
(A) Experimental design depicting the standard baseline training steps in 5-CSRTT 
as well as attentional manipulations. (B,C) cEPOR TG mice showed better 
attentional performance reflected by shorter reaction times. (D) They displayed less 
premature responses under lower cognitive demands and (E) were overall faster in 
progressing through the consecutive training steps. (F,G) Additionally, they were less 
distractible and more resistant towards irrelevant competing auditory stimuli. N=7-11 
per group; mean±SEM presented. 
 
 
Figure 5: cEPOR TG mice show increased impulsivity and reduced behavioral 
control under conditions of high cognitive challenge. 
(A) cEPOR TG mice were more distractible in trials comprising low frequency 
stimulus presentations (longer inter-trial interval) and (B) more impulsive in sessions 
including an irrelevant auditory distracter. (C) Additional evaluation of these 
phenomena using the marble burying test confirmed the impulsive phenotype. N=7-
11 per group; mean±SEM presented. 
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Figure S1: Expression of HA-cEPOR in the 'TG2' line. Forebrain-specific 
expression of HA-cEPOR transgene also in line 'TG2' was revealed by 
immunohistochemistry.  A monoclonal antibody against the HA-tag was used to stain 
coronal sections of hippocampus. HA-cEPOR expression is absent in WT mice (A 
and B). Similar to the line 'TG1', HA-cEPOR expression is restricted to the pyramidal 
neurons of cortex (C), CA1 (D), CA3 subregions of hippocampus and granular layer 
of dentate gyrus. Scale bars; 100µm and 500µm. 
 
Figure S2: Overexpression of cEPOR does not affect overall brain morphology. 
(A) Coronal sections from WT and TG mice were stained with haematoxylin-eosin 
and (B) Luxol Fast Blue. General brain morphology and myelin architecture were 
comparable between WT and TG mice. Scale bars; 1mm. 
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6. SUMMARY & CONCLUSIONS 
In the first original publication we studied the effect of combining a complexin2 null 
mutation (genetic predisposition) with a juvenile parietal neurotrauma as a second hit 
(environmental trigger) on inducing cognitive phenotypes relevant to schizophrenia in 
mice. Several months after lesion, only Cplx2 null mutants showed reduced pre-pulse 
inhibition (measurement for sensory motor gating), deficit of spatial learning, and loss 
of inhibition after MK-801 administration. Forced alternation in T-maze, object 
recognition, social interaction and elevated plus maze tests were unaltered in all 
experimental groups. Additionally, we have replicated the previously reported mild 
motor phenotype of Cplx2 null mutants. However, this phenotype was accentuated 
upon lesion. Finally, MRI volumetrical analysis revealed a decrease of hippocampal 
volume exclusively in lesioned Cplx2 null mutants. This goes in concert with the 
observed deficits in spatial learning, which rely on the hippocampus.  
Taken together, the combination of Cplx2 null mutation with juvenile neurotrauma 
provided a further proof for the interaction between genetic predisposition and 
environmental triggers in the emergence of schizophrenia. This model satisfied 
almost all validity issues, which have to be met while modeling schizophrenia in 
rodents.  
From there, we wanted to investigate potential treatment approaches of cognitive 
dysfunctions in brain diseases. Since there are no satisfying treatments for cognitive 
decline in schizophrenia and other neuropsychiatric diseases and due to the often 
reported neurodegeneration in the schizophrenic brain, we aimed at delineating the 
spectrum of cognitive domains potentially targeted by EPO (as a promising 
neuroprotective candidate). For this purpose, in the second project we made use of a 
sequential operant paradigm for rodents, which addresses different types of learning, 
attention and executive functions – the five choice serial reaction time task. We found 
upon 3-week EPO treatment of young healthy male mice improvements in 
associative, operant and discriminant learning. Moreover, EPO treated mice were 
faster in acquiring the task, i.e. reacting correctly to a short randomly appearing 
visual stimulus in one of five possible locations. Furthermore, EPO led to more stable 
cognitive performance. For the first time, this study showed (1) the effect of EPO on 
higher cognitive functions in healthy young mice, which is similar to our previous 
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findings in chronic schizophrenia patients (Ehrenreich, Hinze-Selch et al., 2007) and 
(2) the long lasting effect of this neuroprotective compound, since the cognitive 
improvements were detected up to 3 months after termination of EPO treatment. This 
again parallels its enduring action in a neurological population (Ehrenreich, Fischer et 
al., 2007).  
Up to that point the cellular contribution of EPO-mediated action was still obscure. 
For gaining more mechanistic insight on EPO action on higher cognitive functions, we 
designed the third study, in which we over-expressed EPO receptor (EPOR) in 
selected neurons. We developed a transgenic mouse model expressing EPOR under 
the α-calcium/calmodulin-dependent protein kinase II (α-CaMKII) promoter, i.e. in 
pyramidal neurons of cortex and hippocampus, i.e. in brain regions heavily involved 
in higher cognition. Behavioral tests revealed improved spatial learning abilities, 
enhanced social memory and superior attentional functions of EPOR transgenic 
mice. Along these lines, transgenic mice had enhanced synaptic plasticity, which was 
indicated by increased long-term potentiation. However, perhaps as a price for higher 
cognition, transgenic mice had signs of reduced behavioral control under higher 
cognitive challenge and were mildly hyperactive in the open field. This study showed 
for the first time the effect of selectively stimulating EPOR in neuronal subpopulations 
involved in higher cognition. By circumventing the hematopoietic system this study 
proved that EPO-mediated cognitive improvement is due to the receptiveness of 
neuronal structures to EPO. In contrast to the cognitive advantages, over-stimulation 
of EPOR in selected brain areas led to hyperactivity and decreased behavioral 
control under cognitive challenge.   
Taken together, the work presented in this thesis showed, that EPO is a very 
attractive and promising neuroprotective agent for deficits of higher cognitive 
functions. The findings presented in this work open new avenues for treating 
neuropsychiatric cognitive deficits. This has still to be addressed in the here 
proposed mouse model of schizophrenia. The knowledge gained here will be further 
pursued. We are planning to look at the effect of over-expressing EPOR in 
interneurons, and thus stimulating inhibitory properties of neuronal networks. 
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30.07. – 01.08.2009 8th International Lübeck Conference on the Pathophysiology 
and Pharmacology of Erythropoietin and other Hematopoietic 
Growth Factors 
 Poster presentation 
 Lübeck, Germany 
 
20.04.2009 4th Mini-Symposium of the Center for Systems Neuroscience 
 Organizing committee 
Göttingen, Germany 
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25. – 29.03.2009  32nd Göttingen Neurobiology Conference 
 Attended 
 Göttingen, Germany 
 
02. – 04.10.2008 Intensive workshop neuroanatomy 
 Attended 
 München, Germany  
  
26. – 27.09.2008 4th Brainstorming Conference 
 Poster presentation 
 Hannover, Germany 
 
29.03 – 01.04.2007 31st Göttingen Neurobiology Conference 
 Attended 
 Göttingen, Germany 
 
15. – 16.07.2005 International Symposia on Schizophrenia of the Göttingen  
14. – 15.09.2006 Research Association for Schizophrenia (GRAS) 
18. – 19.09.2008 Organizing committee 
    Göttingen, Germany 
  
 
9.  Scientific Talks 
 
 
 
06.05.2010  The effects of EPO on higher cognitive processes in mice 
Workshop on novel approaches to neuroprotection and 
neuroregeneration. Jerusalem, Israel 
 
13.08.2009         Erythropoietin improves operant conditioning and stability 
of cognitive performance in mice   
 Ahmed El-Kordi 
 Summer Symposium of the MPI of Experimental Medicine 
 Göttingen, Germany  
 
06.06.2009 Complexin2 is a modifier gene of cognition in 
schizophrenia 
Sergi Papiol and Ahmed El-Kordi 
Retreat of the DFG Research Center Molecular Physiology of 
the Brain (CMPB), Bad Salzdetfurth, Germany  
 
27.02.2009 Rett syndrome – Of Mice and Girls 
Ahmed El-Kordi 
Retreat of Section B2 “From synaptopathies to system 
dysfunctions” of the DFG Research Center Molecular 
Physiology of the Brain (CMPB) Seeburger See, Germany  
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